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ABSTRACT 
 
Cancer and malaria are among the most life-threatening diseases globally.  Cancer is 
responsible for about 125,000 annual deaths globally. In 2015, the World Health 
Organization report estimated that 236000-635000 people died of malaria. These 
diseases are complicated by the development of resistance to available 
chemotherapeutic agents. Natural products have been recognized for their major 
applications in the identification of drug leads in drug discovery. Viola philippica Car, 
Viola yedoensis Makino (Violaceae), Triclisia subcordata Oliv (Menispermeaceae) and 
Cyclicodiscus gabunensis Harms (Fabaceae) are medicinal plants traditionally used for 
the treatment of various diseases including malaria or cancer in China and West Africa. 
However, the bioactive compounds are unknown. Therefore, this study evaluated the in 
vitro anticancer and antimalarial activities of the four medicinal plants and searched their 
bioactive compounds. The in vitro anti-ovarian cancer and antimalarial assays were 
demonstrated respectively using sulforhodamine B dye and Syber green 1 fluorescence 
assay methods. Bioassay-guided fractionation and purification were performed. 
Structural elucidation was performed by nuclear magnetic resonance spectroscopy and 
mass spectrometry analysis. Results revealed the anticancer and antimalarial activities of 
T. subcordata; V. philippica, and V. yedoensis to be bisbenzylisoquinoline alkaloids 
(cycleanine, isochondodendrine and 2′-norcocsuline) and/or cyclotides. The cycleanine 
analogues were synthesized and found to be more potent than cycleanine. Induction of 
apoptosis by these alkaloids has also been determined. This study could serve as basis 
for the support of use of these plants in cancer and/or malaria treatment. The BBIQ 
alkaloids and analogues could serve as lead compounds in drug discovery. Future in vivo 
studies need to be carried out on these alkaloids to get drug approval.    
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CHAPTER ONE 
INTRODUCTION 
 
1.1 Natural Products 
 
Natural products generally comprise products of life (Samuelson, 1999). In organic 
chemistry, natural products mainly denote organic compounds produced in living 
organisms by both primary and secondary metabolic pathways (Hanson, 2003). But 
in the areas of pharmacognosy and medicinal chemistry, natural products are limited 
to secondary metabolites from living organisms or natural sources (Bhat et al., 2005, 
Cragg et al., 2009, Williams & Lemke, 2002). The primary metabolites including the 
amino acids lipids, carbohydrates, and nucleic acids are the principal components or 
the molecular building blocks of life. The living organism cannot do without primary 
metabolites because they are produced for survival and the self-utilization by the 
organism. Primary metabolites exert innate influence on the organisms that produce 
them (Kossel, 1891, Kliebenstein, 2004, Karlovsky, 2008) The secondary metabolites 
are  produced by organism  for different reasons like symbiotic attraction or 
protection in a competitive predator environment (Kliebenstein, 2004, Karlovsky, 
2008). Hence, they are species-limited in distribution. The secondary metabolites 
affect the biochemical signal and transduction pathways of the source organism 
(Demain & Fang, 2000, Cragg et al., 2009, Hanson, 2003) which could be attributed 
to their numerous pharmacological effects (Demain & Fang, 2000) Natural products 
could sometimes be used to denote pure compounds of plant origin (Heinrich et al., 
2012). For this thesis, the discussion will focus mainly on natural products of plant 
origin.  
2 
 
Plants are the main source of chemical compounds with varied structural diversity 
known as phytochemicals (Crozier et al., 2008). A long history of the use of plants for 
food and medicines by human revealed an in-depth knowledge of medicinal 
properties and uses of many plants (Brouwer et al., 2005, Hesham et al., 2013). In 
many parts of the world, traditional medicines have found wide applications in 
treatment of various diseases including cancer and malaria (Adebayo & Krettli, 
2011). Plants have been reported to exert wide influence and applications in the 
traditions and cultures of many developing countries (Delgado et al., 2011, Hesham 
et al., 2013). Per the World Health Organization reports (LeGrand & Wondergem, 
1989, Cordell, 1995), about 80% of the global population use plants as primary 
source for health treatment.  Besides, traditional medicines are still the only source of 
health treatment for about 60% of the worlds’ population, especially in many rural 
areas of developing countries (Hesham et al., 2013).  
Natural products of plants origin offer good sources for identification and discovery of 
drug leads or novel compounds in modern drug research (Cragg et al., 2009, Cragg 
et al., 1997). Reports showed that ethnobotany and ethnopharmacology exert 
significant contribution in drug discovery and development (Heinrich, 2000, Heinrich 
& Gibbons, 2001). It was reported that as at 1990, about 80% of drugs in use 
comprised of natural products or analogues derived or inspired by them (Li and 
Vederas 2009). It was also revealed that plant-derived drugs make up significant part 
of natural product-pharmaceuticals (Schmidt et al., 2007, Newman & Cragg, 2012). 
More than 100 natural product-based drugs were reported to be in clinical studies 
from 2001 to 2008 (Li & Vederas, 2009) . 
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1.2. Cancer and Anticancer Natural Products 
1.2.1. Cancer 
 
Cancer is a collective name that designates diseases of unregulated cell growth of 
abnormal cell. It may be transferred from one tissue to another through blood and 
lymph. Individual cancer   is named after the affected or cancerous tissue. Cancer 
has been reported to be among the most lethal cause of deadly diseases of human 
and to be responsible for 25% death globally (Fouche et al., 2008, Jemal et al., 2009, 
Siegel et al., 2015). For example, ovarian cancer is an unregulated growth condition, 
arising from the cells in and around ovary and fallopian tube. Epithelia ovarian cancer 
ranks most common type and targets surface layer of ovary. Ovarian cancer is 
responsible for about 125,000 annual deaths with 204,000 incidences globally (Rauh-
Hain et al., 2011). It is the most lethal of all the gynecological malignancies (Rauh-
Hain et al., 2011). About 4,272 deaths were recorded from ovarian cancer in the UK 
in 2011 (Cancer research UK). Ovarian cancer is ranked the 5th cause of death 
among women in the UK (Rauh-Hain et al., 2011). 
The increased challenges in failure of cancer treatment could be attributed to 
insufficient cancer measures such as chemotherapy, radiotherapy and surgical 
procedures (Fadeyi et al., 2013). Evidence has shown that plant products could offer 
a better option in the treatment and management of cancer because plants are 
inexhaustible reservoir of active agents for treatment of diseases (Cragg et al., 2009, 
Cragg et al., 1997, Fouche et al., 2008),  as revealed by ancient traditional medicinal 
practices (Kim & Park, 2002, Lee, 2010, Mann, 2002). The major contributions of 
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ethnobotany and ethno-pharmacy in discovery and development of anti-cancer drugs 
has been revealed (Heinrich & Bremner, 2006). 
1.2.2 Anticancer natural products 
 
Plant-derived anticancer drugs include vinca alkaloids, vinblastine and vincristine 
isolated from the Madagascar periwinkle or Catharanthus roseus (L) (Guéritte & 
Fahy, 2005) and camptothecin derived from stem wood of the Chinese tree, 
Camptotheca acuminate. The analogues of camptothecin including topotecan and 
irinotecan are also anticancer drug approved by FDA (Li et al., 2015b) (Figure 1.1).  
Camptothecin and its analogues exert their mechanism of action by inhibition of DNA 
topoisomerase 1, with S-phase specific killing as their primary mechanism of killing 
(Liu et al., 2000). Another famous plant-derived drug is paclitaxel (‘Taxol’) (Figure 
1.2) isolated from the bark of the pacific yew tree, derived from Taxus brevifolia 
(Cragg et al., 1997). Paclitaxel binds to β-tubulin subunits of micro-tubules which 
disrupt the equilibrium between monomeric and polymeric tubulin, stabilizes the 
nucleation center (Rao et al., 1994, Schiff, 1997, Schiff et al., 1979). 
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Figure 1.1 Structures of plant-derived natural products used for the treatment of 
cancer. 
The most prevalent challenges in the treatment of cancer include resistance, toxicity, 
low specificity of the available cytotoxic agents and economic problems for 
developing countries (Hesham et al., 2013, de Mesquita et al., 2009). These 
problems, call for urgent need for research aimed at the investigation, identification 
and discovery of novel anticancer compounds. Bioassay-guided fractionation is an 
established reliable procedure used in identification of novel drugs of natural origin. It 
is most likely that many more efficient natural products for treatment of diseases, 
particularly cancer are yet to be discovered. 
1.2.3 Apoptosis: programmed cell death 
 
The drugs used in treatment of cancer can cause cell death. The type and magnitude 
of stimuli (drugs) could affect the nature of cell death elicited by the stimuli, which 
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could be due to necrosis or apoptosis. Drug – induced cell death in tumour is mostly 
carried out by apoptosis. It has been stated that at low doses, the cancer 
chemotherapeutic agents could cause apoptosis and at high dose they cause 
necrosis (Elmore, 2007)  
Apoptosis is a programmed cell death involving coordinated destruction of cell, 
protein and DNA fragmentation. The cell to be eliminated stimulates enzymes that 
destroy the cells’ nuclear DNA, or nuclear and cytoplasmic proteins. Apoptosis can 
also be caused by both physiological and other pathological factors (Elmore, 2007).   
The morphological features of apoptosis include cell shrinkage, chromatin 
condensation, and cytoplasmic blebs formation, fragmentation of DNA or formation of 
apoptotic bodies and destruction of the apoptotic bodies by phagocytes or 
microphages and dendrites cells via phagocytosis. The unique feature of apoptosis is 
protein hydrolysis which is carried out by cysteine proteases members known as 
caspases. Apoptosis is controlled by two gene family namely: Bax, Bcl2 or BclxL 
(anti-apoptotic) which obstruct the efflux of cytochrome c from mitochondria and 
block Apaf1.  
The two major pathways involve in mechanism of apoptosis have been identified as 
intrinsic and extrinsic pathway or executioner pathways (Figure 1.2). During extrinsic 
pathway, DNA injury or stress stimuli activates the Fas (protein associated with tumour 
necrosis factor TNF1) and the cross-link ligands (FasL) which contain death domains 
receptors. The group of Fas associated death domain (FADD) receptors bind to 
procaspase 8 to activate cascade of caspases 8 which in turn activates caspases 3 to 
elicit execution pathways. This can lead to degradation or phagocytosis of the dead or 
injured protein by microphages or dendrite cells, or fragmentation of DNA completing 
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the apoptosis process. In the extrinsic pathway, DNA injury of stress stimuli triggers 
increased mitochondria permeability and efflux of cytochrome c causing apoptosis. 
The cytochrome c leaks out from mitochondria, and binds to the apoptosis activating 
factor 1 (Apaf1) which activates the cascades of caspase 9. This triggers activation of 
caspases 3 and 6 which also leads to the execution pathway causing apoptosis 
(Figure 1.2) (Robinson et al., 2013, Stephen, 2005). 
 
Figure 1.2  Schematic illustration of  mechanism of apoptosis (Robinson et al., 2013, 
Stephen, 2005). The apoptosis mechanism comprises two major pathways namely:  
extrinsic  and intrinsis pathways. The former is triggered by binding of death receptor 
ligands to group of FADD giving rise to activation of caspases 8, caspase 7 and 
caspase 3 which leads to apoptosis. Also, the  intrinsic pathway involves the 
activation of Bax and Bak caused by DNA damage of stress . Activation of 
proapoptotic factor (Apaf1)  induced by cytrochrome C leakage from mitochondrial 
membrane permeability leads to activation of caspase 9 which in turn activates 
caspase 3 causing apoptosis. 
8 
 
The detection of morphological change of cells, activity of caspases, DNA 
fragmentation, membrane alteration, and mitochondrial change have been developed 
to assay apoptosis and previously described in detail (Elmore, 2007). 
 
1.3 Malaria and Antimalarial Natural Products 
 
Malaria is caused by protozoan parasites from Plasmodium species and is among 
the most lethal infectious parasitic diseases globally. About three hundred million 
people are annually infected with malaria in developing countries such as Central 
and South America, Asia, and Sub-Saharan Africa (Greenwood & Mutabingwa, 2002, 
Snow et al., 2005). Besides, about 1.1-2.7 million people infected with malaria, 
especially children less than five years old die every year (Snow et al., 2005, 
Greenwood & Mutabingwa, 2002). Human malaria is transmitted by female 
Anopheles mosquitoes but caused by four Plasmodium species namely, P. 
falciparum, P. vivax, P. ovale and P. malariae. The most widespread and severe 
disease is caused by P. falciparum, which transiently infects the liver before invading 
red blood cells of the mammalian host (Figure 1.3).  
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Figure 1.3 The life-cycle of malaria (Batista et al., 2009). 
   Clinical manifestations occur at the erythrocyte stage and can include fever, chills, 
and anemia, as well as delirium, metabolic acidosis, cerebral malaria and multi-organ 
system failure, which may be followed by coma and death (Batista et al., 2009).    
 
Figure 1.4 Structure of two potent antimalarial natural products. 
 
   Quinine (Figure 1.4) an aminoquinoline alkaloid isolated from the bark of Cinchona 
nitida(Rubiaceae) is one of the oldest and most important antimalarial drugs and is 
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still used today (Greenwood et al., 2005, White et al., 1983). Artemisinin (Figure 1.4) 
extracted from sweet wormwood (Artemisia annua) is the most potent antimalarial 
available (White, 2008, Klayman, 1985), rapidly killing all asexual stages of 
Plasmodium falciparum. Artemisinin is widely used to treat multidrug-resistant 
malaria (White, 2008). A Nobel Prize in Physiology and Medicine in 2015 was 
awarded for the discovery of artemisinin. A total of 266 antiplasmodial natural 
products belonging to the groups of alkaloids, terpenes, quassinoids, flavonoids, 
limonoids, chalcones, peptides, xanthones, quinones, sesquiterpenes, coumarins 
and miscellaneous compounds, as well as 37 promising semisynthetic antimalarial, 
have been reviewed and reported (Batista et al., 2009). 
In the next two sections, two specific types of natural products from plants – 
cyclotides and bisbenzylisoquinoline (BBIQ) alkaloids will be reviewed regarding their 
structure, sources and biological activities including anticancer and/or antimalarial 
activities. 
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1.4 Plant Cyclotides 
Cyclotides are highly stabilized cyclic peptides from plant family which are rich in 
disulfide bonds arranged in a knotted pattern that are connected to cysteine residues in 
a combinatorial cyclic backbone (Craik et al., 1999). The special structures of cyclic 
peptides bestow on them a remarkable stability and various biological activities. The 
cyclotides (28-37 aa) have been reported to be true gene products which differentiate 
them from a range of smaller cyclic peptides (5–12 aa) that are found in fungi and 
bacteria. The latter such as gramicidin and cyclosporine are typically synthesized by 
multi-enzyme complexes (Jennings et al., 2001). Therefore, cyclotides differ from other 
circular proteins in that they possess very distinct three-dimensional structures and, 
despite their small size, may be regarded as mini proteins (Jennings et al., 2001). This 
attribute arises mainly from the knotted network of disulfide bonds that stabilizes the 
structures.  
1.4.1 Discovery of cyclotides 
 
In the early 1970s, it was observed by a Norwegian Physician, Lorents Gran, on his Red 
Cross relief mission in Congo, Africa, that women from Lulua tribe of Congo were 
drinking the boiled water extract from the leaves of an African plant known as 
Oldenlandia offinis (Roam and Schult) DC (Rubiaceae) as tea to accelerate or speed up 
childbirth and to reduce time of labor (Gran, 1973, Gran et al., 2000). Some women 
applied it directly to the vagina during labor (Craik et al., 1999, Craik, 2009, Craik, 
2010). He then came back to his laboratory in Norway, when he finished his Red Cross 
assignment, together with his colleagues and investigated the bioactive constituent of 
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the plant leaves that could be responsible for the oxytocic effect or the uteroactive 
function, inducing birth labour. 
 In women, oxytocin has been known for its wide application or function in induction 
of birth labour. It initiates the contraction of women womb or uterine muscle to 
stimulate or strengthen labour during child birth. Oxytocin also induces or improves 
the prostaglandins production thereby increasing contraction of uterine muscle and 
elicit or enhances delayed labour. Oxytocin could also cause production of breast 
milk with improved lactation for baby. Two different oxytocic bioactive constituents 
were isolated from the O. affinis extract, at the Department of Pharmacognosy, 
University of Oslo. These included serotonin and a polypeptide. As serotonin is easily 
degraded in the gastrointestinal tract, the oxytocic activity of the drug was reported to 
be due to the polypeptide (kalata B1), which was expressed at high levels in the plant 
(1-2 mg/g of dried crude powder of the plant) (Gran, 1973). After the analysis, 
Lorents Gran, partially characterized one of the major bioactive compounds-the 
polypeptide, which he discovered to be a peptide of 30-amino acids and named the 
bioactive compound ‘Kalata B1’ after the native or local name of that plant ‘Kalata 
Kalata’ (Gran, 1973). Conversely, it was about twenty-five years later that its full 
amino acid sequence and three-dimensional (3D) structure was revealed for the first 
time - this was later shown to be cyclic (Saether et al., 1995). It was amazing to note 
that the peptide did not have termini, it is head-to-tail cyclized and it had three 
disulfide bonds arranged in a knotted topology (Craik et al., 1999, Craik, 2001, Craik, 
2009). It was reported that the N- and C-termini were blocked (Herrmann et al., 
2008b) but it was not until 1995 that the macrocyclic nature of kalata B1 was 
revealed (Saether et al., 1995).  
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At that time three similar proteins had been reported from two additional Rubiaceae 
species: the circulins A and B from Chassalia parvifolia Schum (Gustafson et al., 
2004, Gustafson et al., 2000), and cyclopsychotride A from Psychotria longipes 
Muell. Arg. (Witherup et al.,1994). In addition, a peptide, named Violapeptide-I, had 
been isolated and partially characterized from Viola arvensis Murr which belongs to 
the plant family of Violaceae (Schoepke et al., 1993). Many additional cyclotides 
have been discovered. These include the varv peptides A–H from Viola arvensis 
(Claeson et al., 1998; Goransson et al., 2004), several peptides from Viola odorata, 
Viola hederaceae and Oldenlandia affinis (Craik et al., 1999), several new circulins 
(Gustafson et al., 2000) and the cycloviolins (Hallock et al., 2000, Schoepke et al., 
1993). It was reported that the number of cyclotides from Viola odorata L. was 30 
(Ireland et al., 2006) but it has been suggested that the number of different cyclotides 
in one species may be over 100 and that the total number in the Violaceae alone 
might exceed 9000. It was suggested that if this is true, the cyclotides would be one 
of the largest protein families known (Simonsen et al., 2005).  
1.4.2 Extraction, Purification and Isolation of Cyclotides 
 
A range of approaches to isolate cyclotides from plant tissues has been established 
(Göransson et al., 2004, Craik et al., 1999, Claeson et al., 1998). During cyclotides 
extraction, three main features of cyclotides are usually considered for proper 
extraction purification and identification of cyclotides. These features of cyclotides  
applied in identification during extraction include the following  after alcohol -based 
extraction:  (1) identification of the late-eluting fractions on reversed-phase high 
performance liquid chromatography (RP-HPLC); (2) confirmation that their masses 
are consistent with typical cyclotides, i.e., 2700 - 3800 Da; and (3) observation of an 
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increase in mass of 18 Da on cleavage with endo-GluC (Gruber et al., 2008; Craik & 
Conibear, 2011, Craik et al., 2012, Tan & Zhou, 2006, Poth et al., 2011). The 
characteristic late elution on HPLC (Craik & Conibear, 2011) arises from the 
presence of a patch of hydrophobic residues on the surface of cyclotides (Rosengren 
et al., 2003).  
A fractionation protocol for polypeptides isolation from plants biomass as developed 
by Claeson et al. is another good method adopted by many researchers (Claeson et 
al., 1998). The procedure enabled isolation of a highly-purified polypeptide fraction 
from plant biomass to be isolated and purified using HPLC (Tan & Zhou, 2006). The 
protocol is as follows: the dried ground plant materials are first defatted or pre-
extracted with dichloromethane (CH2Cl2) to remove complex fat-soluble substances 
like chlorophyll, lipids and other low molecular–weight substances such as 
terpenoids, and phenylpropanoids. The polypeptides are not extracted by 
dichloromethane because of its insolubility in this solvent (Claeson et al., 1998). The 
polypeptide-rich crude extract (i.e. air-dried plant residues) is then re-extracted with a 
solvent such as 50% ethanol [EtOH-H2O (1:1)]. It has been reported that many of the 
investigated polypeptides have good solubility in 50% alcohol than pure alcohol or 
water (Claeson et al., 1998). Besides, the use of aqueous alcohol in the extraction 
could confer protection against microbial invasion of the plant biomass and ethanol 
does not extract most polysaccharides or enzymes (Claeson et al., 1998). The 
acidified extract is filtered through polyamide gel to remove tannins before being 
partitioned between H2O and n-BuOH and HPLC on a C18 (CH3CN-H2O) column for 
final purification (Claeson et al., 1998). 
1.4.3 Method of detection of cyclotide 
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Chemical methods of detection test for cyclotides have been established (Tan & 
Zhou, 2006). A good specific method for detection of cyclotides has been reported to 
be ‘TLC protosite’ reaction with ninhydrin reagent. This is a sensitive chemical 
detection method for plant cyclic peptides. It can be effectively used to detect 
whether plant extracts contain cyclopeptides as well as a guide to isolation, 
separation and purification of cyclopeptides (Tan & Zhou, 2006). The details of this 
new method are as follows: the sample is dotted at one corner of each of two 
identical 25 mm x 50 mm silica gel plates (plates 1 and 2), and these plates are 
developed with CHCl3-CH3OH (8.5:1.5 or 9:1). After removal of the solvent, plate 2 is 
hung in a sealed glass vessel containing small bottle of 1 mL of concentrated HCl. 
The vessel is placed in    in a drying incubator (110 °C) for 1-2 h to allow plate 2 to be 
hydrolyzed. After it is cooled for a few minutes, plate 2 is taken out, and the HCl is 
removed. Then plates 1 (nonhydrolyzed plate) and 2 (hydrolyzed plate) are sprayed 
with 0.2% ninhydrin- acetone reagent and colored after heating with a drier for 
several minutes. The above-mentioned process is repeated once more. If there are 
some purplish red spots in most cases and/or yellow spots in a few cases for plate 2, 
but there are no spots in the same locations on plate 1, this indicates that the 
detected samples contain cyclopeptides. This is because cyclopeptides got 
hydrolyzed by HCl to release amino group which reacted with ninhydrin to produce 
the purple colour product (Rheuman reaction). The plate that was not hydrolyzed by 
HCl did not release amino acid for ninhydrin reaction. Ninhydrin (triketohydrine) is 
oxidizing agent at slightly low PH which reacts with amino group to produce purple 
coloured Dikehydrine.  Molecular mass of cyclotides should fall within 2700 - 3800 
Da by mass spectrometry and on cleavage produces a difference of 18 Da (Tan & 
Zhou, 2006, Craik & Conibear, 2011).  
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1.4.4 Primary structures /Sequencing of cyclotides 
 
Cyclic peptides exhibit sequencing problem because they neither contain an N- nor a 
C-terminus, thus blocking conventional sequencing approaches such as Edman 
degradation as well as more recent MS-based approaches (Craik & Conibear, 2011). 
Besides, cyclotides are highly resistant to enzymatic degradation in their natural 
oxidized state (Colgrave et al., 2005, Craik & Conibear, 2011, Colgrave, M.L., Craik, 
D.J., 2004). Therefore, the established method for preparing cyclotides for 
sequencing has been developed to reduce the disulfide bonds, alkylate the free 
thiols, and then cleave the cyclic peptide with selected enzymes to liberate termini for 
sequencing (Goransson & Craik, 2003, Göransson et al., 2009, Craik & Conibear, 
2011). Endoproteinase Glu-C (endo-Glu-C) has been extensively used for this 
purpose and has the advantage that so far, all cyclotides, except for kalata B12, have 
a conserved Glu in loop 1 in addition to few other Glu residues in the sequence 
(Colgrave et al., 2004, Colgrave et al. 2005, Craik & Conibear, 2011). Thus, there is 
generally only one target site for endo-GluC. Trypsin has also been widely used in 
sequencing procedure, as has a combination of both enzymes (Chen et al., 2005). 
Edman sequencing has now been essentially replaced with MS-based approaches in 
which a series of fragment ions can be used to successfully trace the amino acid 
sequence (Craik & Conibear, 2011). 
The identification of free cysteine residues and disulfide bond is important for clear 
observation of protein function and structure. The existences of Matrix-assisted laser 
desorption/ionization (MALDI) and electrospray ionization (ESI) has helped in very 
efficient detection and analysis of biomolecules (Ten-Yang et al., 2000; Aebersold & 
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Mann, 2003). Usually, when the concentration of protein for analysis is very small, 
the MS techniques are universal procedures to apply for knowledge of the free 
cysteine residues and disulfide linkages in the peptides. Chromatographic separation 
of the disulfide–linked peptides produced from chemical and enzymatic cleavage of 
protein is usually necessary for MS determination of the location of disulfide bonds 
(Cole et al., 1999, Yen et al., 2000). The purified disulfide-rich peptides are then 
ionized by MALDI or ESI-MS, and identified by means of mass mapping. To ascertain 
the location of the disulfide-linkage, the disulfide containing peptides could be further 
reduced and alkylated to measure the mass to charge ratio of each individual peptide 
contained in the disulfide bond. Otherwise disulfide—rich peptides could also be 
confirmed using tandem mass spectrometry (MS/MS) or post source decay (PSD) 
analysis without chemical modification (Cole et al., 1999). 
Tandem MS sequencing after reduction and digestion of peptide fractions is an 
efficient method for the identification and elucidation of the primary structures of new 
and known cyclotides (Goransson & Craik, 2003). To characterize any given 
cyclotide and elucidate its structure effectively, the disulfide bonds of the cyclotides 
should be reduced and cleave to provide or expose the C-termini which usually 
contains Glu that would be cleaved and fragmented for proper MS/MS analysis. 
Therefore, the purified cyclotides compounds in the eluents, from reversed-phase 
preparative HPLC are chemically and enzymatically treated before proceeding to 
tandem mass spectrometry (MS-MS) for sequence analysis. They are first reduced to 
break the disulfide bonds using tris(2-carboxyethyl) phosphine (TCEP) and/or 
subsequently S-carbamidomethylated, and digested with trypsin or endoproteinase 
Glu-C:  a procedure that increased the mass of each cyclotide, confirming the 
presence of six cysteine moieties. Either trypsin or endoproteinase Glu C or both   
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are used to prepare linear fragments of the modified proteins, yielding fragments 
cleaved at the C-terminus of cationic residues (Arg, or Lys) or anionic residue (Glu), 
respectively. The fragments are fully sequenced by MS-MS analyses. Another 
advantage of tandem MS sequencing is that it is possible to unambiguously define 
amino acid sequences for a mixture of cyclotides. However, it is also more common 
recently, to carry out the sequencing of natural peptides based on identification and 
utilization of their encoding nucleic acids, and this has been particularly successful 
for cyclotides (Craik & Conibear, 2011). A database that contains cyclotides 
sequences (www.cybase.org.au) has been developed to curate the sequences of 
cyclotides and other circular proteins, both at the amino acid and nucleic acid levels  
(Wang et al., 2008, Mulvenna, J.P., Wang, C., Craik, D.J, 2006, Craik & Conibear, 
2011).  
1.4.5 Three-dimensional structures (NMR and X-ray) 
 
Nuclear magnetic resonance (NMR) spectroscopy and X-ray crystallography have 
immensely contributed to our in-depth knowledge of three-dimensional structure of 
proteins and the existence and structural necessity of disulfide bonds (Brunger, 
1997). The elucidation of three-dimensional structures of cyclotides so far reported 
has been carried out almost exclusively by NMR (Craik & Daly, 2007, Craik & 
Conibear, 2011) with the exception of one cyclotide, varv F, which both NMR and X-
ray structures were reported (Craik & Daly, 2007, Craik & Conibear, 2011). In all 
cases, the cystine knot forms the core of the molecule and is surrounded by a β-
sheet structure comprising a well-defined β-hairpin and a less ordered third β-strand. 
The unique cyclic cystine knot structure of the prototypic cyclotide kalata B1 was first 
reported in 1995 using NMR (Saether et al., 1995). 
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Figure 1.5 Ribbon structure of an exemplary cyclotide - Varv F (PDB code: 3E4H) 
(Burman et al., 2014). 
 
1.4.6 Classification of Cyclotides 
 
Cyclotides are grouped into two major subfamilies namely, the Mobius and Bracelet 
subfamilies based on topological differences, which are depending on the presence 
or absence of cis-Pro amide bond or motif (Figure 1.6) (Burman et al., 2014, Craik et 
al., 1999, Craik & Conibear, 2011). There is a recently discovered group known as 
circular trypsin inhibitors that comprise only two (MCoTI-I and MCoTI-II) from 
Momordica cochinchinensis of Curcubitaceae family (Burman et al., 2014). The 
bracelet subfamily group contains trans-amide bond but lack the cis-Pro bond. The 
Mobius subfamily contains a cis-Pro amide bond that creates a twist in the circular 
peptide backbone. In addition to the cis-Pro bond, Mobius and bracelet cyclotides 
differ in size, amino acid composition, and the nature of their inter-cysteine loops. A 
typical bracelet cyclotide contains one or two more residues than Mobius 
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counterparts. “Cyclization of any ribbon-like entity can be done in many ways but the 
two topologically simplest are by connection of the ends of the linear ribbon with no 
twist (i.e. bracelet-like), or with a single twist. The latter results in what is commonly 
known as a Mobius strip, which has the fascinating property of having just a single 
continuous side, compared to two sides of a bracelet” (Craik et al., 1999, Craik & 
Conibear, 2011). 
There is no Pro amide bond at the corresponding position in circulin A, cycloviolacin 
O1 and other members of subfamily 1, and hence these can be regarded as bracelet-
like molecules. It is therefore convenient to distinguish the two subfamilies of 
cyclotides as the bracelet cyclotides (subfamily 1) and the Mobius cyclotides 
(subfamily 2). 
 
The major challenge or difficulty in extraction or study of cyclotides is head to tail 
cyclization of cyclotides. There is no free N- and C-terminal in cyclotides. Cyclotides 
are N-C cyclized. This offers great problem in study of cyclotides as series of steps or 
methods such as reduction, alkylation to free thiol group and enzymatic degradation 
to release cleave N and C- terminal bonds and fragment the long peptide residues 
need to be employed before sequence of cyclotides could yield good results.  Also 
for chemical test for identification of cyclotides using ninhydrin test, acids hydrolysis 
needs to be applied to release free amid bond that could react to produce the colour 
reaction. Change. All these multiple processes are expensive and time-consuming 
procedures which render them very challenging in study of cyclotides.  
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Figure 1.6 Surface and sequence representation of typical cyclotides (Burman et al., 
2014). The backbone aligned models display the distribution of 
hydrophobic/hydrophilic regions on the protein surface and their amphipathic 
structure. Hydrophobic residues (Ala, Leu, Ile, Pro, Trp, Phe, Val) are in green, 
cationic (Arg, Lys) in blue, and anionic (Glu) in red. A) Cycloviolacin O2 and Kalata 
B1; B) Cycloviolacin O2 and cyclopsychotride (Bracelet); Kalata B1, Varv A, Varv F 
(Mobius); MCoT1-11 (Cyclic T) (Burman et al., 2014). 
1.4.7 Production of cyclotides 
 
Cyclotides can be extracted and purified in great quantity from plant materials as high 
as 1g/kg of plant tissue (Craik & Conibear, 2011), because the biosynthetic 
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procedure for cyclotides has been effectively and evolutionarily improved in nature 
(Reinwarth et al., 2012). This could be attributed to some important functions of 
cyclotides in plants. Such functions include protective functions (as plant defense), 
Cyclotides protect their plants from predators hence their uses as insecticides 
(insecticidal function) and anthelminthic. (Seather, 1995). Other biological function of 
cyclotides include antibacterial, cytotoxic and others stated in section 1.4.9   
1.4.7.1 Chemical synthesis 
 
Irrespective of the complex molecular scaffold of cyclotides, they are amazingly 
accessible by to solid phase peptide synthesis (SPPS). Chemical synthetic method 
for production of cyclotide can provide access to modified and “grafted” versions of 
cyclotides (Figure 1.7).  Although naturally occurring cyclotides contain a wealth of 
sequence diversity, the capacity to chemically synthesize cyclotides provides 
opportunities to explore the structure–activity relationship of individual peptides by 
making mutants with specific sequence, and to develop cyclotides with new biological 
activities (Craik & Conibear, 2011). Chemical synthesis has been suggested to 
exhibit a clear benefit as against the recombinant route because it creates 
opportunity for an easy incorporation of synthetic element at any required position in 
the sequence (Reinwarth et al., 2012). Different procedures have been established 
over the previous years for the synthesis of cyclotides. The first step involved in 
cyclotide synthesis, is the assembly of the polypeptide chain. Chain assembly by 
SPPS, the routine method for peptide synthesis, involves coupling successive N-
protected amino acids to a growing peptide chain which is attached, by the C-
terminus, to a polymer resin (Craik & Conibear, 2011). The mixture of the reaction 
enables byproducts and excess reagents to be easily washed away, thereby greatly 
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simplifying purification and increasing yields. The process can also be automated, 
and this allows for rapid synthesis of peptides of up to approximately 50 residues in 
length (Craik & Conibear, 2011). It was stated that the most reasonable procedure 
applied in chemical synthesis of cycloids is a thioester-mediated approach or method 
in which linear cyclotide precursors are synthesized with a cysteine residue at the N-
terminus and a thioester linker at the C-termini (Gunasekera et al., 2006).The 
complete synthesis of functional cyclotide involves sequential chain assembly, 
cyclisation and oxidation of the cysteine residues to form into their correct pairs of 
disulfide bonds i.e. oxidative folding (Cemazar et al., 2012, Craik & Conibear, 2011). 
 
 
Figure 1.7 Application of cyclotide scaffold in peptide engineering (Wong et al., 
2012).    
 
The stability of scaffold of cyclotides makes them an ideal template for peptide 
engineering and drug design (Figure 1.7). By grafting natural peptide antagonists 
onto the cyclotide kalata B1, orally active peptides were engineered and potentially 
useful therapeutics for the treatment of inflammatory pain. In this case, the entire 
loop 6 of kalata B1 was replaced with the peptidic bradykinin B1 receptor antagonist 
DALK (red in scheme) to obtain the cyclic bradykinin antagonist ckb-kal (Wong et al., 
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2012).  Generation of oxytocin-like peptide based on cyclotides with nanomolar 
affinity to G-protein-coupled receptor was also achieved (Koehbach et al., 2013) 
Reports showed that MCoTI-II is a significantly more potent matriptase inhibitor than 
SFTI-1. Deregulation of matriptase activity is implicated in several diseases including 
cancer. Therefore, inhibition of matriptase could have therapeutic potentials 
(Quimbar et al., 2013). The potential of bioengineered cyclic peptides for the 
treatment of multiple sclerosis (MS) was also demonstrated. This was achieved by 
grafting the active epitope (myelin oligodendrocyte glycoprotein) into the cyclotide 
scaffold to achieve improved stability and bioavailability of the epitope (Thell et al., 
2016, Wang et al., 2013).  Ji et al. reported the engineering of the cyclotide MCoTI-I 
to efficiently antagonize intracellular p53 degradation. The resulting cyclotide MCo-
PMI could bind with low nanomolar affinity to both Hdm2 and HdmX, showed high 
stability in human serum, and was cytotoxic to wild-type p53 cancer cell lines by 
activating the p53 tumor suppressor pathway both in vitro and in vivo (Ji et al., 2013).  
Cyclotides are toxic against cancer and non-cancerous cells and their toxicity 
correlates with their ability to target and disrupt lipid bilayers that contain 
phosphatidylethanolamine phospholipids (Henriques et al., 2012, Troeira Henriques 
et al., 2014). It was suggested that cyclotides anticancer therapeutics activity could 
best be achieved by combination of their amenability to epitope engineering with their 
ability to bind cancer cell membranes (Henriques et al., 2012, Troeira Henriques et 
al., 2014).  
 
1.4.7.2 Plant cell culture - based production of cyclotides  
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Plant cell culture is another way of production of cyclotide (Dörnenburg, 2008). 
Numerous problems connected with low production by cells slow growth, genetic 
instability of high–producing cell lines, poor control of cellular differentiation and 
inability to maintain photoautotrophic growth, have limited the expansion in the 
production of cyclotides using plant cell culture. Although considerable progress has 
been made to stimulate formation and accumulation of secondary metabolites using 
plant cell cultures during the past decades (Zhao, J & Verpoorte, R, 2007), few 
processes have proven to be economically viable. A strategy for enhancement of 
product yield has been reported (Dörnenburg, 2008, Dörnenburg, 2010). 
1.4.7.3 Production by recombinant method 
 
Bacteria possess the features for production of circular proteins and therefore can be 
used as expression systems. Bacteria do not produce cyclotide-like peptides in 
sufficient amount after transformation with the gene for their precursor proteins. So, 
they cannot be used for direct production of cyclotide (Dörnenburg, 2008, Katsara et 
al., 2006). Conversely an attempt to produce MCoTI-II inside living E. coli cells 
produced low expression (Dörnenburg, 2008, Katsara et al., 2006). The method 
reported by Avrutina et al to produce cyclotides has an advantage of the combination 
of economical and high efficient yield recombinant production of the linear peptide 
precursors that are already folded and oxidized, and chemical synthesis (Avrutina, 
2008, Dörnenburg, 2008, Dörnenburg & Heike, 2010, Kimura et al., 2006). 
 
1.4.8. Distribution of cyclotide in plants 
 
26 
 
About 280 different cyclotides have been isolated from more than 40 plant species 
since cyclotides were first discovered (Burman et al., 2014). Among the plant families 
found containing cyclotides include Violaceae, Rubiaceae, and Cucurbitaceae. 
Recently, cyclotides have also been found in Fabaceae, Solanaceae and linear 
cystine knot peptides from Clitoria ternatea of the pea (Fabaceae)  (Nguyen et al., 
2011, Poth et al., 2011c) and Petunia x  hybrida (diamond pearly shades) a hybrid or 
species  of the potato (Solanaceae) (Burman et al., 2014, Poth et al., 2011a, Poth et 
al., 2011b, Poth et al., 2013). Panitides L1-9 (linear peptides) were isolated from 
Poaceae (Nguyen et al., 2013). Violaceae seems to be the richest source of 
cyclotides with almost all the species investigated containing cyclotides unlike the 
Rubiaceae  (Craik et al., 2012, Nguyen et al., 2012, Nguyen et al., 2013, Poth et al., 
2011a, Pinto et al., 2012, He et al., 2011, Poth et al., 2012, Wang et al., 2008). It was 
reported that an estimate of the number of different cyclotides in the Violaceae could 
be about 5000-25,000, and proposed that cyclotides are ubiquitous among all 
Violaceae species (Burman et al., 2015). But this number was later proposed to be 
greater than   30000 with discovery of additional cyclotides from Viola baoshanensis 
(Zhang et al., 2015).The reason for the abundance of cyclotides in Violaceae is likely 
unknown. However, it could be probably because of adaptive measures of plants for 
protective and defensive mechanism naturally developed by violaceae to carry out 
their insecticidal and anthelminthic activities against insects, pests and nematodes 
which are likely more prevalent in geographical regions commonly found violaceae 
plants. Besides, violaceae are more common in temperate region than the tropical 
climate region. Therefore, it is likely that the enzyme (Butelase 1) which is 
responsible for backbone cyclization in the biosynthesis of cyclotides is favoured by 
temperate climate or cold region or might not withstand the relatively high climatic 
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temperature of the tropical region.  Cyclotide-like genes and linear peptides have 
been found in Poaceae although there was no circular cyclotides identified in these 
plants (Burman et al., 2014, Nguyen et al., 2013).    
 
1.4.9 Biological activities of cyclotides 
 
The mechanism of action of cyclotides was reported to be the penetration of cell lipid 
bilayer membrane, preformation and destabilization through hydrophobic and 
phosphoethanolamin specific interaction (Wang et al., 2012).The presence of 
glutamic acid in loop 1 of the cyclotides improves stability and is essential for the 
membrane disrupting activity of cyclotides (Wang et al., 2012) .  
Cyclotides exhibit a range of interesting bioactivities, including in vivo (rat model) 
uterotonic (Gran et al., 2000, Saether et al., 1995); and In vitro including  anti-HIV 
(Gustafson et al., 2004), antimicrobial (Tam et al., 1999), cytotoxic  (Hernandez et al.,  
2000, Lindholm et al., 2002,  Svangard et al., 2004,  Tang et al., 1999), hemolytic  
(Schoepke et al., 1993; Tang et al., 2010), neurotensin antagonistic (Witherup et al., 
1994), insecticidal (Jennings et al., 2001), and trypsin inhibitory activities (Hernandez 
et al., 2000). Their natural function as plant defense agents was deduced from 
reports that cyclotides effectively inhibited the growth of two common cotton pests, 
Helicoverpa punctigera and H. armigera, when the larvae of these pests were fed 
with a cyclotide-containing diet (Jennings et al., 2005). Cycloviolacin VY1 from Viola 
yedoensis showed inhibition against influenza A H1N1 (Liu et al., 2014). Varv A, varv 
F, and cycloviolacin O2 showed potent activity in a panel of 10 different human tumor 
cell lines (Burman et al., 2014). 
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Anticancer activity of hedyotide B5 (HB5) to HB9 has been demonstrated (Ding et al., 
2014). Cyclotides from Citoria teratea exerted anticancer and chemosensitizing 
activities in the lung cancer cell line A549 (Sen et al., 2013). Kalata B1, and kalata B2 
caused antischistosome activity/anthelminthic effects against Schistosoma japonicum 
and Schistosoma mansoni (Malagón et al., 2013), Kalata (KB2) and Cycloviolacin O2 
(CyO2) caused anti-staphylococcal activities (Fensterseifer et al., 2015). Cyclotides 
from Hedyotis diffusa, Diffusa cyclotide 1 to 3 (DC1-3) showed anticancer (activity in 
a cell growth assay or ability to cause cancer cell death) activities against prostate 
cancer cell lines. Cliotide (ctc13, ctc15, ctc17-ctc19, and ctc21-ctc53) exerted 
immunostimulating activity and antibacterial effect against Gram-negative bacteria 
(Nguyen et al., 2016). The vigno 5, a natural cyclic peptide from Viola ignobilis, 
induces apoptosis via the mitochondrial pathway in cervical cancer cells (Esmaeili et 
al., 2016).  
A wide range of biological and pharmacological activities of cyclotides is listed in 
Table 1.1.  
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Table 1.1 In vitro biological activities of cyclotides. 
 
Cyclotide Plant source Biological activity  Reference 
MCoTI  M. cochinchinensis Trypsin inhibitor 
 
 (Hallock et al., 
2000) 
MCoTII  M. cochinchinensis Trypsin   inhibitor 
 
(Hallock et al., 2000) 
Varv A V. tricolor, V. 
arvensis, and V. 
odorata 
Cytotoxic 
 
Svangard et al. 
2004; Lindodholm et 
al 2002. 
Varv E V. tricolor Cytotoxic 
 
Svangard et al. 
2004; Lindodholm et 
al 2002  
Varv B V. arvensis Cytotoxic (Hernandez et al., 
2000). 
Varv C V. arvensis Cytotoxic  (Hernandez et al., 
2000). 
Varv D V. arvensis Cytotoxic 
 
(Hernandez et al., 
2000). 
Varv E V. arvensis Cytotoxic 
 
(Hernandez et al 
2000) 
Varv F V. arvensis Cytotoxic 
 
(Hernandez et al., 
2000, Lindodholm et 
al., 2002) 
Varv G V. arvensis Cytotoxic (Hernandez et al., 
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 2000). 
Varv H V. arvensis Cytotoxic 
 
(Hernandez et al., 
2000). 
Cycloviolacin 
O2 
V. odorata Cytotoxic; Antibacterial 
against 
Staphylococcal aureus 
 
(Svangard et al., 
2004, Lindodholm et 
al., 2002, 
Fensterseifer et al., 
2015, Pränting et 
al., 2010). 
Vitri A V. tricolor Cytotoxic 
 
(Goransson et al., 
1999) 
Kalata B2 
 
O. affinis 
H. punctigera  
H. armigera 
Insecticidal and 
antibacterial activity  
 
(Jennings et al. 
2005; Fensterseifer 
et al. 2015). 
Kalata B1 
 
O. affinis 
 
Oxytocic activity 
 
(Gran, 1973) 
 
Cyclopay- 
chotride A 
P. longipes 
 
Antimicrobial activity 
 
(Witherup et al., 
1994) 
Cycloviolacin 
O24 
Viola odorata 
 
Anti-HIV (Ireland et al., 2008) 
Cycloviolins 
A–D 
Leonia cymosa 
 
Anti-HIV (Hallock et al., 
2000) 
Tricyclon A Viola tricolor 
 
Anti-HIV (Mulvenna et al., 
2005). 
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Circulins C  C. parviflora Anti-HIV activity (Shenkarev et al., 
2006). 
Circulins D  C. parviflora Anti-HIV activity (Shenkarev et al., 
2006). 
Circulins E  C. parviflora Anti-HIV activity (Shenkarev et al., 
2006). 
Circulins F  C. parviflora Anti-HIV activity (Shenkarev et al., 
2006). 
Palicourein  P. condensata Anti-HIV activity (Jennings et al, 
2005) 
Cycloviolin 
A-D 
L. cymosa Anti-HIV activity 
(2946.57) 
(Jennings et al, 
2001) 
Cycloviolin 
A-D 
L. cymosa Anti-HIV activity 
(2910.33) 
(Jennings et al. 
2001) 
Cycloviolin 
A-D 
L. cymosa 
 
Anti-HIV activity 
 
(Jennings et al. 
2001) 
Palicourein P. condensata Anti-HIV activity (Bokesch et al., 
2001). 
Cycloviolin 
A-D 
L. cymosa Anti-HIV activity (Jennings et al. 
2001) 
Vhl-1 V. hederaceae Anti-HIV activity (Craik et al. 1999) 
Cycloviolacin 
Y1 
V. yedoensis Anti-HIV activity (Wang et al. 2008) 
Cycloviolacin 
Y4 
V. yedoensis Anti-HIV activity  (Wang et al., 2008) 
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Cycloviolacin 
Y5 
V. yedoensis Anti-HIV activity (Wang et al., 2008) 
Cycloviolacin 
O3, O8, O14, 
O15, and 
O16 
V. odorata Anthelmintic activity 
 
(Colgrave et al., 
2008). 
 
Cycloviolacin 
H4 
V. hederaceae 
 
Hemolytic activity  
 
(Chen et al., 2005). 
Cycloviolins 
A-D 
 
Leonia cymosa 
 
anti-HIV activity (Hallock et al.  
2000) 
circulin A  
circulin B  
Chassalia parvifolia Antimicrobial and anti-
HIV activities 
(Tam et al., 1999) 
Kalata B1 O. offinis Uterotonic (Gran, 1973) 
cyclopsychot
ride A 
Psychotria longipes  Neurotensin antagonist (Witherup et al., 
1994) 
cycloviolacin 
VY1 
V. yedoensis 
(Violaceae) 
Anti-influenza A H1N1      
virus 
(Liu et al., 2014) 
panitides L1-
9, 
Panicum laxun 
(Poaceae) 
Cytotoxic against HeLa 
cells and antibacterial 
(Nguyen et al., 
2013) 
hedyotide B5 
- HB9 
Hedyotis biflora Cytotoxicity against 
pancreatic cancer cell 
lines. 
(Ding et al., 2014). 
kalata B1 / 
kalata B2 
O. offinis  Antischistosome 
/anthelminthic activity 
(Malagon et al., 
2013) 
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cliotides Clitoria ternatea 
(Fabaceae) 
Gram-negative-specific 
antibacterial activity; 
anticancer and 
chemosensitizing activity 
against lung cancer cell 
line A549  
(Nguyen et al., 
2016; Sen et al., 
2013) 
Diffusa 
cyclotide 1 to 
3 (DC1-3) 
Hedyotis diffusa  Anti-prostate cancer 
activity  
(Hu et al., 2015). 
Cliotides: 
ctc13, ctc15, 
ctc17-ctc19, 
ctc21-ctc53 
Clitoria ternatae Antibacterial and 
immunostimulating 
activity. 
(Nguyen et al., 
2016) 
vigno 5 Viola ignobilis Anticancer cervical 
cancer activity 
(Esmaeili et al., 
2016) 
 
The mechanism of action of cyclotides was reported to be the penetration of cell lipid 
bilayer membrane, preformation and destabilization through hydrophobic and 
phosphoethanolamin specific interaction (Wang et al., 2012). The presence of 
glutamic acid in loop 1 of the cyclotides improves stability and is essential for the 
membrane disrupting activity of cyclotides (Wang et al., 2012) .  
The rapid kinetics and the broad spectrum of the toxic activities of cyclotides were 
likely due to their membrane disruption ability (Svanglard et al., 2007). Such activity 
was achieved by high affinity to the target membrane. This could be potentiated by 
the hydrophobic and electrostatic forces that drive adsorption of cyclotides toward the 
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lipid core and anionic surface of the target membranes (Burman et al., 2014). 
Reports showed that cyclotides were among the group of peptides with affinity for 
phosphatidylethanolamine (PE) membrane lipids, which was a characteristic feature 
among both subfamilies of cyclotides (Henriques et al., 2012). 
1.4.10 Perspective and outlook 
 
Foregoing data has demonstrated the potential for cyclotides to be used as 
anticancer therapeutics. The exceptional stability of cyclotides to heat, chemical and 
proteolytic degradation together with synthetic accessibility have bestowed them 
strong attraction for pharmaceutical, agrochemical industries as lead for drug 
discovery and as scaffolds in peptide–based drug design. For instance, linear 
peptides may have good potential features as drug lead but because they are prone 
to enzymatic and thermal cleavage and may have low bioavailability these could 
prevent their application as lead candidate in drug discovery and design by 
pharmaceutical industry. Cyclization of linear disulfide–rich peptides is a good 
strategy that has been adopted to enhance the stability of some potent but unstable 
peptides, to greatly improve their biopharmaceutical properties. The investigation of 
anti-ovarian cancer or other biological activities of cyclotides will be an interesting 
area to explore. Hence, there is increasing interest in exploring the plant kingdom to 
identify further cyclotides and more biological activities of this largest family of 
cyclized backbone of plant kingdom. 
However, there have been some challenges in the study of cyclotides and the 
application of the cyclotides in preclinical or in vivo studies. Some of the challenges 
include the cyclic nature that hinders exposure of free N and C-terminus for easier 
sequence and characterization of cyclotides. Also, the low therapeutic index and 
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hemolytic features of some cyclotides could challenge more interest in further 
expansion and clinical application of cyclotides. Cyclotides tend to exert high toxicity 
or low therapeutic index hence not very much interest has been shown in clinical 
studies of cyclotides. All these could offer limitations to the exploration of research 
and interest in the cyclotides applications. 
More so, in this study, there was limitation on the in vivo study of cyclotides in animal 
model due to financial challenges on high cost of animal studies, more facilities and 
limited time frame for PhD study.   
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1.5 Bisbenzylisoquinoline Alkaloids  
 
Bisbenzylisoquinoline (BBIQ) alkaloids are among different large classes of alkaloids 
common in plant species. BBIQ alkaloids are prevalent in the families like 
Menispermeaceae, Annonaceae, Berberidaceae, Monimaiaceae and Ranunuclaceae 
(Angerhofer et al., 1999, Schiff, 1997, Schiff et al., 1979).  
 
 
 
Figure 1.8 Chemical structures of cycleanine and tetrandrine: two typical examples 
of BBIQ alkaloids. 
 
The BBIQ alkaloids are made up of two isoquinolines (‘head part’) linked to two 
benzyl moieties (‘tail part’) through two types of linkage such as head-to-tail (e.g. 
cycleanine) and head-to-head (e.g. tetrandrine). The majority of BBIQ alkaloids are 
produced by combination of two coclaurine units (biscoclaurines), a fewer number by 
combination of coclaurine and reticuline units (coclaurine-reticulines) and in some by 
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condensation of two moieties of reticuline (bisreticulines) (Angerhofer et al., 1999, 
Schiff, 1997, Schiff et al., 1979).  The two moieties could often be largely joined by 
one or more diaryl ether bridge or occasionally by carbon bridges or methylene-oxy 
bridge (Angerhofer et al., 1999). The BBIQ alkaloids are therefore grouped based on 
the nature, the number and location where the bridge is attached.  
Previous reviews on structure, spectra characteristics and botanical structures of 
BBIQ alkaloids have been reported (Guha et al., 1979, Schiff, 1997) . The differences 
in the chemical structures of BBIQ alkaloids are reported to be responsible for their 
varied pharmacological or biological activities (Angerhofer et al., 1999). Many of the 
plants that contain BBIQ alkaloids have been reported to exhibit history of medicinal 
applications traditionally, in treatment of various diseases such as malaria, cancer, 
amoebic dysentery, leishmaniasis, and bacterial infection (Likhitwitayawuid et al., 
1993, Marshall et al., 1994, Angerhofer et al., 1999). The BBIQ alkaloids were 
reported to exhibit varied biological and pharmacological activities including 
cytotoxicity (Likhitwitayawuid et al., 1993), antimalarial (Angerhofer et al., 1999, 
Marshall et al., 1994, Ye & Van Dyke, 2016) anticancer activities (Sun & Wink, 2014, 
Wang et al., 2010), inhibition of histamine release (Nakamura et al., 1992), anti-
leishmanial and anti-trypanosomal effects (Camacho et al., 2002). 
Here, BBIQ alkaloids which have been reported to exert anticancer or antimalarial 
activities are listed or discussed. Lists of BBIQ alkaloids reported in the Web of 
Science from 1990 to 2016, to exert potent in vitro or in vivo anti-cancer or 
antimalarial activity (IC50 < 20 µM) are compiled (Table 1.4). 
Tetrandrine and Fangchinoline 
Previous reports have shown that Tetrandrine (1), fangchinoline (5) and tricordatine 
(36) (Table 1.4) were the only BBIQ reported in Triclisia subcordata to the best of our 
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knowledge (Tackie et al., 1974; Dwuma-Badu et al.,1975; Guha et al., 1979; Uche et 
al., 2016) . Tetrandrine (1) and fangchinoline were also isolated from the dried root of 
Stephenia tetrandra S Moore (Xu et al., 2011, Xiao et al., 2015, Wu et al., 2014, 
Schiff, 1997, Lin et al., 1993, Li et al., 2015) and other botanical sources (Table 1.4) 
(Schiff, 1997). Tetrandrine and fangchinoline exhibited in vitro  pharmacological 
actions, including in vitro anti-cancer (Li et al., 2015, He et al., 2011b) and 
antimalarial activities (Marshall et al., 1994, Lin et al., 1993, Chea et al., 2010, 
Angerhofer et al., 1999, Ye & Van Dyke, 2016). They have been reported to cause   
in vitro inhibition of proliferation, and induced apoptosis of hepatoma, breast cancer 
and leukaemia  cells  (Sun & Wink, 2014, Chen et al., 2010, He et al., 2011b, Chen 
et al., 2009, Deng et al., 2015). Li et al showed that, in vitro antiproliferative effects of 
Fangchinoline on human prostate cancer cells could be due to its contributed by its 
suppression on of the proteasome β1 subunit (Li et al., 2015b). 
Report from an in vitro study has shown that BBIQ alkaloids, such as tetrandrine 
could have clinical applications in China for treatment of diseases like lung cancer, 
leukaemia and amoebic dysentery (Mashall et al., 1994).  Evidence showed that 
tetrandrine could suppress metastatic phenotype of prostatic cancer (Kou et al., 
2016), induce apoptosis of colon cancer and inhibition of xenograft tumour growth by 
inhibition of Wnt-β-catenin signalling (He at al., 2011). Tetrandrine potentiated activity 
of the anti-cancer drugs like daunorubicin, vinblastine, doxorubicin in the P-
glycoprotein (P-gp) expressing multi-drug resistance (MDR) cell line (Liu et al., 2013, 
Liu et al., 2000, Liu et al., 2015). Tetrandrine was reported to exert radio-sensitization 
effects, MDR reversal and anti-proliferation effects on the malignant brain tumour 
(gliomas) (Chen et al., 2010). 
39 
 
In one study, tetrandrine  reduced the paclitaxel concentration required to achieve 
50% inhibition of cell growth to HCT15 (P-gP-positive) cells about 3100-fold, while  
did not affect the accumulation and residual rate of rhodamine 123 in SK-OV-3 (P-gp-
negative) cells (Yu-Jen, 2002, Li et al., 2015) . Therefore, tetrandrine was concluded 
to enhance the cytotoxicity of drugs via modulation of P-gP in the resistant cancer 
cells (Yu-Jen, 2002, Li et al., 2015). Tetrandrine could also increase growth 
suppression and apoptosis induced by cisplatin and cause redistribution of the cell 
cycle in ovarian cancer cells (Yu-Jen, 2002, Li et al., 2015).  In vivo tetrandrine and 
cisplatin exhibited synergistic and growth inhibition effects, which supported the 
application of tetrandrine as an adjunct to cisplatin in the chemotherapy of ovarian 
cancer (Zhang et al., 2011). Tetrandrine in combination with doxorubicin showed a 
significant synergistic effect in multidrug resistant Caco-2 and CEM/ADR5000 cancer 
cells. It could also reverse the multidrug resistance by reducing the expression of P-
glycoprotein (Sun & Wink, 2014, Liu et al., 2015) Tetrandrine has been demonstrated 
to exert potent antimalarial activities as well as synergism with chloroquine in both 
chloroquine sensitive and resistant strains of falciparum malaria (Plasmodium 
falciparum) with little toxicity (Ye & Van Dyke, 2016). 
Ye and Van Dyke also demonstrated the in vitro antimalarial activities and the 
combination therapy of other BBIQ alkaloids like isotetrandrine (2), phaeanthine (3), 
pycynamine (4), fangchinoline (5), berbamine (6), obamegine (7), cycleanine (8), 
cepharanthine (10), methoxyadiantifolin (11), and thalicarpine (12) with respect to 
their IC50 and as ratio of chloroquine (CQ) sensitive to CQ resistant strain of P. 
falciparum respectively as shown (Table 1.4). The link between the ether bridges in 
the bisbenzylisoquinoline probably had essential contribution in the antimalarial 
function of BBIQ alkaloids (Ye and Van Dyke, 2015). Cepharanthine (10), 
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stephilababerine (19), Obaberine (20), daphnandrine (21), norobaberine (22), 2–
norethalrugosine (34), and 2–norcepharanthine (23) all from tubers of Stephania 
erecta Craib (Menispermaceae) were reported to exert antimalarial and non-selective 
cytotoxicity (Likhitwitaywuid et al., 1993). 
Reports have also shown the multidrug resistant (MDR) proteins in both cancer and 
malaria exhibit similar genetic sequence (Ye and Van Dyke, 2015). It was reported 
that decrease in the lipophilicity of BBIQ alkaloids could lead to decrease in 
cytotoxicity and anti-plasmodial activity due to alteration in cell membrane 
permeability (Angerhofer et al., 1997). The pharmacological activity of BBIQ alkaloids 
was demonstrated to be affected by their configurations and type of aromatic 
substituents present in the BBIQ alkaloids (Angerhofer et al., 1997). Since most of 
antimalarial and anticancer BBIQ alkaloids bind to MDR pump to elicit their effects, it 
is more likely that water soluble BBIQ alkaloids could exert more potent antimalarial 
and anticancer activities against MDR strains than the fat-soluble ones (Ye and Van 
Dyke, 2015). Penduline (71) was also shown to exert antiplasmodial effect (Valentin 
et al., 1997). 
Angerhofer et al reported the antimalarial effects of 53 BBIQ on both chloroquine 
sensitive (D6) and resistant strains (W2) (Table 1.4 Compound 1 - 53).  This report 
revealed the IC50 of the 53 BBIQ to be in range of 29 – 1530 nM for the chloroquine 
sensitive D6 and 59 strains and greater than 16400 nM in the resistant W2 strain 
(Table 1. 4) (Angerhofer et al., 1999, Marshall et al., 1994, Likhitwitayawuid et al., 
1993, Kaur et al., 2009, Saxena et al., 2003). The compounds with most antimalarial 
selectivity among the 53 BBIQ reported included cycleanine (8), tecmuconine (14), 
malekulatine (15), and repandine (24) (Angerhofer et al., 1999; Kaur et al., 2009). 
Mashall et al reported the antimalarial activities of 24 BBIQ on chloroquine resistant 
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strain of P. falciparum (Table 1.4; Compound (55-69)). Among the 24 BBIQ the range 
of IC50 of antimalarial agent was found to be 0.1 – 89 µM for thalisopidine (58) and 
cocsuline (64) (Table 1.4) (Mashall et al., 1994).  Antimalarial activity of some other 
BBIQ alkaloids have also been reported, such as curine (43) (IC50 = 353 nM) and 
isochondodendrine (63) (IC50 = 892 nM) from the bark of Isolona ghesquiereina 
(Mambu et al., 2000, Kaur et al., 2009), Penduline (71) (2.8 µM) (Valentin et al., 
1997), rodiasine (72) (1.1 µM) (Roumy et al., 2007, Kaur et al., 2009), 
norcepharanthine, cepharanoline and fangchinoline (0.2 - 0.3 µM) (Chea et al., 
2010). Costaricine (18) was demonstrated to be the most bioactive antiplasmodial 
BBIQ alkaloids among the 16 isolated from Nectandra sacicfolia (H.B.K) Nees 
(Lauraceae) with IC50 of 50 ng/ml (the chloroquine-sensitive D6) and 294 ng/ml (the 
chloroquine-resistant W2) (Böhlke et al., 1996).Cepharanthine (10) was among the 
BBIQ alkaloids shown to be active against malarial parasites (Angerhofer et al., 
1999). 
Stebisimine (73), puetogaline B (74) ,1,2-dehydrotelobine (75), and 2′-norcocsuline 
(40), and isolated from Anisocycla grandidieri Baill. (Menispermaceae) were reported 
to exert antiproliferative activity against cancer cell lines including ovarian, breast and 
hepatocellular carcinoma (Liu et al., 2013). Marshall et al demonstrated the 
antiplasmodial activity and cytotoxicity of 16 BBIQ (Table 1.4; 5-7, 55, 56, 60-69). 
Berbamine (6), obamegine and thalisopidine (59) showed very potent antiplasmodial 
activity relative to other BBIQ alkaloids, with IC50 less than 1 µM. Berbamine (6) also 
exerted the highest cytotoxicity. Cyleapeltine (15), homoaromaline (27), limacine 
(28), and tharugosine (29) all from Cyclea barbata (Wall) (Menispermaceae) were 
reported to exhibit cytotoxicity and antimalarial activities (Lin et al., 1993). 
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Table 1.2 List of antimalarial BBIQ alkaloids with IC50 on P falciparum CQ-sensitive 
and resistant strains. 
 
Antimalarial BBIQ, 
Compound number 
and / botanical 
source(s) (family) 
Chemical Structures  
 
IC50 (µM) References 
D6     W2 
Tetrandrine (1) 
Stephania tetrandra S. 
Moore; Cocculus 
pendulus; Cyclea 
barbata; Cyclea 
burmanni; Pachygone 
dasycarpa, 
(Menispermaceae)   
 
 
 
 
0.2-
2.9 
0.2-
1.2 
 
 
Ye and 
VanDyke, 
2015, 
Angerhofer et 
al., 1999; 
Lin et al. 
1993. 
Isotetrandrine (2) 
Stephania erecta. 
Cocculus pendulus, 
Stephania 
cepharantha 
(Menispermaceae) 
 Berberis heteropoda.  
B. koreana, B. 
nummularia B. 
valdiviana 
(Berberidaceae) 
0.3 -
4.8 
0.1 -
1.4 
Ye and 
VanDyke, 
2015, 
Angerhofer et 
al. 1999, 
Marshal et 
al.1994, 
 
Schiff, 1997. 
Phaeanthine (3) 
Phaenthus 
Ebractedatis 
Cyclea burmann,   
Phaeanthus 
crassipetalus 
(Menispermaceae).      
0.3 -
6.0 
 
 
0.5-
5.0 
 
 
Ye and Van 
Dyke, 2015; 
Angerhofer et 
al., 1999 
Marshal et 
al., 1994. 
Pycnamine (4) 
Pycnarrhena 
manillensis Vidal 
        
 0.8 -
3.8 
 
0.8 -
4.2 
Ye and Van 
Dyke, 2015; 
Marshal et 
al.1994 
Fangchinoline (5) 
Stephania rotunda   
Lour., S. tetrandra 
Radix Pachgona 
dasycarpa, 
Strychnopsis thourasil  
(Menispermacaea).   
 
 
 
 
 
- 
0.3 -
2.2 
 
 
 
 
 
Ye and Van 
Dyke, 2015, 
Desgrouas et 
al. 2014, 
Chea et al., 
2010, 
Angerhofer et 
4
2
3 6
7
8
9
10
11
13
14
3'
4'5'
9'
N
CH3
H3CO
H
N
CH3
OCH3
H O
OCH3
O
10'
11'
12'
13'
14'
5
1
1'
8'
2'
Phaeanthine    R, R  
Isotetrandrine  R, S
Tetrandrine     S, S
43 
 
 
al., 1999, 
Marshal et al. 
1994, Schiff. 
1997 
Berbamine (6) 
 
Berberis aggregata   
(Berberidaceae), 
Cyclea barbata, 
Stephena cepharantha 
(Menispermaceae)  
0.1-
4.6 
0.3-
1.9 
Ye and Van 
Dyke, 2015; 
Angerhofer et 
al., 1999; 
Marshal et al. 
1994, Schiff 
1997. 
Obamegine (7) 
  
Stephania 
cepharantha Hayata 
(Menispermacaea).  
 
 
 
0.4 -
6.6 
0.5-
4.8 
Ye and Dyke, 
2015, 
Angerhofer et 
al. 1999, 
Marshal et al. 
1994, 
Schiff, 1997. 
Cycleanine (8) 
Stephania 
cepharantha 
Hayata 
(Menispermaceae) 
 
 7.0 
 
9.7 
 
 
Ye and Van 
Dyke, 2015, 
Angerhofer et 
al., 1999.  
 
 
 
 
 
 
 
 
 
 
 
 
4
2
3 6
7
8
9
10
11
12
13
14
3'
4'5'
9'
N
CH3
H3CO
O
H
R2
N
CH3
OCH3
H O
R1
10'
11'
12'
13'
14'
5
1 1'
8'
2'
Berbamine           R, S     OCH 3      OH
Fangchinoline      S, S      OH        OCH 3
Pycnamine       R, R     OCH3     OH
                                                      R 1           R 2
4
2
3 6
7
8
9
10
11
12
13
14
3'
4'5'
9'
N
CH3
H3CO
O
H
OH
N
CH3
OCH3
H O
OH
10'
11'
12'
13'
14'
5
1 1'
8'
2'
Obamegine  R, S
N CH3
H
N
H
CH3
OCH3
OCH3
H3CO
O
O
H3CO
Cycleanine   R, R
44 
 
Hernandezine (9) 
Cocculus pendulus 
(Menispermaceae) 
Thalictrum flavun L 
(Ranunculaceae) 
 
3.7 1.3 Ye and Van 
Dyke, 2015, 
 
Schiff, 1997. 
Cepharanthine (10) 
Stephania 
cepharantha Hayata   
 
 
Stephania erecta Criab  
 
(Menispermaceae)   
 
 
0.2 - 
17 
 
1.2-
13 
 
 
 
0.5 – 
1.3 
 
Ye and Van 
Dyke 2015; 
Angerhofer et 
al. 1999, 
 
Likhitwitayaw
uid et 
al.,1993; 
Saxena et al., 
2003 
Methyoxyadiantifoline 
(11) 
 
 
 
32 42 Ye and Van 
Dyke, 2015 
Thalicarpine (12) 
Thalictrum 
dasycarpum Fish & 
Lall 
(Rannuclaceae) 
10 9.4 Ye and Van 
Dyke, 2015 
  
N
CH3
OCH3
OCH3
H3CO
N
CH3
H3CO
O
O
OCH3
4
1
2
3 6
7
8
9
10
11
12
13
14
1'
3'
4'5'
9'
8'
10'
11'
12'
13'
14'
5
Hernandezine  S, S  
4
2
3 6
7
8
9
10
11
12
13
14
3'
4'5'
9'
N
CH3
O
O
OOCH3
N
CH3
OCH3
O
HH
10'
11'
12'
13'
14'
5
1
1'
8'
Cepharanthine  R, S
N
CH3
OCH3
R
N
CH3
H3CO
O
O
H
H
4
1
2
3 6
7
8
9
10
11
12
13
14
1'
3'
4'5'
9'
8'
10'
11'
12'
13'
14'
5
Methoxyadianthifoline  S, S    R  =   OCH 3
Thalicarpine                  S, S   R =  H
2'
45 
 
Antimalarial BBIQ 
alkaloids 
  Chemical structure IC50 (µM) 
 
References 
D6                             W2 
Neothalibrine (13) 
 
Thalictrum revolutum 
DC. 
 
0.04
7 
0.215 Angerhofer et 
al.,1999 
Temuconine (14) 
Aristolochia elegans 
(Aristolochiaceae) 
0.21
3 
0.227 Angerhofer et 
al.,1999 
 
Malekulatine (15) 
 
Hernandia Sonora L 
(Hernandiaceae) 
 
0.06
1 
0.164 Angerhofer et 
al., 1999 
 
 
Schiff ,1997 
Cycleapeltine (16) 
 
Cyclea barbata (Wall) 
Miers 
(Menispermaceae) 
 
 
0.04
8 
0.067 Angerhofer et 
al.,1999 
Limacusine (17) 
Anisocycla jollyana 
(Menispermaceae) 
0.06
4 
0.192 Angerhofer et 
al., 1999 
 
 
4
2
3 6
7 NN
H
O
H
OCH3
CH3
OCH3
OCH3
OR1 OR2
CH3
9
10
11
13
14
3'
4'5'
9'
10'
11'
12'
13'
14'
5
1
8'
2'
8
7'
                                            R1        R 2
Neothalibrine   S, S          H         CH 3
Temuconine     R, S       CH3      H
4
2
3 6
7 NN
H
HCH3
OCH3
OCH3
OH
CH3
O
OH
H3CO
OCH3
OCH3
9
10
11
14
3'
4'5'
9'
10'
11'
12'
13'
14'
5
1
8'
2'
8
7'
Malekulatine   R, S
4
2
3 6
7
9
10
11
14
3'
4'5'
9'
10'
11'
12'
13'
14'
5
1
8'
2'
8
7'
N
H
R2O
CH3R1O
N
H
CH3
OCH3
OR3
O
O
                                          R1      R 2      R 3
Cycleapeltine  S, S         H        CH3      CH3
limacusine    R , R         H       CH3      CH3
46 
 
Costaricine (18) 
Nectandra sacicfolia 
(H.B.K) Nees 
(Lauraceae) 
 
 
 
0.05
0 
0.294 Bohlke et al., 
1996 
 
 
Stephibaberine (19) 
Stephania erecta  
(Menispermaceae). 
 
 
 
0.21
4 
0.510 Angerhofer et 
al.,1999 
 
Likhitwitaywui
d et al., 1993 
Obaberine (20) 
Berberis heterobotrys 
(Berberidaceae) 
Stephenia erecta 
Craib 
(Menispermaceae) 
0.37
1 
0.341 Angerhofer et 
al.,1999 
 
 
Schiff, 1997 
 
Daphnandrine (21) 
Stephania erecta 
Craib. 
(menispermaceae) 
 
 
0.10
6 
0.375  
 
Angerhofer et 
al.,1999 
 
 
 
Schiff, 1997 
2-norobaberine (22) 
Stephania erecta 
Craib. 
(menispermaceae) 
0.07
5 
0.154 Angerhofer et 
al.1999;  
 
Schiff, 1997 
 
2-norcepharanthine 
(23) Stephania 
totunda Lour. 
(Menispermacaea)  
0.07
9 
0.219 
 
0.300 
Angerhofer et 
al.,1999; 
Chea et al., 
2010; 
(Desgrouas 
et al., 2014). 
Repandine (24)    Angerhofer et 
4
1
2
3 6
7
8
9
10
11
12
13
14
1'
3'
4'5'
9'
8'
10'
11'
12'
5
Costaricine
N
H
OCH3
OH
H
N
H
H3CO
O
H
OCH3
OH
4
2
3 6
7
9
10
11
14
3'
4'5'
9'
10'
11'
12'
13'
14'
5
1
8'
2'
8
7'
N
H
R2O
CH3R1O
N
H
CH3
OCH3
OR3
O
O
Obaberine         R, S       CH3    CH3     CH3
                 R1        R 2       R 3
Stephibaberine  R , S    CH 3       H       CH3
4
2
3 6
7
9
10
11
14
3'
4'5'
9'
10'
11'
12'
13'
14'
5
1
8'
2'
8
7'
N
H
R2O
CH3R1O
N
H
H
OCH3
OCH3
O
O
2 - norobaberine           R, R     CH3     CH3     
2 - norcepharanthine  R, R       CH 2     CH2     
                                 R1        R 2       
Daphnandrine            R , R       H         CH3
47 
 
Cyclea barbata 
(Menispermacaea) 
 
 
 
 
 
0.04
2 
 
0.067 
al.1999; 
Schiff ,1997 
 
 
 
Candicusine (25) 
Curarea candicans   
 Barneby & Kurkoff 
(Menispermaceae) 
0.02
9 
0.105 Angerhofer et 
al.,1999 
Aromoline (26) 
Berberis heteropoda 
(berberidacaea) 
Stepehania 
cepharantha Hayata 
(Menispermaceae) 
 
 
 
0.44
6 
1.4 
 
Angerhofer et 
al.,1999; 
 
Marshall et 
al. 1994 
 
 
Schiff 1997 
Homoaromaline (27)  
Cyclea barbata (Wall) 
Miers 
Anisocycla 
jollyana(Pierre) Diels 
(Menispermaceae) 
0.17
3 
  
0.23
2 
 
0.474
; 
 
0.451 
Angerhofer et 
al.1999; 
Marshall et 
al. 1994; 
Lin et al., 
1993; 
 
Schiff, 1997 
Limacine (28) 
Spirospermum 
penduliforum Thou 
Phaeanthus 
crassipetalus Becc 
(Menispermaceae) 
 
 
 
86 
53 
 
263 
164 
 
 
Angerhofer et 
al.,1999; 
Lin et al.., 
1993 
Thalrugosine (29) 
Cyclea barbata, 
Stephenia erecta 
(Menispermaceae) 
0.19
9; 
0.06
5 
0.374
; 
0.078 
Angerhofer et 
al.,1999; 
Lin et al.., 
1993 
Atherospermoline 
(30) 
Pachygone  
dasycarpa 
0.23
2 
0.623 Angerhofer et 
al.1999 
4
2
3 6
7 NN
H
O
H
OR2
CH3
OCH3
H3CO
CH3OR1
O
9
10
11
13
14
3'
4'5'
9'
10'
11'
12'
13'
14'
5
1
8'
2'
8
7'
                                                       R1         R 2     
Limacine                    R, R       H        CH 3
Thalrugosine               R, S      H         CH 3
Artherospermoline     S, S      H          H  
4
2
3 6
7
8
9
10
11
13
14
3'
4'5'
9'
N
R3
H3CO
H
N
CH3
OCH3
H O
R1
12
O
R2
10'
11'
12'
13'
14'
5
1
1'
8'
2'
                     R1               R2              R3
Homoaromaline     R, S          OH             OCH 3         CH3
Aromaline           R, S             OH              OH            CH3
48 
 
N-methyl-7-O-
desmethylpeinamine 
(31) Pachygone 
dasycarpa 
 
 
0.13
4 
0.609 Angerhofer et 
al.1999 
2-Norberbamine (32) 
Pycnarrhena ozantha 
Diels 
(Menispermaceae) 
 
 
0.04
7 
0.193 Angerhofer et 
al.1999 
2-norisotetrandrine 
(33) 
0.10
6 
0.728 Angerhofer et 
al.1999 
2-northalrugosine 
(34) 
Pycnarrhena ozantha 
Diels 
(Menispermaceae) 
0.11
5 
0.21 Angerhofer et 
al.,1999 
 
Tricordatine (36) 
Pachygone 
dasycarpa 
(Menispermaceae) 
 
 
0.09 0.259 Angerhofer et 
al.1999, 
 
Schiff, 1997 
12-O-
methyltricordatine 
(37) Pachygone 
dasycarpa 
0.03 0.112 Angerhofer et 
al.1999 
N-methyltelobine 
(38) 
 
0.16
9 
0.451 Angerhofer et 
al.1999 
4
2
3 6
7 NN
H
O
H
OH
CH3
OCH3
H3CO
CH3OH
O
9
10
11
13
14
3'
4'5'
9'
10'
11'
12'
13'
14'
5
1
8'
2'
8
7'
N-methyl -7- O-desmethylpeinamine  S, R   
4
2
3 6
7 NN
H
O
H
OR2
H
OCH3
H3CO
CH3OR1
O
9
10
11
13
14
3'
4'5'
9'
10'
11'
12'
13'
14'
5
1
8'
2'
8
7'
                                        R1            R 2
2 - norberbamine      S,S      CH3        H
2 - northalrugosine   S, S       H        CH3  
4
2
3 6
7
9
10
11
13
14
3'
4'5'
9'
10'
11'
12'
13'
14'
5
1
NN
H
O
H
OR2
CH3
CH3
R1O
O
O
2'
8
7'
                                                   R1          R 2
Tricordatine                        S, R       H          H
12 -O - methyltricordatine   S, R       H        CH 3  
N - methyltelobine                S, R      CH3    CH3
49 
 
 
  
Cepharanoline (39) 
Stephania rotunda 
Lour. 
(Menispermacaea)   
 
 
0.2        - Chea et al., 
2010; 
 
Desgrouas et 
al. 2014 
 
2′-Norcocsuline (40) 
Pachygone 
dasycarpa 
(Menispermaceae) 
 
 
0.48 0.281 Angerhofer et 
al.,1999 
1,2-dehydrotelobine 
(41) 
Anisocycla Jillana 
(Pierre) Diels 
(Menispermaceae) 
 
0.55
4 
0.464 Angerhofer et 
al.1999; 
 
 
Schiff, 1997 
4
2
3 6
7
8
9
10
11
12
14
3'
4'5'
9'
10'
11'
12'
13'
14'
5
1
1'
8'
N
CH3
H
N
CH3
OCH3
H
OH
O
O
O
O
Cepharanoline
4
2
3 6
7
9
10
11
13
14
3'
4'5'
9'
10'
11'
12'
13'
14'
5
1
NN
H
O
H
OH
CH3
H
H3CO
O
O
2'
8
7'
2' - norcocsuline                       
4
2
3 6
7
9
10
11
13
14
3'
4'5'
9'
10'
11'
12'
13'
14'
5
1
NN
H
O
H
OCH3
CH3
H
H3CO
O
O
2'
8
7'
1, 2 - dehydrotelobine                     
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Antimalarial BBIQ 
alkaloids 
Chemical structure IC50 (µM) 
           
References 
D6 W2 
Thalmirabine (42) 
Thalictrum 
foetidum 
Thalictum minus 
(Ranunculaceae) 
 
 
 
0.2
24 
0.11
0 
Angerhofer et 
al.,1999 
 
 
(-)-curine (43) 
Cissampelos 
muccronata, 
Cyclea barbata, 
Stephania epigeae 
(Menispermacaea) 
 
0.1
28 
0.38
7; 
0.35
3 
Angerhofer et 
al.,1999; 
 
Mambu et al., 
2000, 
 
Kaur et al., 
2009 
 
Schiff, 1997 
(+)-2′-
norcuricycline (44) 
 
0.5
3 
0.67
6 
Angerhofer et 
al.,1999 
 
 
2′-
norisocuricycline 
(45) 
1.2
7 
0.66
2 
Angerhofer et 
al.,1999 
curicycleatjenine 
 (46) Cyclea 
atjehensis Forman 
(Menispermaceae) 
2.3
2 
1.20 Angerhofer et 
al., 1999 
Isocuricycleatjine 
(47) Cyclea 
atjehensis Forman 
(Menispermaceae) 
6.8
9 
4.03 Angerhofer et 
al., 1999 
Isocuricycleatjenin
e (48) 
Cyclea atjehensis 
Forman 
(Menispermaceae) 
0.6 1.05 Angerhofer et 
al.,1999 
4
2
3 6
7
9
10
11
13
14
3'
4'5'
9'
10'
11'
12'
13'
14'
5
1
N
N
H
O
H
OCH3
CH3
CH3
OCH3
OCH3
H3CO
O
H3CO 2'
8
7'
Thalmirabine                    
N CH3
H
N
H
CH3
OCH3
OH
H3CO
O
OCH3
O
Curine
N R2
H
N
H
CH3
H3CO
O
OR1
O
O
O
                                           R1     R 2
2'- norcuricycline        R, S    CH3    H
2' - norisocuricycline  R , R   CH3    H
Curicycleatjenine        S, R    CH3  COCH3
Isocuricycleatjine      R. R       H     COCH3
Isocuricycleatjenine   R, R   CH 3   COCH3
51 
 
Isocuricycleatjehi
mine 
(49) Cyclea 
atjehensis Forman 
(Menispermaceae) 
 
4.9
8 
2.10 Angerhofer et 
al.,1999 
Cycleatjehenine 
(50) 
Cyclea atjehensis 
Forman 
(Menispermaceae) 
 
0.1
15 
0.06
6 
Angerhofer et 
al.,1999 
 
Cycleatjehine (51) 
 
Cyclea atjehensis 
Forman 
(Menispermaceae) 
 
0.1
1 
0.05
9 
Angerhofer et 
al.,1999 
3′,4′-
dihydrocycleatjehe
nine 
(52) Cyclea 
atjehensis Forman 
(Menispermaceae) 
 
 
0.3
46 
0.16
9 
Angerhofer et 
al.,1999 
 
 
2′-noratjecycline 
(53) Cyclea 
atjehensis Forman 
(Menispermaceae) 
 
 
 
0.3
48 
 
 
 
 
0.19
9 
 
 
 
 
 
Angerhofer et 
al.,1999 
 
 
 
 
 
 
 
 
N-acetyl-2′-
noratjecycline (54) 
Cyclea atjehensis 
Forman 
(Menispermaceae) 
1.0
3 
0.60
5 
Angerhofer et 
al.,1999 
Funiferine (55) 
Guatteria boliviana 
(Annonaceae) 
 
 
 
- 0.6 Marshall et al., 
1994 
N
N
H
CH3
OCH3
H3COOR
O
OH
O
CH2
Cycleatjehinine  R = CH 3
Cycleatjehine    R = H
N
N
H
CH3
OCH3
H3COOCH3
O
OH
O
CH2
3', 4'-dihydrocycleatjehenine
NH
N
H
CH3
OCH3
H3COOR
O
OH
O
CH2
H
2' - noratjecycline                   R =  H
N - acetyl
--
2'-noratjeecycline    R = COCH 3
N
N
H
CH3
H3CO
O
OCH3
O
O
O
Isocuricycleatjehimine   
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Tiliageine (56) 
Guatteria boliviana 
(Annonaceae) 
- 6.3 Marshall et al., 
1994 
 
 
 
 
Daphnoline (57) 
 
Pachygone 
dasycarpa 
(Menispermaceae) 
 
 
- 1.0 Marshall et al., 
1994 
 
- 1.1 Marshall et al., 
1994,  
 
Angerhofer et 
al.1999; 
 
Lin et al., 
1993; 
 
Schiff, 1997 
Oxyacanthine HCI 
(58) Berberi spp 
Berberis 
amurensis 
(Berberidaceae) 
Thalisopidine (59) 
Triclisia patens 
(Menispermaceae) 
 
- 0.1 Marshall et al., 
1994,  
Marshall et al., 
1994, 
 
Camacho et 
al., 2002 
 
Tetrandrine   
methiodide (60) 
 
 
- >0.0
65 
Marshall et al. 
1994. 
 
4
2
3 6
7
8
9
10
11
13
14
3'
4'5'
9'
N
R3
H3CO
H
N
CH3
OCH3
H O
R1
12
O
R2
10'
11'
12'
13'
14'
5
1
1'
8'
2'
                     R1               R2              R3
Daphnoline         R, S            OH               OH               H
Oxyacanithine      R, S           OCH3          OH           CH3
4
2
3 6
7
8
9
10
11
12
13
14
3'
4'5'
9'
N
CH3
H3CO
H
N
CH3
OCH3
H O
OCH3
O
OH
10'
11'
12'
13'
14'
5
1 1'
8'
2'
Thalisopidine  S, S
4
2
3 6
7
8
9
10
11
13
14
3'
4'5'
9'
N
+
CH3
H3CO
H
N
CH3
OCH3
H O
OCH3
O
CH3
OCH3
10'
11'
12'
13'
14'
5
1
1'
8'
2'
Tetrandrine  methiodide S, S
53 
 
Dinklacorine (61) 
Tiliacora dinklagei 
Engl 
(Menispermaceae) 
 
- 3.9 Marshall et al., 
1994 
Trigilletimine (63) 
Triclisia gilletii (De 
Wild.) Staner and 
T. patens Oilv., 
(Menispermaceae)
  
 
 
- 42 Marshall et al., 
1994 
Cocsoline (64) 
Cocculus 
pendulus 
(Menispermaceae) 
 
 
 
 
 
- 1.2 Marshall et al., 
1994 
Cocsuline (65) 
Cocculus 
pendulus 
(Menispermaceae) 
- 0.5 Angerhofer et 
al., 1999 
Isotrilobine (66) 
Anisocycla 
jollyana 
(Menispermaceae) 
- 2.1 Marshall et al., 
1994 
Cocsuline 
methiodide (67) 
- >18 Marshall et al., 
1994 
Gilletine (68) 
Stephania 
cepharantha   
 
Hayata 
(Menispermacaea)
. 
 
- 1.8 Marshall et al., 
1994 
4
2
3 6
7
8
9
10
N
CH3
H
N
CH3
OCH3
H
H3CO
O
O
OH
12
13
14
3'
4'5'
9'
10'
11'
12'
13'
14'
5
1 1'
8'
2'
Dinklacorine   R, S
4
2
3 6
7
8
9
10
11
13
14
3'
4'5'
9'
10'
11'
12'
13'
14'
5
1
8'
2'
N
H3CO
N
CH3
H
O
O
O
OCH3
Trigilletimine
4
2
3 6
7
8
9
10
11
13
14
3'
4'5'
9'
10'
11'
12'
13'
14'
5
1
8'
2'
N
H3CO
N
H
O
O
O
H CH3
R2
R1
                                         R 1              R 2
Cocsoline  S, S      H          CH
Cocsuline  S, S      CH3      OH
Isotrilobine  S, S   CH3         OCH3
4
2
3 6
7 NHN
H
O
O
H
OCH3
CH3
OHOCH3
O
9
10
11
13
14
3'
4'5'
9'
10'
11'
12'
13'
14'
5
1
8'
2'
Gilletine S, R
8
7'
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D6 and W2 represent CQ-sensitive and resistant strains of P. falciparum, 
respectively.  
 
  
Insularine (69) 
Cissampelos 
insularis Makino, 
C. 
ochiaiana Yamam
oto (Menispermac
eae) 
 
- 2.1 Marshall et al., 
1994 
Cepharanoline  
(70) 
Stephania rotunda 
Lour. 
(Menispermacaea)   
 
 
- 0.2 Chea et al.  
2010; 
 
Desgrouas et 
al., 2014 
 
Penduline (71) 
Isopyrum 
thalictroides 
(Ranunculaceae) 
  
 
 
 
 
- 
 
 
2.8  
 
Valentin et al., 
1997 
 
Rodiasine (72) 
Pseuoxandra 
cuspidata 
(Annonaceae).  
 
- 1.14
0 
Roumy et al., 
2006; Kaur et 
al., 2009 
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Table 1.3 List of anticancer BBIQ alkaloids. 
 
Anticancer 
BBIQ 
alkaloids/botan
ical source 
chemical structure 
 
Cell lines IC50 
(µM) 
 
Reference 
Tetrandrine (1) 
Stephania 
tetrandra 
 
 
 
HelaG2 
 
Hepatocell
ular 
carcinoma 
cells Huh7, 
U251, 
HCT116 
and A549 
cells 
 
9.0 Likhitwitaywui
d et al., 1993 
 
 
(Likhitwitaya
wuid et al., 
1993a, Mei et 
al., 2015) 
Cycleanine (8) 
Triclisia 
subcordata 
 
 
Ovcar-8 7.4 Uche et al., 
2016 
Stebisimine 
(73) 
Anisocycla 
grandidieri Baill 
(Menispermace
ae) 
 
 
 
A2780 
H460 
MCF-7 
UACC-257 
>10  Liu et al., 
2013 
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Puetogaline B 
(74) 
Anisocycla 
grandidieri Baill 
(Menispermace
ae) 
 
A2780 
H460 
MCF-7 
UACC-257 
>10 Liu et al., 
2013 
1,2-
dehydrotelobine 
(75) 
Anisocycla 
grandidieri Baill 
(Menispermace
ae) 
 
 
A2780 
H460 
MCF-7 
UACC-257 
1.1 – 
6.3 
Liu et al., 
2013 
2’-
norcocsuline 
(40) Anisocycla 
grandidieri Baill 
(Menispermace
ae) 
 
A2780 
H460 
MCF-7 
UACC-257 
2.2 – 
4.2 
Liu et al., 
2013 
Isoliensinine 
(77)  
Nelumbo 
nucifera Gaertn. 
(Nymphaeaceae
) 
 
breast 
cancer 
cells 
MDA-MB-
231cells 
18.3 Zhang et al., 
2015 
 
Paudel and 
Panth, 2015 
liensinine (78) 
Nelumbo 
nucifera Gaertn. 
(Nymphaeaceae
breast 
cancer 
cells 
MDA-MB-
>18 Zhang et al., 
2015 
 
Paudel and 
4
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) 231 Panth, 2015 
Neferine (79) 
 Nelumbo 
nucifera Gaertn. 
(Nymphaeaceae
) 
breast 
cancer 
cells 
MDA-MB-
231cells 
lung 
cancer 
cells 
Hepatocell
ular 
carcinoma 
HCC 
Hep3B 
cells 
>18 Zhang et al., 
2015, Yoon 
et al., 2013, 
Paudel & 
Panth, 2015, 
Poornima et 
al., 2014 
Fangchinoline 
(5) 
 Prostate 
PC-3 cells 
and LnCap 
cells 
- Li et al., 2015 
Cepharanthine 
(10) 
Stephania 
epigeae 
(Menispermace
ae) 
 
cancer cell 
lines 
A-549,  HL-
60, MCF-7, 
SMMC-
7721, and 
SW480 
- Lv et al., 
2013 
 
 
 
 
Liu et al demonstrated the anticancer activities of four BBIQ alkaloids (Table 1.4) 
alkaloids isolated from Anisocycla grandidieri Baill (Menispermaceae) on ovarian 
cancer cell line (A2780), lung cancer cell line (H460), breast cancer (MCF-7), and 
UACC-257 melanoma (Liu et al., 2013). The BBIQ showed anticancer activities with 
IC50 ranging from 1.1 to 20 µM. 2′-Norcocsuline exhibited most growth inhibition 
activity.  
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Murebwayire et al reported that phaentharine (3) isolated from Triclisia sacleuxii 
(Pierre) Diels showed cytotoxicity and antiplasmodial activity (Murebwayire et al., 
2008). The configuration at chiral center and substitution on the aromatic rings of 
BBIQ affect the cytotoxicity and antiplasmodial actions of BBIQ (Angerhofer et al., 
1999). Cepharanthine (10) was reported to exhibit potent anticancer activity on six 
human cancer cell lines (Lv et al., 2013). Fangchinoline (5) caused cytotoxicity in 
prostate breast cancer (Li et al., 2015, Deng et al., 2015). Isoliensinine (77), 
liensinine (78) and Neferine (79) all from Nelumbo nucifera Gaertn (Nymphaeaceae) 
(Mukerhjee et al., 2006) showed cytotoxicity effect on human breast cancer cell lines 
with isoliensinine (77) exerting highest anticancer activity (Zhang et al., 2015). 
Neferine (79) was also demonstrated to exhibit anticancer activity against lung 
cancer cells and hepatocellular carcinoma HCC Hep3B cells (Poornima et al., 2014, 
Yoon et al., 2013). 
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1.6. Selected plants used in this research Study 
1.6.1. Viola philippica Car 
 
Viola philippica Car (family Violaceae) is a perennial shrub that bears an ornamental 
flower (Figure 1.9). It is geographically distributed in China, Japan and North Korea. 
Viola philippica is used in Chinese traditional medicines for the treatment of cancer 
(Deng et al., 2013, He et al., 2011a), pains, inflammatory conditions, detoxification, 
and heat-cleansing (He et al., 2011a, Deng et al., 2013). The young leaves are used 
as edible vegetable (Peng, 2003).  Previous studies have shown that Viola philippica 
contains flavone, actinomycetes (Deng et al., 2013) and cyclotides like Viphi A, 
ViphiB, Mram 8, Viphi D–G, Viba 17, Viba 15, Varv A, Kalata B1 and Cycloviolacin 
O2 (He et al., 2011a). 
 
 
Figure 1.9 Photograph of Viola philippica Car. 
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1.6.2 Viola yedoensis Makino 
 
Viola yedoensis Makino Violaceae is a perennial shrub that produces violet flowers 
(Figure 1.10). Its’ geographical distributions include China, Japan, and Korea. (Wang 
et al., 2007). The dried whole plant of Viola yedoensis (“Zi Hua Di Ding”) is an 
important constituent of the Chinese traditional medicines for the treatment of 
infectious diseases, detoxificant, anti-inflammatory and analgesic. The tender leaves 
are used as vegetable. (Wang et al., 2007) 
 
Figure 1.10 Photograph of Viola yedoensis Makino. 
In Chinese traditional medicine, the decoction of Viola yedoensis is taken as a tea 
and used to resolve toxic heat, swelling, carbuncles, sores, boils, treat snake bites, 
bronchitis, hepatitis, acute nephritis, appendicitis, and enteritis (Wang et al., 2007). 
Some bioactive constituents have been isolated from V. yedoensis and identified 
(Wang et al., 2007) Cyclotides from Viola yedoensis have been reported to inhibit the 
growth of human immunodeficiency virus (HIV) (Wang et al., 2007) and certain 
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bacteria. Some of already identified cyclotides from V. yedoensis include kalata B1, 
varv A, varv E, cycloviolacins Y1, Y2, Y3, Y4, and Y5 (Wang et al., 2007) 
 
1.6.3 Triclisia subcordata Oliv                          
Triclisia subcordata Oliv (Family Menispermaceae) is called Izuzu and Alugboran in 
Ibo and Yoruba (in Nigeria) languages, respectively. It is a slender woody twiner of 
low land rain-forest, with broad- vein and reticulate leaves (Figure 1.11), small 
flowers in short pedunculated clusters and pubescent fruits. Traditionally, the root of 
T. subcordata is used in south eastern part of Nigeria for the treatment of cancer, 
malaria, snake bite, edema, anemia, gout, debility, malnutrition, dropsy, bacterial 
infection, infertility (Abo et al., 2011), anti-inflammatory and as a pain killer (oral 
interview and reports from traditional medicine practitioners in Nigeria). Previous 
studies have been done on pharmacological activities of T. subcordata such as 
antibacterial (Abo et al., 2011), antiulcer and antihistamine activities (Asuzu & Anaga, 
1996). But there is gap in the anticancer and antimalarial in vitro activities of T. 
subcordata. It is therefore, a novel study to evaluate the in vitro these activities of T. 
subcordata and to elucidate the structure of the bioactive principle(s) of T. 
subcordata. A previous study has identified and reported a few alkaloids from T. 
subcordata. Phytochemical studies in the 1970s revealed the presence of only three 
BBIQ alkaloids such as tricordatine (Tackie et al., 1973; Guha et al., 1979), 
fangchinoline (Tackie et al., 1974), and tetrandrine (Dwuma-Badu et al.,1975; Guha 
et al., 1979) from T. subcordata.  It is possible that T. subcordata may likely contain 
more alkaloids. Plants from Menispermaceae family have been revealed to be rich in 
alkaloids. BBIQ alkaloid is among the commonest alkaloids present in 
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Menispermaceae family. This study therefore, also targets to identify and semi-
synthesize novel bioactive anticancer and antimalarial alkaloids. 
It is in the light of this, that this study seeks to contribute in the closure of this gap 
created. It probably could help to establish for the first time, a scientific data on the 
anticancer and more information on antimalarial activities of T. subcordata. 
 
 
                       
Figure 1.11 Photograph of Triclisia subcordata. 
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1.6.4 Cylicodiscus gabunensis Harms  
 
Cylicodiscus gabunensis Harms is a member of the plant family of Mimosaceae. It is 
a large tree of about 180-200ft (Okokon et al., 2006) in height which is prevalent in 
tropical rain forest of west and central Africa (Tene et al., 2011) The stem bark is 
traditionally used in Nigeria and Cameroon for the treatment of cancer, malaria, 
fever, headache, filariases, rheumatism and gastrointestinal problems (Okokon et al., 
2006, Tene et al., 2011). Some studies have reported on the antibacterial, 
antidiarrheal, in vivo antimalarial activities, and bioactive constituents like triterpenoid 
saponins, a diterpene derivative called cyclodione and coumestan glycosides of C. 
gabunensis (Tchivounda et al., 1991, Kouitcheu et al., 2006, Okokon et al., 2006, 
Tane et al., 1995, Nchancho et al., 2009, Tene et al., 2011). Therefore, the rationale 
for the use of this plant as traditional remedy has created the need to demonstrate 
scientifically that the molecules in this plant may possess therapeutic effect against 
cancer and malaria.  
 
Figure 1.12 Photograph of Cylicodiscus gabunensis (Ayarkwa & Owusu, 2008). 
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1.7 Aims and Objective of this study 
1.7.1 The aims of this research are to: 
 investigate the anticancer or antimalarial activities of Viola philippica, V. 
yedoensis, Triclisia subcordata, and Cylicodiscus gabunensis; 
 evaluate and characterize the anticancer-cyclotides of Viola philippica and 
yedoensis 
 Evaluate the anticancer and antimalarial activities and elucidate the structures 
of alkaloids from Triclisia subcordata. 
 Carry out semi-synthesis or modification of bioactive alkaloids of T. subcordata 
(cycleanine) and determine the anticancer and antimalarial effects of the semi-
synthesized products. 
 Determine the molecular mechanism of cell death caused by the identified 
alkaloids on ovarian cancer cell lines. 
 monitor cell distribution and uptake of cycleanine and semi-synthesized 
cycleanine by cells  
 To evaluate the anticancer and antimalarial effects of extract of C. gabunensis  
 
1.7.2     Objectives of this study include: 
 To carry out the extractions of V. philippica and yedoensis, T. subcordata, 
and C. gabunensis.  
 To screen V. philippica, V. yedoensis, T. subcordata, and C. gabunensis 
extracts and fractions for in vitro anticancer activities. 
 To carry out in vitro antimalarial activities of T. subcordata, and C. 
gabunensis fractions and extracts. 
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 To isolate, purify and identify purified cyclotides from V. philippica and 
yedoensis. 
 To carry out electrospray mass spectrometry, MALDI-TOF mass 
spectrometry analysis, to determine the masses and characterize the 
cyclotides of V. philippica and yedoensis. 
 To characterize bioactive cyclotides responsible for the anticancer activities 
of V. philippica and yedoensis. 
 To carry out bio-assay guided assay on the crude extracts, fractions and total 
alkaloids of T. subcordata. 
 To isolate and purify the bioactive alkaloids of T. subcordata by 
chromatography techniques such as silica gel column, thin layer 
chromatography (TLC), and both analytical and semi-preparative HPLC. 
 To carry out liquid chromatography-mass spectrometry (LC-MS) and nuclear 
magnetic resonance (NMR) spectroscopy analysis, to determine the 
structures of anticancer and antimalarial bioactive alkaloids of T. subcordata. 
 To carry out caspase 3/7 activity assay on the identified alkaloids and 
cyclotides to determine the level of caspase activation. 
 To do western blot or immunoblotting assay to check for the cleavage of poly 
ADP ribose (PARP cleavage) on cancer cell lines. 
 To quantitatively and qualitatively evaluate the DNA fragmentation caused by 
apoptosis of some of the identified alkaloids on ovarian cancer cell line by 
use of flow cytometry. 
 To evaluate the cell fluorescence activity/cell distribution of the semi-
synthesized cycleanine by use of fluorescence microscopy and azide-
containing dye (via click chemistry). 
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Hypothesis 
The overarching research question that prompted this study has been the traditional 
uses of Viola philippica, V. yedoensis, Triclisia subcordata, and Cylicodiscus 
gabunensis in treatment of cancer and malaria. This issue has generated hypotheses 
in this study which states that: 
 Viola philippica, V. yedoensis, Triclisia subcordata, and Cylicodiscus gabunensis 
exert cytotoxicity on ovarian cancer cells and antimalarial activity on plasmodium 
falciparum. The molecular mechanism of cell death induced by bioactive compounds 
from Triclisia subcordata is probably by apoptosis. 
Therefore, to test the above hypotheses in this study, four different ovarian cancer 
cells were employed in this research to demonstrate the cytotoxicity of the identified 
bioactive novel or test compounds (natural products) on both sensitive and chemo 
resistant strains of ovarian cancer cells and on plasmodium falciparium strain for 
antimalarial activity. 
Therefore, the rationale for this study is the use of these plants as traditional 
remedies has created the need to identify the molecules in them that may possess 
therapeutic activity. 
 Also, the choice of combination of plant families used in this study was based on 
diverse interest of financial sponsor, student and supervisor since there was no 
relationship among the plant families used in this research. As a pharmacognosist, I 
developed interest on the identification of novel bioactive compounds responsible for 
the cytotoxicity and antimalarial activity of Triclisia subcordata after an oral interview 
with traditional medicine practitioner in Nigeria who claimed that Triclisia subcordata 
is ‘a very powerful remedy ‘in Nigeria for traditional treatment of malaria and cancer. 
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Already I had pre-existing research proposal on evaluation of stem bark of 
Cylicodiscus gabunensis for its malaria and cancer treatment because throughout my 
childhood, Cylicodiscus gabunensis was used by my parents as traditional remedy in 
treating us malaria. So, having recognized these two plants as strong traditional 
remedy for both cancer and malaria, a research proposal was made and gained 
funding from Nigerian government (NDDC and ETF) to sponsor this research. The 
aim was to determine the bioactive components of these plants and to ascertain 
authenticity of the claims by the traditional medicine practitioners. 
However, my supervisor (Dr Wen-Wu Li) had different research interest focused on 
Viola yedeonsis and Viola philippica which he revealed to me after presenting my 
sponsor’s approved research proposal. Literature also revealed that Viola yedeonsis 
and Viola philippica have application in Chinese traditional medicine, in combination 
therapy for treatment of cancer. This prompted the combination of the four plants 
selected in this study. This was to marry the interest of financial sponsor, supervisor 
and student. 
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CHAPTER TWO 
MATERIALS AND METHODS 
 
2.1 Viola philippica Cav. and Viola yedoensis Makino 
2.1.1    Plant materials and reagents 
The aerial parts of Viola philippica Cav. were collected from Yongchuan, Chongqing, 
China in April 2012. The plant was identified by Prof. Qian Wang, Chengdu Institute 
of Biology, Chinese Academy of Sciences, and a voucher specimen was deposited in 
the herbarium of Chengdu Institute of Biology, Chinese Academy of Sciences.  The 
aerial parts of Viola yedoensis Makino (Synonym for V. philippica var. philippica) 
produced in Jiangsu Province, China were purchased from herbal medicine shop, 
Chongqing, China. A voucher specimen (No. ISTM004) was deposited in the Institute 
for Science and Technology, Keele University.    
All the chemicals used were of analytical grade. Methanol, ethyl acetate, 
dichloromethane, chloroform, acetonitrile and trifluoroacetic acid (TFA) were products 
of Sigma-Aldrich. Trypsin-ultra, mass spectrometry grade (Bio Labs), endo-
proteinase GluC (Bio Labs), formic acid, zip tip (Millipore), ammonium bicarbonate 
(NH4HCO3), Tris (2-caboxyethyyl) phosphine hydrochloride (TCEP) (Thermo 
Scientific, UK). 
2.1.2 Extraction and purification of cyclotides from V. philippica and V. 
yedoensis 
The extraction of V. philippica and V. yedoensis crude powder was done by 
previously established method with little modification (Claeson et al., 1998, 
Göransson et al., 2004). Briefly, V. philippica and V. yedoensis crude powder (800g) 
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was pre-extracted with 3.5 L of dichloromethane (CH2Cl2, or DCM) and filtered after 
24 h. This was repeated thrice within 96h. After evaporation of DCM, the DCM extract 
of V. philippica (VP-DCM) and V. yedoensis (VY-DCM) were obtained and kept 
aside. The plant residues were dried and macerated with 3.5 L methanol/water 
(MeOH/H2O, 3:2) daily for 96 h (Figure 2.1). The pre-extraction with dichloromethane 
was important to remove the chlorophyll, fats, and low molecular weight compounds 
that could interfere with the isolation of our targeted metabolites – cyclotides 
(Claeson et al., 1998). The MeOH/H2O crude extract was concentrated, using a 
rotary evaporator, water bath (Grant JB series, temperature at 40-50oC) and vacuum 
pump (V-700 by Buchi). The yields of methanol/water extract for V. philippica (VP-
MW) and V. yedoensis (VY-MW) were 14.6% (116.9g) and 13.9% (111.8g), 
respectively. These crude extracts were subjected to liquid-liquid partition using n-
butanol and H2O. A crude MeOH/H2O extract was dissolved with equal volumes of 
100ml/100ml butanol/H2O and poured into a separating conical flask. Then 250 ml of 
butanol and 250 ml of distilled water were poured into the separating column/flask 
containing the dissolved extract, properly shaken and allowed to settle for 10 - 20 
minutes. The lower aqueous phase was collected and this was repeated thrice 
(Figure 2.1). Their butanol fractions denoted as VP-MW-BU and VY-MW-BU, and 
aqueous fractions denoted as VP-MW-A and VY-MW-A, were separately mixed 
together and dried with rotary evaporator and lyophillizer, respectively.  Ninhydrin 
reagent test for cyclotides was used with thin layer chromatography (TLC) to detect 
the presence of cyclotides in these fractions, per already known procedure with little 
modification (Tan & Zhou, 2006). The Isolation of cyclotides from V. philippica and V. 
yedoensis was done with gel column chromatography of column of 3 x 42 cm length 
loaded with silica gel of 70 – 230 mesh (Sigma-Aldrich) by washing with a mixture of 
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CHCl3 and MeOH with increasing the percentage of MeOH until 100% at the rate of 
70 drops/minute. The mixture of cyclotides was further purified using semi-
preparative HPLC. The reversed-phase HPLC was adopted for purification because 
cyclotides have been reported to appear as late eluting peaks in HPLC (Claeson et 
al., 1998, Goransson et al., 2004, Tan & Zhou, 2006b). Semi-preparative HPLC was 
carried out using Agilent 1220 LC, USA. The mobile phase was a mixture of 0.1 % 
TFA (A) and 80% acetonitrile containing 0.1 % TFA (B). The composition of the 
mobile phase was rising from 10 % to 70 % B over a period of 25 min and kept at 
100 % B for 6 min or 11 min on a semi-preparative HPLC column (Phenomenex, UK; 
Jupiter C18 reverse phase, 300 A, 5 μm particle size, 9.4 × 250 mm) at a flow rate of 
4 ml/min. Eluted fractions at different retention times were collected and freeze-dried 
on a lyophilizer to give purified cylcotides. Thus, two main fractions from V. philippica 
eluted at 18 mins and 19 mins were collected and lyophilized to give VP18 (5mg) and 
VP19 (4mg). Similarly, two major fractions of V. yedoensis eluted at 18 and 19 mins 
were obtained and denoted as VY18 (6mg) and VY19 (5mg), respectively. For 
analysis of the purity of the isolated cyclotides, a gradient from 20 % B to 80 % B 
over a period of 25 min and 100% B for 6 min was applied on an analytical HPLC 
column (Phenomenex, UK; Jupiter C18 reverse phase, 300 A, 5 μm particle size, 4.6 
× 250 mm) at a flow rate of 1 ml/min.   
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Figure 2.1 Flowchart of the extraction and enrichment of cyclotides from plants. 
2.1.3 Mass spectrometric analysis of cyclotides from V. philippica and V. 
yedoensis 
2.1.3.1 Methods for cyclotides reduction, and enzyme digestion  
Reduction of cyclotides by TCEP  
To ca. 6 nmol of cyclotide (~20 µg) in 20 µL of 0.1 M NH4HCO3 (pH 8.0) was added 1 
µL of 0.1 M tris(2-carboxyethyl) phosphine hydrochloride (TCEP) in 0.1 M 
NH4HCO3 (pH 8.0), and the solution was incubated at 65 °C for 10 min (Wang et al., 
2008).   
Trypsin digestion ONLY 
To the 10 µL reduced peptide (10 µg), 0.5 µL of trypsin (0.5 µg/µL) was added, to 
give a final peptide-to-enzyme ratio of 40:1. The trypsin incubation could proceed for 
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1 h at 37 °C. The digestions were quenched by the addition of an equal volume 10 µL 
of 0.5% HCO2H and desalted using Zip tips (Millipore), which involved four washing 
steps [step 1: washing with100% acetonitrile; step 2: washing with 0.5 % HCO2H; 
step 3: absorb digestion peptide samples; step 4: elution in 10 µL of 80% CH3CN (0.5% 
HCO2H)]. Samples were stored at 4 °C prior to analysis. 
A combination of trypsin and endoGlu-C digestion 
To the 10 µL reduced peptide (10 µg), 0.5 µL of trypsin (0.5 µg/µL) was added. The 
trypsin incubation could proceed for 1 h at 37 °C, then 0.5 µL of endoGlu-C (0.5 
µg/µL) was added and a further 3 h incubation at 37 °C. The digestions were 
quenched by the addition of an equal volume of 0.5% HCO2H and desalted using Zip 
tips (Millipore), which involved four washing steps as described above. Samples were 
stored at 4 °C prior to analysis. 
Chymotrypsin digestion ONLY 
To the 10 µL reduced peptide (10 µg), 0.5 µL of chymotrypsin (0.5 µg/µL) was added, 
to give a final peptide-to-enzyme ratio of 40:1. The chymotrypsin incubation could 
proceed for 3 h at 37 °C. The digestions were quenched by the addition of an equal 
volume 10 µL of 0.5% HCO2H and desalted using Zip tips (Millipore), which involved 
four washing steps as described above. Samples were stored at 4 °C prior to 
analysis. 
2.1.3.2 MALDI 4800 MS and MS/MS  
Digested peptides were mixed in a 1:1 ratio (v/v) with α-cyano-4-hydroxycinnamic 
acid (CHCA, 10 mgml-1 in 0.1% TFA, 80% acetonitrile) on a stainless steel MALDI 
target plate, and analysed by a MALDI time-of-flight (TOF/TOF) instrument (MALDI 
4800, AB Sciex, Warrington, Cheshire). 
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2.1.3.3 Liquid chromatography electrospray ionisation/ Mass spectrometry (LC 
ESI/MS) 
Cyclotides, digested and reduced peptide samples were injected onto a Dionex - 
Ultimate 3000 HPLC system (Thermo Scientific) using a 100% buffer A (5% 
acetonitrile (MeCN), 0.1% formic acid) in a 20 µl loop.  Samples were then separated 
using a silica C18 column (Acclaim PepMap 100 C18, Thermo Scientific) following a 
gradient of 0 to 100% buffer B (95% MeCN, 0.1% formic acid) in 60 min. Spectra 
were accumulated using API 3200 triple quadrupled mass spectrometer (AB Sciex) 
using a Nano spray ion source. Spectra were acquired in Q1 mode in 400-1600 amu 
mass range.   
Q-TOF waters micro mass, Q-Tof premier mass spectrometer was also employed in 
LC-MS, and MS/MS of digested peptides or cyclotides. Mass spectra were acquired 
and analysed to determine the peptide sequence based on both b-series of ions for 
the N-terminal fragments and y-series of ion for C-terminal fragments from MS/MS 
data.  
2.2 Triclisia subcordata Oliv  
2.2.1 General experimental Procedures 
1H NMR, 13C NMR, DEPT, and 2D-NMR (COSY, HMQC and HMBC) spectra were 
obtained on a Bruker 400 or 500 MHz instruments. Chemical shifts were reported in 
δ (ppm) using the solvents (CDCl3 or CD3OD) standard and coupling constants (J) 
were measured in Hertz. Silica gel (Sigma-Aldrich) was used as an adsorbent for 
flash column chromatography. Dragendorff’s reagents were purchased from Sigma-
Aldrich. 
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2.2.2 Plant Material 
The plant materials from Triclisia subcordata were collected in batches (1 and 2) in 
April 2012 and 2014 from Imo state, Nigeria, respectively, and identified by a 
taxonomist, H.D Onyeachusim. The voucher specimens (number: UUH1817) was 
deposited at University of Uyo, Akwa Ibom state, Nigeria. The root bark of the plant 
was cut into pieces, air-dried and pulverized. 
2.2.3 Extraction and fractionation of T. subcordata.  
First Batch: The powdered root bark of Triclisia subcordata (250 g) was extracted 
with 1L of 50 % ethanol by a Soxhlet apparatus. The extract was concentrated to 
dryness using rotary evaporator.  The total extract (TSS) was subjected to further 
solvent partition per a previously established procedure (Kikueta et al. 2013) to yield 
the chloroform fraction containing enriched alkaloid (TSS1), the aqueous extract 
(TSS2), and the aqueous methanol fraction (TSS3) (Figures 2.2). 
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Figure 2.2 Scheme of extraction by Soxhlet apparatus, fractionation, purification and 
isolation of anti-cancer alkaloids from T. subcordata (Batch 1) 
 
After first batch extraction and preliminary assay of fractions and compounds got, it 
was discovered that the method needed little modification and optimization to make it 
simpler steps for economic reasons. Also, to rule out the possibility of some alkaloids 
being destroyed by heat from Soxhlet apparatus. New method was therefore 
employed in second batch extraction to take care of the possible problems eminent in 
the first extraction. The second method was also specific method for alkaloid 
extraction since it became obvious from our first batch extraction and preliminary 
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assay that the targeted bioactive compound of T. subcordata were likely to be mainly 
alkaloids. These were subsequently targeted during second batch extraction. It is 
also a well-known fact that some alkaloids could be degraded by heat. So, high 
temperature was not employed in the second batch extraction. It was by simple 
maceration at room temperature to ensure that our targeted bioactive components 
were not degraded products. 
 
Second batch: The 1.8kg powdered root of T. subcordata was extracted by 
maceration using 8 L of 5% acetic acid for 48h three times. The extract was 
combined and dried with a rotary evaporator. The crude extract was subjected to 
alkaloid extraction by alkalinisation with ammonium hydroxide (NH4OH) (pH 9-10) 
and subsequent partition with chloroform to get 22.6 g total alkaloid (Figure 2.3).  
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Figure 2.3 Scheme of extraction by maceration, fractionation, isolation and 
purification of anti-cancer alkaloids from T. subcordata root. 
2.2.4 Phytochemical screening 
Preliminary phytochemical tests were carried out on plant extracts to screen them for 
preliminary bioactive constituents using a characteristic colour reaction changes to 
detect  the presence of phyto-constituents according to previously established 
procedures (Harborne, 1998, Trease & Evans, 1998, Uche & Ezugwu, 2009, Ijeoma 
et al., 2011, Edeoga et al., 2005, Sofowora, 1982) (Table 2). 
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Table 2.1 Preliminary Phytochemical screening of crude extract of Triclisia 
subcordata  
root. 
Test observation inference 
Test for Alkaloids 
A 2.0 g   extract + 5 mL 1% 
HCl + warmed, and filtered. 
Then 1 mL filtrate + 2mL 
Dragendorff’s reagent. 
 
A 1mL filtrate + 1 mL 
Mayer’s reagent 
 
A 1mL filtrate + 1mL Hager 
reagent (picric acid) 
 
Formation of Orange, 
precipitate observed. 
 
 
Formation of milk /white 
precipitate observed 
 
Formation of yellow 
precipitate observed   
 
Alkaloids present  
+++ 
 
 
Alkaloids present 
+++ 
 
Alkaloids present 
+++ 
Test for Saponins 
A 0.5g extract + shaken 
with water in a test tube 
Formation of Frothing which 
persisted on warming. This 
was confirmed by 
Hemolysis test. 
Evidence for presence 
of Saponins 
++ 
 
 
Test for Tannins 
A 1.0g of extract + 5ml 
distilled water+ filter, 2mL 
filtrate + Ferric chloride test 
Blue black precipitate 
observed    
Evidence for the 
presence of tannin  
+++ 
 
Detection of diterpene  
 
Copper acetate Test: A 
1.0g extracts were 
 
 
Formation of emerald 
green color. 
 
 
indicates the 
presence of 
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dissolved in water and 
treated with 3 drops of 
copper acetate solution.  
 
Liebermann-Burchard 
test: A 2.0g extracts were 
treated with chloroform 
and filtered. The filtrates 
were treated with few 
drops of acetic anhydride, 
boiled and cooled. Conc. 
Sulphuric acid was added.  
 
Salkowiski’s test: A 2.0g 
extracts were treated with 
chloroform and filtered. 
The filtrates were treated 
with few drops of Conc. 
Sulphuric acid, shaken 
and allowed to stand. 
 
Test for Flavonoids 
Alkaline Reagent Test: A 
1.0g extracts were treated 
with three drops of sodium 
hydroxide solution.  
Lead acetate test: A 1.0g 
extracts were treated with 
three drops of lead 
acetate solution.  
 
Shinoda reduction test 
 
 
 
 
 
 
Formation of brown ring at 
the junction  
 
 
 
Appearance of golden 
yellow color  
 
 
 
 
Formation of intense 
yellow color, which 
becomes colorless on 
addition of dilute acid,  
 
 
 
Formation of yellow color 
precipitate  
 
 
 
 
Orange coloration observed 
 
diterpenes. 
++ 
 
 
indicates the 
presence of 
phytosterols.  
 
++ 
 
 
indicates the 
presence of 
triterpenes 
++ 
 
 
 
 
indicates the 
presence of 
flavonoids 
++ 
 
 
indicates the 
presence of 
flavonoids.  
++ 
 
 
++ 
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Cardiac glycosides 
 
A 2.0g extracts were 
treated with sodium 
nitropruside in pyridine 
and sodium hydroxide.  
 
No pink to blood red 
colour formed. 
  
 
indicate the absence 
of cardiac glycosides.  
- 
Modified Borntrager’s 
Test:  
 
A 3 .0g extracts were 
treated with Ferric 
Chloride solution and 
immersed in boiling water 
for about 5 minutes. The 
mixture was cooled and 
extracted with equal 
volumes of benzene. The 
benzene layer was 
separated and treated 
with ammonia solution.  
 
 
No coloration formed in 
the ammonia layer, 
indicates the absence of 
anthranol glycosides.  
 
 
No anthranol glycoside 
observed 
Carbohydrates: 
Molisch’s Test:   
A 2-mL filtrate from the 
extract was treated with 2 
drops of alcoholic α-
naphthol solution in a test 
tube + 2 drops of H2S04    
 
 
formation of the violet ring 
at the junction  
 
 
indicates the 
presence of 
Carbohydrates 
++ 
 
+ represent trace; ++ moderately present: +++ much present, --absence 
2.2.5 Liquid chromatography-mass spectrometry (LC-MS) 
1μL of alkaloid sample in methanol (0.1 mg/ml) was injected onto a Waters BEH C18 
(2.1x100 mm 1.7 µm particle size) reversed phase column via a Thermo Scientific 
Ultimate U3000 ultra-performance liquid chromatography (UPLC) system. Alkaloids 
were separated using a linear gradient method utilising mobile phase A (Milli-Q water 
with 0.1% formic acid) and mobile phase B (acetonitrile with 0.1% formic acid). The 
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gradient consisted: 0 min (95% A), 1 min (95% A), 7 min (100% B), 7.01 min (95% A) 
and 10 min (95% A). The flow rate was maintained at 0.4 ml/min throughout. 
The outlet from the chromatography system was directly coupled to a HESI II 
electrospray ion source on a Thermo Scientific Q-Exactive Orbitrap mass 
spectrometer system which was used to generate ions from the LC eluent and create 
a mass chromatogram and spectra. The MS method utilised a full-MS mode 
experiment in positive ion mode, 140,000 resolution, an AGC target of 3e6, max ion 
injection time of 200 ms and a scan range of 300-2500. 
2.2.6. Isolation of alkaloids of T. subcordata.  
2.2.6.1 Isolation of cycleanine from batch 1 plant.   
The TSS1 (273 mg), which showed most cytotoxic activity, was subjected to silica gel 
chromatography eluting with CHCl3 with increasing amount of MeOH to give 40 
fractions. The eluted fractions were tested, identified and combined as guided by 
Dragendorff’s reagent test, thin layer chromatography and UV detector at 254 nm 
and 365 nm. Dragendorff’s and Mayer’s reagents were used as the preliminary test 
for alkaloids using chemical colour reaction tests of alkaloids (Sofowora, 1998, 
Trease and Evans, 1998). The combined fractions were concentrated in vacuum with 
a rotary evaporator. Cycleanine (145 mg) was recrystallized from 1-4th fraction 
(TSS1.1). Fractions 5-8 were combined as TSS1.2 (27.8 mg) and further purified by 
using HPLC on an Agilent 1220 LC system (USA). UV detector was set at 254 nm 
wavelength.  The mobile phase was a mixture of 0.1 % TFA (A) and 80% acetonitrile 
containing 0.1 % TFA (B). The composition of the mobile phase was rising from 10 % 
to 70% B over a period of 25 min and kept at 100 % B for 6 min on a semi-
preparative HPLC column (Phenomenex, UK; Jupiter C18 reverse phase, 300 Å, 5 
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μm particle size, 9.4 × 250 mm) at a flow rate of 4 ml/min. Eluted fractions at different 
retention times were collected and freeze-dried in a lyophilizer. For analysis of the 
purity of the isolated alkaloids, a gradient from 10 % B to 70% B over a period of 25 
min and 100% B for 6 min was applied on an analytical HPLC column (Phenomenex, 
UK; Jupiter C18 reverse phase, 300 A, 5 μm particle size, 4.6 × 250 mm) at a flow 
rate of 1 ml/min.  
Cycleanine (1), white powder.  1H and 13C NMR (CDCl3) (Tables 4.3 and 4. 4). LC-
ESI-MS, m/z: 623.3118 [M + H] +; 312.1610 [M + 2H]2+.  
TFA salt of cycleanine (1a), white powder. 1H and 13C NMR (CDCl3) (Tables 4.3 and 
4.4). LC-ESI-MS, m/z: 623.3074 [M + H] +; 312.1579 [M + 2H]2+.  
2.2.6.2 Isolation of BBIQ alkaloids (from Batch 2) 
 
The total alkaloid (22.6 g) was purified using combined methods of column 
chromatography described above, recrystallization and HPLC procedure to yield 
three pure alkaloids including cycleanine (1, 83.7%), isochondodendrine (2, 7.5%) 
and 2′-norcocsuline (3, 1%). Cycleanine was obtained by crystallization, 
isochondodendrine was isolated from silica gel column chromatography and 2′-
norcocsuline was isolated by HPLC.  
Isochondodendrine (2), white powder, 1H and 13C NMR (CDCl3) (Table 4.3 and 4.4). 
Positive HR-ESI-MS, m/z: 595.2807 (Calcd. mass for C36H39N2O6, [M + H]
 +, 
595.2808).  
TFA salt of 2′-Norcocsuline (3), 1H and 13C NMR (CDCl3) see Table 4.5 and 4.6. 
Positive HR-ESI-MS, m/z: 549.2384 (Calcd. mass for C34H33N2O5, [M + H]
 +, 
549.2389).  
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Conversion of 2’-norcocsuline (3) TFA salt to its free base, 2’-norcocsuline was 
carried out by first alkalinisation and subsequent extraction with CHCl3 to give its free 
base form. 1H and 13C NMR (CDCl3) of 3 are also listed in Table 4.5 and 4.6. 
2.2.7   Semi-synthesis of (aminoalkyl)cycleanine analogues 
2.2.7.1 Synthesis of 5-[(dimethylamino)methyl] cycleanine (4)  
Cycleanine (1, 1.0 g, 1.6 mmol) isolated from this plant was combined with 10 ml 
concentrated HCl and paraformaldehyde (0.1 g, 3.4 mmol) and the reaction mixture 
was stirred on ice for 3h. The reaction mixture was concentrated to dryness. After 
evaporation of HCl under vacuum, the mixture product was dissolved in 30 mL 
acetonitrile, treated with 1.6mL of 2 M dimethylamine in THF and NaOH pellet (128 
mg), and stirred at room temperature for 3h. After filtration, a yellow powder was 
obtained. The product was further purified by silica gel column chromatography (5 - 
50 % CHCl3/MeOH). The fractions containing the product were combined and 
evaporated to produce a yellow powder (20 mg, yield 7.8%, purity > 98%). 1H and 
13C NMR (CD3OD) for 4 (Table 5.1 and 5.2). Positive HR-ESI-MS, m/z: 680.3692 
(Calcd. mass for C41H50N3O6, [M + H]
 +, 680.3700).  
2.2.7.2 Synthesis of 5-[(propargylamino)methyl] cycleanine (5) 
Cycleanine (1g, 1.6mmol) was combined with 10 ml concentrated HCl and 
paraformaldehyde (0.1 g, 3.4 mmol) and the mixture was stirred on ice for 3 h. The 
reaction mixture was concentrated to dryness and the residue was dissolved in 30 
mL acetonitrile, treated with 200µL propargylamine and NaOH pellet (128 mg), and 
stirred at room temperature for 3h.  After filtration, a yellow powder (1.29 g) was 
obtained and further purified by silica gel column chromatography as described 
above for compound 5. 1H and 13C NMR (CD3OD) for 5 (Table 5.1 and 5.2). Positive 
HR-ESI-MS, m/z: 690.3507 (Calcd mass for C42H48N3O6, [M + H]
 +, 690.3538). 
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2.3 Cylicodiscus gabunensis 
2.3.1 Plant materials  
The stem bark of Cylicodiscus gabunensis Harms (Mimosaceae) was collected from 
Orlu L.G.A., Imo state Nigeria in September 2011. The plant materials were identified 
and authenticated by H.D Onyeachusim, a taxonomist. A voucher specimen 
(UPH1028) was deposited in the Herbarium of Botany department, University of Port 
Harcourt, Nigeria.  
2.3.2 Extraction of Cylicodiscus gabunensis   
Cylicodiscus gabunensis stem bark was cut into pieces, air dried and reduced to 
powder. The crude powder (200g) was pre-extracted with 1L hexane by maceration. 
The extract was dried and extracted thrice with 1L of 70% ethanol using cold 
maceration. The combined extracts were dried using rotary evaporator to get the 
ethanol extract (CGE, 24g). 
2.3.3. Fractionation of the ethanol extract of C. gabunensis (CGE) 
CGE (24 g) was dissolved in water and partitioned with ethyl acetate and n-butanol 
sequentially to give the ethyl acetate fraction (CGEEA, 1.8g), butanol fraction 
(CGEBU, 16.6g) and aqueous fraction (CGEAQ, 3.2g). These fractions were 
screened for both anticancer and antimalarial activities. 
2.4 Anticancer activity of plant extracts and pure compounds 
2.4.1 In vitro cytotoxicity  
2.4.1.1 Cell lines  
The human ovarian cancer cell lines (Ovcar-8, Ovcar-4, A2780 and Igrov-1) and 
normal human ovarian epithelial (HOE) cells were used in this study. Ovarian cancer 
cell lines were products of American tissue culture collection (ATCC). The Ovcar-8 
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cell line originated from ovarian carcinoma that was resistant to carboplatin 
(Robinson et al., 2013). The Igrov-1 cell line originated from an ovarian carcinoma 
that was sensitive to chemotherapy treatment (Robinson et al., 2013). The Ovcar-4 
cell line was produced from the cisplatin resistant ovarian cancer patient (Robinson 
et al., 2013). A2780 was obtained from a human ovarian carcinoma before exposure 
to drug treatment (Robinson et al. 2013). Human Ovarian Epithelial (HOE) cells were 
bought from Applied Biological Materials (ABM) Inc. HOE originated from normal 
ovarian epithelium and immortalized using SV40 large T antigen (Robinson et al. 
2013). 
 2.4.1.2 Cell culture. 
 HOE, Ovcar-8, Ovcar-4, A2780 and Igrov-1 cells were grown in   Roswell Park 
Memorial institute (RPMI 1640, Lonza) medium was employed in culturing of human 
ovarian cancer cell lines (. The medium was supplemented with 10% fatal bovine 
serum (FBS, Lonza), penicillin-streptomycin (50 µg/ml: Lonza) and glutamine (2 mM: 
Lonza). These were incubated and maintained in a standard humidified incubator 
(Pamassonic incubator: MCO-18AC: S/N 13020089) conditions of 37 °C, 5% carbon 
dioxide (CO2). 
All cells were routinely sub-cultured when they were more than 80% confluent (as 
determined using an Olympus CKX41 light microscope). To detach adherent cells 
from the culture flask for routine passage or experimentation, cells were washed with 
1 mL phosphate buffered saline (PBS; Lonza) and subsequently exposed to 1 mL 
0.01% trypsin (Lonza) in PBS. The cells were shaken and incubated at 37°C to 
facilitate detachment. After complete detachment of cells, 1.1 mL of RPMI 1640 
enriched medium was used to neutralize the trypsin. This was transferred into a 
sterile 15 mL polypropylene tube (Sarstedt) and centrifuged at 150 g for 3 minutes at 
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room temperature using a Thermo Scientific (Heraeus Megafuge 8) centrifuge. The 
cell pellets were re-suspended in fresh medium after aspiration of the culture. The 
cells were maintained in T75 sterile tissue culture flasks (Sarstedt). For assay, a 
minimum number of cells (100 cells) was counted with Neubauer hemocytometer. 
The required number of cells were seeded into an appropriate tissue culture plates 
(96-well or 6-well plates Sarstedt) as described below. 
2.4.1.3 Cell growth assay with sulforhodamine B (SRB) assay  
Plant extracts or pure compounds were solubilized in dimethyl sulfoxide (0.2% 
DMSO; but the maximum concentration of DMSO is usually 0.5%) (or PBS for 
carboplatin) to obtain the following stock concentrations: 100mg/ml of total plant 
extracts or fractions; 20 mM of cyclotides and BBIQ alkaloids (cycleanine, 
isochondodendrine, 2′-norcocsuline, tetrandrine, and semisynthetic cycleanine 
derivatives), 13.5 mM carboplatin (Sigma-Aldrich), and 10 mM paclitaxel (Sigma-
Aldrich). Sulforhodamine B (SRB) and trichloroacetic acid (TCA) were bought from 
Sigma-Aldrich, UK, and acetic acid from Fisher scientific, UK. 
The SRB assay (Vichai & Kirtikara, 2006) was used to evaluate the effects of the 
plant extracts and pure compounds on the growth of ovarian cancer cell lines 
(A2780, Ovcar-8, Ovcar-4, Igrov-1) and on normal human ovarian epithelia (HOE) 
cells. To demonstrate the level of sensitive of our test compounds to pre-and post-
chemotherapy exposed ovarian cancer cell lines, the four-different ovarian cancer 
cells were selected in this study. The reason is, for good identification of new or 
bioactive compounds in ovarian cancer research, it is considered ideal to 
demonstrate the activity of such compounds in chemo-resistant as well as sensitive 
strains of ovarian cancer, probably due to common low prognosis of cancer patients. 
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Cancer cells have been known to be prone to development of resistant to 
chemotherapy because of post exposure or treatment with a cancer chemotherapy. 
Therefore, the four cell lines used in this study include:  
A2780 cell line was produced from a human ovarian carcinoma prior to 
chemotherapy treatment. A2780 used was to investigate test compound sensitivity on 
cancer cells that have no history of chemotherapy treatment and thus could be 
sensitive to cancer drug treatment. 
Ovcar-4 cell line was got from the ascites of cisplatin - resistant ovarian cancer 
patient. This was to ascertain the sensitivity of our test compounds to ovarian cancer 
cells that had developed resistant to cisplatin which is already known cancer 
chemotherapeutic agent. 
Ovcar-8 cell line originated from carboplatin -resistant ovarian carcinoma. This was 
chosen to evaluate the sensitivity the compounds to ovarian cancer cells that had 
developed resistant to carboplatin, a well-known cancer chemotherapeutic agent 
commonly used either as single or in combination therapy for treatment of different 
cancer   
Igrov-1 cell line was derived from a post- chemotherapy sensitive ovarian carcinoma. 
The reason for the choice of Igrov-1 was to determine the sensitivity of our test 
compounds on ovarian cancer cells that have been previously exposed to 
chemotherapeutic agents.  HOE was employed to determine the therapeutic index or 
selectivity of the test compounds.  2000 cells (A2780, Ovcar-8), and 5000 (Ovcar-4, 
Igrov-1, or HOE) cells were seeded in 80 µl of growth medium in each well of a 96-
well plate. After 24 hours 20 µl of plant extracts or pure compounds dissolved in the 
medium (final DMSO concentration 0.2%). After 72 hours, the medium was decanted 
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and the cells were fixed with 10% TCA on ice for 30 min before drying. The cells 
were stained with 0.4% SRB in 1% acetic acid for 30 min, washed with 1% acetic 
acid and dried. Then, 200 µL of Tris-base (10 mM) were added to the dried plates 
and shaken for 5 min to solubilise the SRB dye. The absorbance at 540 nm or 570nm 
was measured using a spectroscopic plate reader (Multi-mode microplate reader 
BioTEK Synergy 2, USA). DMSO or medium was used as negative control while 
paclitaxel or carboplatin or both were used as positive drug controls. The data was 
analysed by non-linear regression using the Graph Pad PRISM 6.0 software to fit a 
4-parameter sigmoidal dose-response curve.  
2.4.1.4 Trypan blue Cell Viability counting 
The viability of cancer cells was measured using trypan blue exclusion method 
(Invitrogen) before seeding cells and after drug treatment of the cells. The cells 
(A2780, Ovcar-8, Ovcar-4, or Igrov-1) (200, 000 cells/well) were seeded into 6 good 
plates, and medium (control), carboplatin, plant extracts, fractions, isolated 
compounds-cycleanine, isochondodendrine, 2′-norcocsuline or tetrandrine (20 µM) 
including semisynthetic cycleanine derivatives were administered to the cells after 
24hr incubation. Then cell viability was determined using Neubauer haemocytometer 
and trypan blue exclusion after 48h treatment. Briefly, 20 μL cells culture were 
collected after trypsinization and mixed with and equal volume of 0.4% trypan blue 
thoroughly. Then 20 μL of the suspension mixture was analysed with a Countess™ 
Automated Cell Counter (Life Technologies, USA) to determine cell viability. 
2.4.2 Apoptosis detection by Caspase – Glo 3/7 activity assay 
The effect of BBIQ alkaloids, cycleanine, isochondodendrine, 2′-norcocsuline, 
tetrandrine and cycleanine derivatives, 5-[(dimethylamino)methyl]cycleanine and 5- 
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[(propargylamino)methyl]cycleanine  on the caspase-3/7 activities was carried out 
using assay kits caspase-Glo 3/7 (Promega Corp., Madison, WI, USA) on a 96-well 
microplate as described previously with little modification (Robinson et al., 2013) 
(Robinson et al. 2013). Briefly, A2780 and Ovcar-8 (2000 cells/well), and Igrov-1 and 
Ovcar-4 (5000 cells/well) cells were incubated in 80 μL growth medium in a 96-well 
plate for 24 hours. Cells were then supplemented with growth medium (control), 
carboplatin, cycleanine or isochondodendrine, 2′-norcocsuline, tetrandrine or 
cycleanine derivatives, 5-[(dimethylamino)methyl] cycleanine (4) or 5- 
[(propargylamino)methyl] cycleanine (5) (final concentration 20 μM) for 48 hours.  
Before adding caspase agents, the morphological changes were observed and the 
images were captured under an inverted light microscope. Then, 100 μL of the 
culture was treated with 25 μL caspase-Glo 3/7 reagent and incubated at room 
temperature on a Rocker (Gyro shaker) for 30 minutes, protected from light. The 
luminescence reading was measured at 570 nm by Multi-Mode Microplate Reader 
BioTEK Synergy 2 (USA). 
2.4.3 Western blot assay for PARP cleavage 
To evaluate apoptosis, 200,000 Ovcar-8 cells/ml were seeded in a 6-well plate, n = 5 
(usually cell density of 105 - 106 range could give sufficient protein for analysis per 
manufacturer’s specifications). These were separately treated with cycleanine, 
isochondodendrine, 2′-norcocsuline, tetrandrine, cycleanine derivatives, 5-
[(dimethylamino)methyl] cycleanine or 5- [(propargylamino)methyl] cycleanine, 
carboplatin (20 µM) or medium for 48 h. Cells were collected by trypsinization, lysed, 
protein concentration determined by the bicinchoninic acid (BCA) assay. Equal 
amounts of proteins (10µg) from total cellular extracts were resolved on 4-20% Tris-
Glycine polyacrylamide gradient gel (Nusep) with hepes running buffer (100 mM 
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hepes, 100 mM Tris and 1% sodium dodecyl sulphate). After electrophoresis, the 
proteins on the gel were transferred to polyvinylidene fluoride (PVDF) membrane. 
The membrane was then incubated with Tris Buffered Saline with Tween (TBST) 
buffer (50 mM Tris hydrochloride (Tris HCl, pH 7.4, 150 mM NaCl, 0.1% Tween 20) 
containing 5% skimmed milk powder for 1.0 hour with gentle rocking on a Stuart 
Scientific Platform Shaker STR6 at room temperature. The membrane was then 
probed with poly (ADP) ribose polymerase (PARP) from rabbit (Cell Signalling 
Technology Inc., USA) (1:1000) for 16 hours at 4°C overnight and washed. Then 
probed with antibodies against poly (ADP) ribose polymerase (anti-rabbit). Then 
incubated with glyceraldehde-3-phosphate dehydrogenase (GAPDH) from mouse 
(Millipore, USA) (1:5000) for 1 hour at room temperature. Then treated with anti-
mouse after incubation.  Proteins were visualised using UptiLight HRP 
chemiluminescent substrate (Uptima) on a FluorChem M Imager.  
2.4.4 Apoptosis analysis by flow cytometry 
0.5 ml of Ovcar-8 cells (300,000 cells/ml) were seeded in 12 well plates for 24h, and exposed 
to medium as control, carboplatin, cycleanine, isochondodendrine, 2-norcocsuline, 
tetrandrine or cycleanine derivatives -5-[(dimethylamino)methyl]cycleanine or 5- 
[(propargylamino)methyl]cycleanine (20 µM). After incubation for 48 h, the cells were 
washed with PBS, trypinsized and stained with fluorescein isothycanate (FITC)-conjugated 
annexin V using Annexin V-FITC kit (Miltenyi Biotec, Germany) and propidium iodide (PI) 
following the manufacturer’s protocol. Apoptotic and live cells were measured using a 
Beckman Coulter Cytomics 500 flow cytometer with CXP software (High Wycombe 
UK). Flow cytometry data was analyzed using Flowing Software (Perttu Terho, Turku 
Centre for Biotechnology, University of Turku, Finland). The percentage of early and 
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later apoptotic, and live cells in three independent experiments were statistically analyzed 
using Graph Pad Prism 6 software.  
2.4.5 Cell cycle analysis by flow cytometry 
Ovcar-8 1 × 106 cells/well were seeded in a 6-well plate. The different cell density 
was considered here because during our pilot study, where different preliminary 
experiments were performed using flow cytometer, it became necessary to optimize 
each assay to get perfect results for specific procedure, provided the cell density falls 
within the manufactures’ range or specifications.  The 6- well seeded cells were 
treated with cycleanine, tetrandrine, isochondodendrine, 2′-norcocsuline, or 
cycleanine derivatives, 5-[(dimethylamino)methyl] cycleanine or 5-
[(propargylamino)methyl] cycleanine   carboplatin (20µM), and medium (control) for 
48 hr. The adherent cells were trypinized and washed with PBS. The cells were then 
fixed with 70% ethanol in cold PBS, and incubated at 4oC for 24 hr. The fixed cells 
were centrifuged at 200 g for 10 mins and the cell pellets were washed twice with 
PBS. Cells were suspended in PBS containing PI (50 µg/mL), Triton X-100 (0.1%, 
v/v), and DNase-free RNase (1 µg/mL). (Robinson et al. 2013). DNA contents were 
determined by flow cytometry using a Beckman Coulter Cytomics 500 flow cytometer 
with CXP software (High Wycombe UK). Flow cytometry data was analysed using 
Flowing Software (Perttu Terho, scattering (FSC) (Turku Centre for Biotechnology, 
University of Turku, Finland). The flow cytometer, FC 500 was used (Beckman 
Coulter (UK) LTD Cytomics FC500, High Wycombe UK).  
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2.4.6 Imaging alkaloids uptake inside cells using click chemistry and confocal 
fluorescence microscopy 
The imaging of alkaloids uptake was done using click chemistry and confocal 
fluorescence microscopy per previous with little modification (Luo et al., 2013). 
Briefly, human Ovcar-8 cell line was maintained in a culture medium consisting of 
RPMI supplemented with 10% FBS and 50µg/mL penicillin-streptomycine and 2mM 
glutamine (Lonza). The cells (5 x104 cells/mL) were seeded in 96 good plates and 
incubated at 5% CO2 and 37
oC overnight. The cells were respectively treated with 
Alexa 488 azid alone with cell (control), 20 µM cycleanine, or 20 µM 5-
[(propargylamino)methyl] cycleanine (5) for 5h. Cells were fixed with 3.7% 
formaldehyde at 4 °C for 30 min and washed 3 times with excess PBS. The fixed 
cells were incubated with the click chemistry reaction buffer (0.1 M Tris buffer, pH 
8.5, with 0.05 % Triton, 20 µM of Alexa 488 azide; 50 µM of CuSO4, 25 µM of Tris(3-
hydroxypropyltriazolylmethyl) amine (THPTA), 2.5 mM ascorbic acid) for in situ 
specifically labelling of 5 with an azide-containing fluorophore in the dark at room 
temperature for 30 mins. After the labelling reaction, the reaction buffer was removed 
and the cells were washed two times with PBS. Florescence signal was measured by 
use of confocal microscope (Olympus U-TBI 90 Olympus 1 X 83 confocal microscope 
3G14189, Japan). Excitation and emission filters for imaging the intracellular uptake 
of monoalkynyl cycleanine (5) were taken at 470/15nm and 515 – 550 nm 
respectively (Luo et al., 2013). The mean fluorescence intensity (MFI) of individual 
cells within selected field of view (FOV) of the fluorescence microscopy data was 
calculated by using ImageJ (Public domain, NIH) software (Luo et al., 2013). The MFI 
of individual cells was corrected by subtracting the background fluorescence signal. 
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The average MFI was calculated by averaging the MFI from selected FOVs (with 
approximately 30−40 cells in total).   
2.5 Antimalarial activity of plant extracts and pure compounds 
2.5.1 Materials  
The following materials or instruments were used: Lumina flow hood-ICN flow. 
BS5726 class11 MSC Gelaik BSB. Incubator/Oven- NUAIRETM DH Auto flow 
incubator, Model No NU.5500E series 11 (CO2 air – jacketed incubator). Centrifuge-
U-320R, BOECO Germany, light microscope (Olympus CX21), Water bath, 
Luminator-Glo-Max Multimode Reader Luminator: Glomax Multi Detection system 
(Promega UK), Tissue culture plates: White 96 multi-good plates - Flat bottom 
suspension cells plates made by Sarstedt. Syber green 1 MSF lysis buffer (100 µl of 
20mM Tris (PH 7.5), 5 nM EDTA, 0.008% (w/v) saponin and 0.08% (V/V) Triton X-
100 containing syber green 1(1 x final concentration from 5000x stock Invitrogen). 
Most of the materials /chemicals used were products of Sigma Aldrich. 
2.5.2 In vitro antimalarial assay 
The previously established standard procedure for in-vitro antimalarial screening or 
assay using MSF containing Syber green 1 fluorescence assay techniques was 
employed with little modification, as described by (Hasenkamp et al., 2013, 
Smilkstein et al., 2004, Wong et al., 2011). Briefly, Plasmodium falciparum Dd2 strain 
was employed for these assays. Transgenic Dd2 chloroquine resistant P. falciparum 
was cultured in standard continuous culture conditions (RPMI 1640), supplemented 
with 37.5mMHEPES, 10mM D glucose, 2mM L-glutamine, 100µM Hypoxanthine- 
(growth biomarker), 8%v/v human serum at 2% haematocrit in atmosphere of 1%, 
O2, 3% CO2 and 96% N2 ;5nM WR99210 and 2.5ug/mL blastidin. (Hasenkamp et al., 
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2013, Smilkstein et al., 2004, Wong et al., 2011). Parasitaemia level and stage were 
determined by light microscopy by use of Giemsa staining of thin blood smears. 
Synchronization of culture was done by sequential sorbitol treatment. The 100uL of 
Dd2 culture mixed with different drug concentrations in 96 well plate and incubated 
for 48h. Then 100uL of the drug treated culture was mixed with Malaria fluorescence 
syber green 1 (MFS) with lysing buffer ((100 µl of 20mM Tris (PH 7.5), 5 nM EDTA, 
0.008% (w/v) saponin and 0.08% (V/V) Triton X-100). This was thoroughly mixed and 
incubated in dark for 1h at room temperature. A two-fold serial dilution was employed 
for a 48hour assay of a trophozoite synchronised culture. Then fluorescence 
emission at 490 measured at excitation 510-570 using Glomax multi-detector 
laminator reader. Each biological replicate recorded, comprises three technical 
replicates on the same 96-well plate. Following capture of the fluorescent signal, the 
parasitaemia was calculated as follows: 100 x [μ(S) − μ (−)/μ (+) − μ (−)], where μ(S), μ 
(+) and μ (−) represent the means of the fluorescent signals for the sample in question 
and 100% and 0% controls, respectively. Then % growth (parasitaemia) was plotted 
against log10-transformed drug concentration and to get IC50, which was determined 
using a nonlinear regression (sigmoidal dose–response/variable slope equation) in 
Graph Pad Prism v5.0 (Graph Pad Software, Inc., San Diego, CA). Chloroquine was 
used as reference control. The antiplasmodial activity is expressed as the 50% 
inhibitory concentrations (IC50).  
2.6 Statistical analysis  
Pharmacological data was analysed by non-linear regression using the GraphPad 
Prism software (GraphPad Software Inc.) to fit a four-parameter sigmoidal dose-
response curve (Hill-equation). The concentration that caused 50% cell growth 
inhibition (IC50) and Hill coefficient were determined. This was repeated at least thrice 
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and the results (IC50) were expressed as mean ± SEM (standard error of mean) of at 
least three or more observations. Analysis of variance (ANOVA) or Student t-test was 
further used to compare the mean of the control with test drugs using statistical 
software of the GraphPad prism. n = 5 independent observations and P <0.05 as 
shown in individual pages. 
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CHAPTER THREE 
ANTICANCER EFFECTS OF VIOLA PHILIPPICA CAV AND VIOLA YEDOENSIS 
MAKINO 
 
3.1 Isolation, identification and structures of cyclotides from V. philippica and 
V.  yedoensis  
 
The combined acid hydrolysis and ninhydrin test indicated that butanol fractions of 
Viola philippica and Viola yedoensis (VP-MW-BU and VY-MW-BU) contained rich 
cyclotides. In order to identify the sequence and structures of the cyclotides, the 
butanol fractions were separately passed through silica gel column chromatography 
with CHCl3:MeOH solvent system with increasing percentage of MeOH for isolation 
of cyclotides-rich fractions according to pre-established procedure (Claeson et al., 
1998, Göransson et al., 2004, Tan & Zhou, 2006, Wang et al., 2007, He et al., 
2011a). Then different fractions of the cyclotides- enriched fractions of V. philippica 
and V. yedoensis respectively (Table 1 and 2) were further tested for the presence of 
cyclotides using Ninhydrin test per previously established procedure for cyclotides 
colour reactions tests (Tan & Zhou, 2006) (Table 1 and 2). Different fractions of the 
Viola exhibited varied degree of colouration with ninhydrin tests. These were further 
confirmed by MALDI-MS. The most highly cyclotides - rich fractions VPF7- VPF9 
(Table 3.1) of V. philippica and VYF7- VY9 for V. yedoensis (Table 3.2) were further 
purified with reversed-phase HPLC and detected by UV light spectroscopy (215 nm) 
(Figure 3.1 and 3.2). 
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Table 3.1 Silica gel column chromatography fractions from butanol fraction of Viola 
philippica (VP-MW-BU) and their ninhydrin test results. Fractions VPF7 –VPF9 were 
purified by HPLC to obtain cyclotides VP18 (5 mg) and VP19 (4 mg) (Figure 3.1).     
             
Code used for 
fractions (F1-F 
9)  
Description of solvent system 
used for elution of each 
fraction 
Weight (mg) 
 
Test for 
cyclotides 
 
VPF1 CHCl3:MeOH (4:1)  102  + 
VPF2 CHCl3:MeOH (3:1)  390 ++ 
VPF3 CHCl3:MeOH (2:1) 300 ++ 
VPF4 CHCl3:MeOH (1:1)  341 ++ 
VPF5 CHCl3:MeOH (1:2) 219  ++ 
VPF6 CHCl3:MeOH (1:3)  83  ++ 
VPF7 CHCl3:MeOH (1:4)  61 +++ 
VPF8 MeOH (100%)  137 +++ 
VPF9 MeOH: H
2
O (3:1)  71 +++ 
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Table 3.2 Silica gel column chromatography fractions from butanol fraction of Viola 
yedoensis (VY-MW-BU) and ninhydrin tests. Fractions F7 – F9 was purified by HPLC 
to get two major cyclotides fractions eluted at 18 and 19 min. These were lyophilized 
to give VY18 (5 mg) and VY19 (6 mg). 
              
Code used 
Fractions  
(F1 – F9) 
Description of Solvent 
system used for elution 
of each fraction. 
Weight  
 
Test for cyclotide 
observation 
VYF1 CHCl3: MeOH (4:1) 2.8g + 
VYF2 CHCl3: MeOH (3:1) 2.3g  + 
VYF3 CHCl3: MeOH (2:1) 430mg ++ 
VYF4 CHCl3: MeOH (1:1) 2.1g ++ 
VYF5 CHCl3: MeOH (1:2)  728mg ++ 
VYF6 CHCl3: MeOH (1:3) 250mg ++ 
VYF7 CHCl3: MeOH (1:4)  117mg ++++ 
VYF8 MeOH  200mg ++++ 
VYF9 MeOH: H2O (3:1) 680mg ++++ 
 
 
The cyclotides eluted from the RP-HPLC chromatogram peaks VP18 and VP19 from 
V. philippica (Figure 3.1), and VY18 and VY19 from V. yedoensis (Figure 3.2).  
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Figure 3.1 Semi-preparative HPLC chromatogram of the butanol fraction of Viola 
philippica (VP-MW-BU).  VP18 (Varv A, Kalata b1, Viba 15, Viba 17 and VP19 (Varv 
A, Varv E, Viba 15, Viba 17; Solvent: Acetonitrile 80%: 0.1% trifloroacetic acid; UV- 
detector 215nm.  
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Figure 3.2 Semi-preparative HPLC chromatogram of cyclotides from Viola yedoensis 
(VY). VY18 (Varv A, Kalata b1, and two unknown peptides) and VY19 (Varv E = 
cycloviolacin O12). The average molecular masses of the two unknown cyclotides 
which were determined by liquid column chromatography -mass spectrometer (LC-
MS) electron-spray ionization (Waters Micromass Q- TOF premium mass 
spectrometer) were found to be 2907.960 and 2894.006 Da. Solvent gradient at initial 
time: (A: 5% Acetonitrile: 0.1% Formic acid) and final time  (B: 95% Acetonitrile: 0.1% 
formic acid) increased from low organic to high organic. Ion source is electron spray 
ionization (ESI-nano spray); Fragmented mode is CID, CAD, IRMPD (y and b-ions); 
MS scan mode is Quadrupole; MS-MS mode is Time of Flight (TOF). 
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The molecular masses of the cyclotides, VP18, VP19, VY18 and VY19 were 
evaluated using HPLC directly coupled (online) to mass spectrometer (LC-MS) by 
electronspray ionization potential (Figure 3.3) and by tandem mass 
spectrometer(MS/MS) using Quadrupole- Time of flight (Q-TOF) mass spectrometer. 
There was an observed increase in molecular mass of cyclotides by 6Da after 
reduction by TCEP (Figures 3.4 and 3.5) which could signify the presence of three 
disulphide bonds in cyclotides. This is consistent with previous studies (He et al 
2011). The MS/MS sequencing of TCEP-reduced and enzymes (trypsin/Endo-Glu-
C/chymotrypsin) digested cyclotides resulted to identification of primary structures of 
alignments of the sequences of the cyclotides from V. philippica (VP) and V. 
yedoensis (VY) (Figures 3.6 and 3.7). The primary structures (sequence) of the 
cyclotides were identified by comparison of alignments of the sequences of the 
cyclotides obtained with the literature search from CyBase (database of known 
cyclotides) (He et al., 2011). For instance, VP18 were identified to contain Varv A 
(Figure 3.6), Kalata b1, Viba 15, Viba 17 (42:26:21:11). VP19 contained cyclotides 
Varv A, Varv E, Viba 15, and Viba 17 (44:11:17:28) (Figure 3.7). VY18 contained 
Varv A, Kalata b1, and two unknown peptides co-eluted in this peak and VY19 was 
Varv E (Cycloviolacin O12). The monoisotopic molecular masses of the two unknown 
cyclotides co-eluted in VY18 are 2907.960 and 2894.006 (Figure 3.3 and 3.4). The 
data obtained were in consistent with previous works (Wang et al. 2008; He et al. 
2011a). 
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Figure 3.3 LC-MS analysis of cyclotides of Viola philippica 10µL (VP18 and VP19) 
and Viola yedoensis 10µL (VY18 and VY19) after reduction and enzyme digest were 
injected into HPLC -MS (ESI) The bottom graph is an expansion of top graph. 
Solvent gradient at Initial time: (A: 5% Acetonitrile: 0.1% Formic acid) ending time (B: 
95% Acetonitrile: 0.1% formic acid) increased from low organic to high organic. 
After first semi - HPLC purification, 200µL of the major chromatogram peaks -  20µg 
(VP18, VP19, VY18 or VY19) were separately subjected to reduction and alkylation 
A 
B 
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of cysteine with 1µL of 0.1M buffered TCEP to identify the presence of three disulfide 
residues which suggested the presence of cyclotides. These peaks were 
subsequently subjected to enzymatic cleavage using Endo- GluC that targets C-
terminal bond cleavage and further digested using trypsin which cleaves at carboxyl -
terminal of arginine and lysine residues to create a sequence specific peptides with 
basic carboxyl terminal (Steen and Mann, 2004). Also in ESI the tryptic peptides are 
double charged and y-ions are common. The final products, 10 µL each peptide was 
further injected to HPLC which was directly coupled online to mass spectrometer 
(LC-MS)- The Waters Q-TOF premium Mass spectrometer. The peptides were 
separated and analyzed (Figure 3.3) by mass to charge ratio through electron spray 
ionization potential mechanism (Steen and Mann, 2004). The signal intensity or mass 
spectrum is directly proportional to analyte concentration (Steen and Mann, 2004).   
Here the peptides were eluted per their hydrophobicity using gradient solvent elution 
with increasing organic solvent (0.1% Formic acid: 95% Acetonitrile). The most 
hydrophobic would be late -eluted and the most hydrophilic would be first eluted 
(Steen and Mann, 2004). The peptides produced at this stage are known as tryptic 
peptides (which are usually doubly charged in electron-sprayed ionization) or 
precursor peptides (Figures 3.3 -3.5) with quadrupole mode. These ions were further 
fragmented by MS-MS using Tandem - mass spectrometer (MS/MS) by time of flight 
(TOF) mass spectrometer scan mode to obtain the final Tandem-MS spectrum of the 
peptides sequence which produced y-ions or b-ions (Steen and Mann, 2004). Usually 
y-ions are common in tryptic peptides. The sequence specific ions were further 
analyzed by Peptide-search, to identify the peptide sequence using mascort generic 
file search engine and Denovosequence auto software. The results of the sequence 
alignment obtained were compared to or matched with existing peptide database – 
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search in CyBase library of cyclotides sequence to identify the actual sequence 
(Figures 3.6 - 3.7). 
 
Figure 3.4 ESI-MS of Viola philippica cyclotides - VP18 (top) and VP19 (bottom) after 
TCEP reduction. Ion source is electronspray ionization (ESI-nano spray). 
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Figure 3.5 ESI-MS of cyclotides VY18 (top) and VY19 (bottom) from Viola yedoensis 
after TCEP reduction. Ion source is electronspray ionization (ESI-nano spray). 
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Figure 3.6 Mass Spectrum of Varv A cyclotide in VP18 after TCEP reduction, 
enzymatic digestion (left) and MS/MS spectrum of a fragment peptide-4 (right). Ion 
source is electronspray ionization (ESI-nano spray); Fragmented mode is CID, CAD, 
IRMPD (y and b-ions); MS scan mode is Quadrupole; MS-MS mode is Time of Flight. 
This shows the bioactive cyclotide to be Varv A 
(GLPVCGETCVGGTCNTPGCSCSWPVCTRN). 
 
 
 
The isolated column chromatography fraction of Viola yedeonsis extract were purified 
by HPLC to identify major peaks and separate the pure compounds. The major peaks 
were subjected to reduction and alkylation of cysteine to identify the presences of 
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three disulfide residues which suggest the presence of cyclotides. These peaks were 
separately subjected to enzymatic cleavage using Endo- GluC that targets C-terminal 
bond cleavage and further digested using trypsin. The final   products were further 
subjected to separation by HPLC with direct online couple to mass spectrometer (LC-
MS) which separated and analyzed the peptides by mass to charge ratio through 
electronspray ionization potential mechanism (Steen and Mann, 2004). The signal 
intensity or mass spectrum is directly proportional to analyte concentration (Steen 
and Mann, 2004).   Here the peptides were eluted per their hydrophobicity using 
gradient solvent elution with increasing organic solvent (0.1% Formic acid:  90% 
Acetonitrile). The most hydrophobic would be late -eluted and the most hydrophilic 
would be first eluted (Steen and Mann, 2004). The electron-sprayed ionized, purified 
and separated peptide ions  were which was scanned by quadrupole mode were 
further  fragmented using tandem Mass Spectrometer  (MS-MS)  by  time of flight 
(TOF) scan mode .Then the cyclotides sequence were determined or identified using 
Mascort generic file search engine and Denovosequence computer auto software 
peptide-search applications to analyze the peptide ions for sequence (Steen and 
Mann, 2004).The results of sequence alignment obtained were compared or matched 
with already known sequence  in the peptide sequence database - searching of  
library of cyclotides sequence (CyBase) (Figure 3.6 - 3.87). 
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Figure 3.7 Alignment of the sequences of the cyclotides isolated and identified from 
V. philippica (VP) and V. yedoensis (VY). The cysteine residues numbered as I-VI 
are highlighted in red colour and the backbone loops are numbered as loop1-6. 
 
3.2 Anticancer activities of the crude extracts and cyclotides of V. philippica 
and V. yedoensis  
  
The anti-cancer activities of extracts and cyclotides of V. philippica and V. yedoensis 
on different ovarian cancer cell lines (Igrov-1; A2780 and Ovcar-8) were done using 
cell growth assay. The results showed that the butanol fraction and the cyclotides of 
V. philippica (VP18 and VP19) and V. yedoensis (VY18 and VY19) exhibited 
significant growth inhibition activities on different ovarian cancer (Igrov-1, A2780 and 
Ovcar-8) cell lines (Tables 3.3 and 3.4; Figures 3.8 – 3.11). The cyclotide, Varv E 
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appeared to be mostly potent against the three ovarian cell lines tested (Table 3.4 
and Figure 3.8). All the cyclotides identified possess glutamic acid residues in loop 1 
(Figure 3.7). This is consistent with previous reports which revealed that glutamic 
acid residues in loop 1 and hydrophobicity of cyclotides are essential for cytotoxicity 
of cyclotides (He et al. 2011a; Hermann et al. 2006; Tang et al. 2010). 
 
Table 3.3 Cytotoxicity IC50 of fractions and cyclotides from V. philippica (VP). Data 
represented as mean ± SEM of the IC50, n = 5 independent experiments. 
 
 
 
 
 
Sample code cyclotides 50% concentration inhibition 
(IC50)    on cell lines 
Igrov-1 A2780 Ovcar-8 
     
VP-MW-BU n-Butanol fraction  6.9±0.1 
µg/mL  
6.5± 
0.4 
µg/mL  
14.7±1.0 
µg/mL 
VP18 
 
Varv A, Kalata b1, Viba 
15, Viba 17 (42:26:21:11) 
8.6±0.5 
µM  
4.1±0.3 
µM  
9.9±0.6 
µM 
VP19 
 
Varv A, Varv E, Viba 15,  
Viba 17 (44:11:17:28) 
 
10.8±1.8 
µM 
6.9±0.6 
µM  
11.1±0.8 
µM 
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Table 3.4 Cytotoxicity of fractions and cyclotides from V. yedoensis (VY). Data  
represented as Mean ± SEM of the IC50, n = 5 independent experiments. 
 
 
 
 
 
Sample Code cyclotide 50% concentration inhibition 
(IC50)     on cell lines 
Igrov-1 A2780 Ovcar-8 
VY-MW-BU n-Butanol fraction 6.7±0.1 
µg/mL  
6.4±0.4 
µg/mL 
14.5±1.0 
µg/mL 
VY18 
 
 
Varv A, Kalata b1, and  
 two unknown peptides 
11.5±0.4 
µM 
9.5±0.3 
µM 
11.2±0.3 
µM 
VY19 
 
Varv E=Cycloviolacin O12  5.5±0.3 
µM 
5.7±0.2 
µM 
6.5±0.4 
µM 
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Figure 3.8 Concentration-response curves of VP18 [Varv A, Kalata b1, Viba 15, Viba 
17 of Viola philippica against Ovcar-8 (A), A2780 (B), Igrov-1 (C) ovarian cancer cell 
lines with normalized (to control) absorbance at 570nm. At concentrations or dose 
range tested (0.16 – 40µM), VP18 showed cytotoxicity of the ovarian cancer cell at 
doses of 5, 10, 20 and 40µM.There was no observed cytotoxicity effects observed 
below 5µM of VP18. A570 on y-axis, represents normalized absorbance at 570nm 
(optical density). Graph determined by four parameters fitting sigmoid curve (graph 
pad prism). Data represented as mean ± SEM of IC50.  C represents IC50 of control 
(no drug, only medium). n = 5   independent experiments. 
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Figure 3.9 Concentration-response curves of VP19 [Varv A, Varv E, Viba 15, Viba 17 
of Viola philippica on Ovcar-8 (A) and   A2780 (B) ovarian cancer cell lines with 
normalized (to control) absorbance at 570nm. At concentrations or dose range tested 
(0.16 – 40µM), VP19 showed cytotoxicity of the ovarian cancer cell at doses of 5, 10, 
20 and 40µM.There was no observed cytotoxicity effects observed below 5µM of 
VP19.A570 on y-axis represents absorbance at 570nm (optical density) normalized. 
Graph determined by four parameters fitting sigmoid curve (graph pad prism). Data 
represented as mean ± SEM of IC50. C represents IC50 of control (no drug). n = 5   
independent experiments 
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Figure 3.10 Concentration-response curves of VY18 [Varv A, Kalata b1, and two 
unknown peptides] of Viola yedoensis on Ovcar-8 (A), A2780 (B), Igrov-1 (C) cancer 
cell lines with normalized (to control) absorbance at 570nm. At concentrations or 
dose range tested (0.16 – 40µM), VY18 showed cytotoxicity of the ovarian cancer 
cell at doses of 5, 10, 20 and 40µM.There was no observed cytotoxicity effects 
observed below 5µM of VY18. A570 represents absorbance at 570nm. (optical 
density). Graph determined by four parameters fitting sigmoid curve (graph pad 
prism). Data represented as mean ± SEM of IC50.  C represents IC50 of control (no 
drug). n = 5   independent experiments. 
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Figure 3.11 Concentration-response curves of VY19 (Varv E = Cycloviolacin O12) of 
Viola yedoensis on Ovcar-8 (A), A2780 (B), Igrov-1 (C) cancer cell lines with 
normalized (to control) absorbance at 570nm. At concentrations or dose range tested 
(0.16 – 40µM), VY19 showed cytotoxicity of the ovarian cancer cell at doses of 5, 10, 
20 and 40µM.There was no observed cytotoxicity effects observed below 5µM of 
VP19. A570 represents absorbance at 570nm (optical density) normalized. Graph 
determined by four parameters fitting sigmoid curve (graph pad prism) Data 
represented as mean ± SEM of IC50. C represents IC50 of control (no drug). n = 5   
independent experiments. 
 
 
115 
 
3.3 Anti-malarial activities of the fractions of V. philippica  
The preliminary in vitro anti-malarial activities of V. philippica extracts and fractions 
were assayed on chloroquine- resistant malaria strain of Plasmodium falciparum. 
Results showed that different extracts and fractions of Viola philippica, at 
concentrations of 5µg/mL, 50µg/mL and 500µg/mL caused decrease in percentage 
growth (parasitamia) of the malaria parasites (Figure 3.12). The butanol fraction (VP-
MW-BU), aqueous extract (VP-MW-A1), aqueous fraction seaparated from 
butanol/water  factionation (VP-MW-A2),  dichloromethane crude extract (VP-DCM), 
the methanol crude extract  (VP-MW)  inhibited growth of malaria parasites (Figure 
3.12). 
 
Figure 3.12 In-vitro preliminary antimalarial assay of different doses (5, 50 and 500 
µg/mL) of extract and fractions of Viola philippica. VP-MW-BU represents butanol 
fraction; VP-MW-A1, water extract; VP-MW-A2, aqueous lower fraction; VP-DCM, 
dichloromethane extract, and VP-MW, crude MeOH extract.  
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From the results of V. philippica  (Figure 3.12), at 50µg/mL  the butanol fraction (VP-
MW-BU) showed highest percentage growth inhibition about 55% while aqueous 
fraction (VP-MW-A2) exhibited the least  percentage parasite growth inhibition 
(Figure 3.12).  
The butanol fraction (VY-MW-BU) of Viola philippica  was subjected to silca gel 
column chromatography (CHCl3:MeOH) as previously described (Tab 3.1). The 
different  column fractions at concentrations (0.5, 5 and 50µg/mL) showed different 
percentage growth inhibition (Fig 3.13). The significant percentage growth inhibition 
was observed at concentration of 50µg/mL in all the fractions (Fig 3.13). Fraction 
VPF6 exhibited most significant percentage growth inhibition with 10% growth of 
malaria parasite at 50µg/mL. VPF5 showed about 15% parasite growth at 50µg/mL, 
VPF3 20% and VPF1 30% (Fig 3.13). The rest of the fractions (VPF2, VPF4, VPF7 
and VPF8) exerted 50% and above parasite growth at 50µg/mL (Figure 3.13). This 
suggested that V.philipicca exhibited moderate in vitro anti-malarial activity. No 
further identification was carried out at this stage. 
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Figure 3.13 Antimalarial activities of silica gel column chromatography fractions of 
butanol extract of Viola philippica. VPF1 represents first silica gel column 
chromatography (chloroform: MeOH) fraction (Table 3.1) of butanol fraction of V. 
philippica (VY-MW-BU).  
 
3.4 Discussion 
In this study, we have isolated, purified, characterized, identified and elucidated 
primary structures of cyclotides from V. philippica [(VP18: Varv A, Kalata B1, Viba 15, 
and Viba 17) and (VP19: Varv A, Varv E, Viba 15, and Viba 17)] and V. yedoensis 
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[(VY18: Varv A, Kalata B1, and two unknown peptides) and (VY19: Varv E)]. All the 
identified cyclotides are known. The two unknown cyclotides with molecular masses 
of 2907.960 and 2894.006 Da, found co-eluted in VY18 are still undergoing further 
analysis for their proper identification and structure elucidation.   
We have also carried out scientific investigation and could establish scientific data on 
the in vitro anti-ovarian cancer activities of the cyclotides of V. philippica and V. 
yedoensis. Although the cytotoxicity of cyclotides had previously been reported 
(Herrmann et al., 2008, Wang et al., 2007, Tang et al., 2010, Svangård et al., 2004, 
Lindholm et al., 2002, He et al., 2011a) this is a novel report of the anti-ovarian 
cancer activities of Varv E and anti-cancer activities of V. yedoensis. Varv E could 
serve as a starting material in drug discovery in search of anti-ovarian cancer drug 
with more potent or improved anti-ovarian cancer activity. However structural 
elucidation of the unknown peptides from V. yedoensis is on-going. We have equally 
done some preliminary in-vitro antimalarial screening of extracts or fractions from V. 
philippica. This report therefore, is a novel report of antimalarial effects of V. 
philippica. However, further study needs to be done to determine the IC50 of V. 
philippica on malaria parasite.  
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CHAPTER FOUR 
 
ISOLATION, IDENTIFICATION AND ANTI-CANCER ACTIVITY OF ALKALOIDS 
FROM TRICLISIA SUBCORDATA 
 
4.1 Results of phytochemical screening tests of extract of T. subcordata root 
 
The preliminary phytochemical screening of ethanol extract of Triclisia subcordata 
root was carried out to identify possible metabolites of crude extracts of Triclisia 
subcordata root. The preliminary screening tests revealed the presence of alkaloids, 
saponins, tannins, steroids (phytosterols), flavonoids, and terpenes (Table 4.1 and 
4.2).  
 
Table 4.1 Preliminary phytochemical screening results of ethanol extracts Triclisia 
subcordata root. 
Phytoconstituents Inference 
Alkaloids +++ 
Saponins ++ 
Tannins +++ 
Flavonoids ++ 
Free Anthraquinone 
Combined anthraquinones 
 - 
 - 
Terpenes/sterols ++ 
Carbohydrates + 
Cardiac glycosides      - 
+ Slightly present; ++ moderately present; +++ much present; - absent. 
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The extraction and fractionation of T. subcordata (Figure 2.2 and 2.3) yielded the 
total crude extract (TSS), the total alkaloid (TSS1), the aqueous fraction (TSS2) and 
the aqueous methanol fraction (TSS3). Both TSS1 and TSS3 showed positive 
Dragendorff’s tests, which indicated the presence of alkaloids in these fractions. The 
TSS1 was further fractionated by silica gel column chromatograph using CHCl3: 
MeOH gradient elution to get different fractions F1 - F47 (Table 4.2). 
Table 4.2 Isolated alkaloids and fractions from total alkaloids (TSS1) of T. 
subcordata by silica gel column chromatography. 
Codes for fractions 
from TSS1 
Dragendorff’s  
test 
weights TLC and Dragendorff’s tests 
observation. 
 F1-4 -- 106mg No colouration. 
 F5 +++ 727mg Single spot (cycleanine) 
 F6 +++ 5. 82g Single spot (cycleanine) 
 F7 +++ 1.40g Single spot 
 F8 +++ 1.28g Single spot 
 F9 +++ 1.76g Double spots 
 F10-11 +++ 3.17g Double spots 
 F12 +++ 140mg Single spot 
 F13-17 +++ 300mg Double spots 
 F18-19 +++ 350mg Double spots 
 F20  +++ 125mg Double spot 
 F21-22 +++ 150mg Double spot 
 F23- 25 
 
+++ 409 mg  Double spot 
Recrystallization: MeOH 
 F26 -27 ++ 118mg Multiple spots 
 F28-30 ++ 300mg Multiple spots 
 F31-32 ++ 40mg Double spots 
 F33-35 +++ 120.9mg  Double spots 
 F36-38 ++ 106mg  Double pots 
 F39 ++ 30.3mg Double spots 
 F44-47  ++ 36mg Single spot  
 
+ represents alkaloids present trace; ++ moderately present: +++ much present; -- 
absent  
 
Different fractions eluted from CHCl3: MeOH (99:1) to CHCl3: MeOH (1: 99) as 
gradient elution gave non- alkaloids fraction (F1-4) that showed negative test results 
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with Dragendorff’s test (Table 4.2); pure alkaloid fractions as F5-6 (identified as 
cycleanine); and other alkaloid fractions such as F7-47 with respective weights 
(Table 4.2). TLC under UV-lamp 360/540nm and using iodine tests and Dragendorff’s 
tests also showed different degree of spots and intensity of orange coloration with 
these compounds, confirming the presence of alkaloids in these fractions (Table 4. 
2).  
 
4.2 Isolation and structure elucidation of alkaloids from T. subcordata 
4.2.1 Structure elucidation of anticancer alkaloids from T. subcordata    
Bioassay-guided fractionation of TSS1 resulted in isolation of three pure alkaloids 
using silica gel chromatography and/or HPLC (Figure 2.2, 2.3). The analytical HPLC 
and LC-MS were carried  out to confirm the purity of the isolated  componds in Figure 
4.1. These were identified on the basis of spectroscopic data including LC-MS, 1H 
NMR, and 13C NMR (Figure 4.2-4.4 and Tables 4.3-4.6) as the BBIQ alkaloids 
cycleanine (1), isochondodendrine (2) and 2′-norcocsuline (3) in comparison with 
their spectroscopic data in the literature (Kanyinda et al., 1997, Liu et al., 2013). The 
quantitative analysis of analytical HPLC of total alkaloids (TSS1) revealed the 
percentage of pure BBIQ in T. subcordata as cycleanine 83.7%; isochondodendrine 
7.5% and 2′-norcocsuline 1% (Figure 4.1A).  
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Figure 4.1 Chromatograms of analytical HPLC of total alkaloids (A), purified 
cycleanine (B), isochondodendrine (C) and 2′-norcocsuline (D). The peaks were 
correlated to the original peaks in the total alkaloid TSS1 (A) chromatogram from 
where they were purified. 
 
Cycleanine was also isolated as a TFA salt form when using HPLC where the solvent 
system contained 0.1 % TFA. 1H NMR and 13C NMR of the TFA salt of cycleanine 
showed slight difference from those of cycleanine (Table 4.3 and 4.4). The structures 
of the three BBIQ alkaloids from T. subcordata were shown in Figure 4.2. Also, the 
123 
 
TFA salt of 2′-norcocsuline exhibited slight difference in 1H NMR and 13C NMR from 
2′-norcocsuline, but when the pure alkaloid (base) from the TFA salt was re-extracted 
by the normal procedure for alkaloid extraction (previously described in Chapter 2) 
the observed 1H NMR and 13C NMR of 2′-norcocsuline became similar and 
comparable to the literature data for 2′-norcocsuline (Tables 4.5 and 4.6). 
Cycleanine (Figure 4.2) has been isolated from many other plants species of the 
Menispermaceae family (Schiff, 1997). Cycleanine was shown to increase the 
intracellular doxorubicin accumulation in the resistant MCF -7 /Adr cell lines (Tian and 
Pan, 1997). Here cycleanine is being isolated and characterized from Triclisia 
subcordata as part of novel contribution to knowledge. 
Tetrandrine, (Figure 4.2) an isomer of cycleanine is also a common BBIQ reported in 
different plants including Triclisia subcordata (Dwum-Badu et al 1995).Tetrandrine 
has been shown to exert various  biological activities including anticancer, (Chen, 
2002), antiallergic, anti-inflammatory, anti-malarial, and cardiovascular effects (Schiff, 
1997).Tetrandrine inhibited the growth of various types of cancer cell line (Chen, 
2009;  He etal 2011; Xu et al 2011) and  could reverse multi-drug resistance by 
inhibiting P-glyco protein activity (Sun and Wink, 2014). 
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Figure 4.2 Structure of three BBIQ alkaloids, cycleanine (1), isochondodendrine (2) 
and 2′-norcocsuline (3) from T. subcordata. Tetrandrine is an isomer of cycleanine 
previously reported in T. subcordata. Structures reported per analysis of results   from 
spectroscopic data from 1H NMR (400 MHz, CDCl3) (Table 4.3) and 
13C NMR (100 
MHz, CDCl3) (Table 4.4) 
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Table 4.3 1H NMR (400 MHz) chemical shift data (δ, ppm) for cycleanine (1), the TFA 
salt of cycleanine (CDCl3), isochondodendrine (CDCl3 + CD3OD (1:1) (Figure 4.3) (2) (J 
values, in Hz, in parentheses). 
 
 
 
 
Position Compound (δH) 
Cycleanine (1) TFA salt of cycleanine  Isochondodendrine (2) 
H-1 4.29, d (10.39) 4.97 br d (6.48) 4.28, d (10.72) 
H-1′ 4.29, d (10.39) 4.97 br d (6.48) 4.28, d (10.72) 
H-3 α, 3.28 m; β, 2.92 m α, 4.00 m; β, 3.24 m α, 3.28 m; β, 2.92 m 
H-3′ α, 3.28 m; β, 2.92 m α, 4.00 m; β, 3.24 m α, 2.92 m; β, 2.92 m 
H-4 α, 3.05 m; β, 2.92 m α, 3.46 m; β, 3.24 m α, 3.15 m; β, 2.90 m 
H-4′ α, 3.05 m; β, 2.92 m α, 3.46 m; β, 3.24 m α, 2.92 m; β, 2.92 m 
H-5 6.57 s 6.66 s 6.57 s 
H-5′ 6.57 s 6.66 s 6.57 s 
H-10 7.05 dd (8.44; 2.08) 7.27 (overlapped, brs) 7.00 (brd) 
H-10′ 7.05 dd (8.44; 2.08) 7.27 (overlapped, brs) 7.00 (brd) 
H-11 6.66 dd (8.44; 2.81) 6.66 (overlapped, brs) 6.49 dd (8.29; 2.64) 
H-11′ 6.66 dd (8.44; 2.81) 6.66 (overlapped, brs) 6.49 dd (8.29; 2.64) 
H-13 5.82 dd (8.31; 2.81) 5.79 br d (6.85) 5.74 dd (8.29; 2.64) 
H-13′ 5.82 dd (8.31; 2.81) 5.79 br d (6.85) 5.74 dd (8.29; 2.64) 
H-14 6.28 dd (8.44; 2.20) 6.28 br d (7.70) 6.19 dd (8.29; 1.51) 
H-14′ 6.28 dd (8.44; 2.20) 6.28 br d (7.70) 6.19 dd (8.29; 1.51) 
H-α α, 2.52 m; β, 3.28 m α, 2.77 m; β, 3.66 m α, 2.50 m; β, 3.29 m 
H-α′ α, 2.52 m; β, 3.28 m α, 2.77 m; β, 3.66 m α, 2.50 m; β, 3.27 m 
6-OMe 3.81 s 3.87 s 3.75 s 
6′-OMe 3.81 s 3.87 s 3.75 s 
7-OMe 3.40 s 3.42 s  
7′-OMe 3.40 s 3.42 s  
N-Me 2.53 s 2.80 s 2.41s 
N′-Me 2.53 s 2.80 s 2.41s 
CF3COOH  12.26 s  
126 
 
Table 4.4 13C NMR (100 MHz) chemical shift data (δ, ppm) for cycleanine (1), the 
TFA salt of cycleanine (CDCl3), isochondodendrine (CDCl3 + CD3OD (1:1) (Figure 
4.4) (2).  
 
 
 
 
Carbon Compound (δC) 
Cycleanine (1)  TFA salt of cycleanine Isochondodendrine (2) 
1 (1′) 60.09 60.81 59.65 
3 (3′) 44.63 43.89 44.15 
4 (4′) 24.67 21.64 23.20 
4a (4a′) 130.31 129.35 129.27 
5 (5′) 109.22 108.87 108.21 
6 (6′) 152.01 153.95 148.04 
7 (7′) 139.02 140.20 136.18 
8 (8′) 143.77 144.79 138.29 
8a (8a′) 125.11 125.49 123.60 
9 (9′) 129.53 128.48 128.58 
10 (10′) 128.73 127.20 128.11 
11 (11′) 117.47 118.49 117.53 
12 (12′) 154.15 154.13 154.25 
13 (13′) 114.05 114.11 113.99 
14 (14′) 128.25 125.49 128.11 
α (α′) 37.96 40.71 37.90 
6-OMe (6′-OMe) 56.07 56.16 55.43 
7-OMe (7′-OMe) 59.63 60.38  
N-Me (N′-Me) 42.34 41.42 41.06 
CF3COOH  116.18  
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Figure 4.3 1H NMR of isochondodendrine (CDCl3 + CD3OD (1:1)). 
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Figure 4.4 13C NMR of isochondodendrine [CDCl3 + CD3OD (1:1)] 
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Table 4.5 1H NMR chemical shift data (δ, ppm) for 2′-norcocsuline (3) and (+)-2′-
norcocsuline-TFA salt (500 MHz, MeOD + CDCl3). 
 
 
prot
on 
2’-
norcocsuli
ne-TFA 
salt  
2’-
norcocsul
ine (3) 
2’-
norcocsul
ine (3) 
 (Liu et al. 
2013)  
prot
on 
2’-
norcocsuli
ne-TFA 
salt  
2’-
norcocsul
ine (3) 
2’-
norcocsul
ine (3) 
(Liu etal. 
2013) 
H-1 4.32 3.34 m 
 
3.32 m H-1′  4.78  4.36 brs 4.35 brs 
H-3 3.15, 3.07  2.65 m 2.67 m; 
 
H-3′ 3.05, 3.23  2.86 m; 
3.33 m 
2.86 m; 
3.17 m 
H-4 3.12, 2.95  2.65 m 2.67 m; 
 
H-4′ 2.95,3.12    
H-5 6.62s 6.63 s 6.62 s H-5′ 6.69 s 6.33 s 6.31 s 
H-8 6.51s 6.17 s 
 
6.15 s H-8’ -   
H-15 3.67, 3.56  2.72 m; 
2.98 dd 
2.67 m; 
2.95 dd 
(14.2, 2.0) 
H-15′ 3.32, 3.12   3.15 m; 
   3.27 dd 
2.62 m; 
3.32 dd 
(15.0, 2.3) 
H-10 6.88 d 6.53 (d, 
1.9)  
 
 6.52 brs  
 
H-10′ 7.12 7.20 dd 
(7.9, 2.1) 
7.19 brd  
H-11 -   H-11′ 6.91 6.97 (dd, 
8.2, 2.5) 
7.00 (dd, 
8.2, 2.4) 
H-13 6.84d   6.93 d 
(8.2) 
 
6.91 d 
(8.1) 
H-13′ 7.23 7.22 (dd, 
8.2, 2.4) 
7.17 
7.21 brd  
H-14 6.90 dd 6.85 dd 
(8.0; 1.6) 
6.82 dd 
(8.1; 1.6) 
H-14′ 7.59 brd 7.68 (dd, 
8.4, 1.3) 
7.66 brd 
N-Me 2.53 (brs) 2.46 s 2.44 s 6′-
OMe 
3.86 s 3.88 s 3.86 s 
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Table 4.6 13C NMR (125 MHz, CD3OD (48.0 ppm as reference) + CDCl3) chemical 
shift data (δ, ppm) for 2′-norcocsuline (3) and the 2′-norcosculine-TFA salt. 
Carb
on  
2′-
norcocsuli
ne-TFA 
salt   
2′-
norcocsul
ine (3) 
2′-
norcocsul
ine (Liu 
et al. 
2013) 
Carb
on 
(+)-2′-
norcocsuli
ne-TFA 
salt  
2′-
norcocsul
ine (3) 
2′-
norcocsul
ine (Liu 
et al. 
2013) 
1 62.8 67.4 67.5 1′ 51.8  54.0 54.2 
3 47.5 49.3 49.6 3′ 40.0 44.6 44.9 
4  23.6 27.7 27.7 4′ 23.1 27.7 28.3 
4a  131.2 - 134.8 4a′ 129.7 - 129.8 
5 118.4 115.4 115.5 5′ 107.9 106.3 106.7 
6  138.5 - 139.5 6′ 146.2 - 146.1 
7 139.8 - 139.7 7′ 130.6 - 135.7 
8 114.4 113.8 114.1 8′ 138.5 - 140.6 
8a   - 133.8 8a′ 121.5 - 122.0 
15 36.1 40.7 41.3 15′ 40.2 38.4 38.7 
9  126.5 - 129.6 9′ 139.9 - 138.9 
10 116.1 116.2 116.6 10′ 130.8 - 131.3 
11 146.2 - 143.7 11′ 123.0 121.2 121.3 
12 148.3 - 148.1 12′ 161.7 - 153.9 
13 115.9 115.3 115.8 13′ 122.4 122.4 122.5 
14  116.8 122.4 122.2 14′ 130.0 128.2 128.2 
N-Me  35.4 42.4 43.0  6′-   
OMe 
55.7 56.1 56.3 
 
-, peaks are not observed due to dilute sample in 13C NMR recording. 
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4.3 Anticancer activities of fractions and alkaloids from T. subcordata 
 
4.3.1 Cell growth assays of fractions of T. subcordata 
 
All the extracts and fractions except aqueous fraction (TSS2) showed different levels 
of growth inhibition of ovarian cancer cells (Table 4.7 and Fig. 4.5). The most potent 
activity was exhibited by the alkaloid-enriched fraction (TSS1). The TSS1 also 
showed some selectivity for the cancer cells because the growth of normal human 
ovarian epithelia cells HOE was inhibited with almost 10-fold lower potency (Table 
4.7).  
 
Table 4.7 The IC50 and SI values of the total extracts and fractions of T. subcordata 
on Ovcar-8, A2780, and normal human ovarian epithelia (HOE) cells (the data are 
expressed as mean ± SEM (n=3). Selective index (SI) is defined as the ratio of IC50 in 
OSE cells to that in the cancer cells. ND represents not determined. 
 
Sample and SI  
IC
50
 (µg/ml) 
Ovcar-8 A2780 HOE 
TSS 4.2 ± 1.1 2.6 ± 1.2 ND 
TSS1 
SI for TSS1 
 2.4 ± 0.5 
 8.2  
2.1 ± 0.9 
9.5 
20 ± 1.3 
- 
TSS2 53 ± 3.0 39 ± 2.4 ND 
TSS3 
SI for SS3 
6.0 ± 2.1 
1.4 
3.5 ± 1.1 
2.4 
8.2 ± 1.1   
- 
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Figure 4.5 Anticancer activities of the total alkaloid extract and other bioactive 
fractions from T. subcordata in Ovcar-8 cells. (A) Total alkaloid extract; (B) F18; (C) 
F21 on ovarian cancer cell lines. The Ovcar-8 ovarian cancer cell lines treated with 
different concentrations of fractions (0.16 – 40 µM) and total alkaloid extract A (0.16 – 
40 µg/mL) over 72h showed significant IC50. Data determined by four parameters 
fitting sigmoid curve represented as mean ± SEM, n = 5. A570 in y-axis represents 
normalized (to control) absorbance at 570nm (optical density). C represents IC50 of 
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control (no drug, only medium). The IC50 of total alkaloids was shown to be 2.3 ± 0.2 
µg/ml, R2= 0.9835. 
4.3.2 Cell growth assays of BBIQ alkaloids of T. subcordata 
 
The IC50 of the BBIQ alkaloids of T. subcordata (cycleanine, isochondodendrine, 2’-
norcocsuline and tetrandrine) were determined on different ovarian cancer cell lines 
and normal HOE cells, to evaluate their potency on these cell lines. These BBIQ 
alkaloids exhibited different IC50 values ranging from 0.8 ± 0.1 to 17.4 ± 0.3 µM 
(Table 4.8). Tetrandrine was previously reported in T. subcordata while cycleanine, 
isochondodendrine and 2′-norcocsuline are new report in T. subcordata in this study.  
Also, this is the first-time report of cytotoxic effects of cycleanine and 
isochondodendrine on ovarian cancer, to the best of our knowledge. Carboplatin and 
paclitaxel were used as positive controls (Table 4.8). The selective index (SI), an 
indicator of safety of these drugs on normal HOE cells is also shown (Table 4.8). The 
SI of cycleanine ranged between 3 and 5 consistent with the preliminary evidence for 
moderate selectivity of TSS1 for cancer cells.    
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Table 4.8 The IC50 and SI values of the BBIQ alkaloids of T. subcordata on Ovcar-8, 
A2780, Igrov-1 and Ovcar-4 cells (the data are expressed as mean ± SEM (n=3).  
Sample name   Cell lines/IC
50 
± SEM (µM
)
 
 
 Ovcar-8  A2780 Igrov-1  Ovcar-4 HOE 
Carboplatin 12 ± 0.9 16 ± 1.0 8 ± 0.7 16 ± 1.1 - 
Cycleanine 
 
7.9 ± 0.6  
 
5.6±0.5 7.2 ± 0.4 
 
14 ± 1.0        
 
35 ± 0.1 
 
SI 3.4 4.6 4.8 2.6  
Isochondodendrine 3.5 ± 0.1 8.0±0.6 9.0 ± 0.5 17 ± 0.3 10.5 ± 1.2 
 
SI 3 2.5 > 1 <1 - 
2′-norcocsuline 
 
SI 
1.9 ± 0.2  
 
1.5 
2.9±0.1    
 
 > 1 
0.8 ± 0.1  
  
3.5 
6.2 ± 0.5 
 
> 1 
8.0 ± 0.2 
 
- 
Tetrandrine 12 ± 1.4 7.7 ± 0.2 6.9 ± 0.6 9.3±0.4  
Paclitaxel  5.8 nM 4.6 nM ND 8.7 nM - 
 
Carboplatin and paclitaxel served as positive control. ND represents not determined. 
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Figure 4.6 Anticancer activities of cycleanine and isochondodendrine on ovarian 
cancer cell lines. Concentration-response curves of cycleanine on Ovcar-8 (A) and 
A2780 (B), isochondodendrine on Ovcar-8 (C) and A2780 (D), respectively. 
Cycleanine and isochondodendrine at dose range of 0.16 – 40 µM over 72h showed 
cytotoxicity on ovarian cancer cells. The dose range that showed most activities 
includes 2.2- 40 µM. Data determined by four parameters fitting sigmoid curve 
represented as mean ± SEM, n=5. A570 in y-axis represents normalized (to control) 
absorbance at 570nm (optical density). C represents IC50 of control (no drug, only 
medium).  
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Figure 4.7 Cytotoxicity of 2′-norcosculine and tetrandrine from T. subcordata. The 
concentration versus response curves of 2′-norcosculine (A-C) on Ovcar-8, Igrov-1, 
A2780 and tetrandrine on Ovcar-8 (D) cancer cell lines. A570 represents normalized 
(to control) absorbance at 570nm. (optical density). 2′-norcosculine and tetrandrine at 
dose range of 0.16 – 40 µM over 72h, showed cytotoxicity on ovarian cancer cells. 
The dose range that showed most activities includes 2.2- 40 µM. Results determined 
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by four parameters fitting sigmoid curve. Data represented as mean ± SEM, n = 5. C 
represents IC50 of control (no drug, solvent).  
 
4.3.3 Cytotoxicity 
 
The trypan blue exclusion method was employed to distinguish cytotoxic and 
cytostatic effects. The viability of A2780, Ovcar-8, Igrov-1 and Ovcar-4 cells was 
reduced substantially by cycleanine, isochondodendrine, 2′-norcocsuline and 
tetrandrine, as well as by the positive control carboplatin, when the four cancer cell 
lines were exposed to the BBIQ alkaloids for 48 h (Figure 4.8). 
 
 
Figure 4.8 Trypan blue exclusion test of cell viability of ovarian cancer cell lines 
exposed to carboplatin, cycleanine, isochondodendrine, 2′-norcocsuline and 
tetrandrine. The percentage of viable cells of A2780, Ovcar-8, Igrov-1 and Ovcar-4 
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cell lines, 48h post-treatment with 20µM carboplatin (positive control), cycleanine, 
isochondodendrine, 2′-norcocucsuline and tetrandrine was determined by countess 
automated cell counter using trypan blue exclusion counting method. Negative 
control group was treated with solvent (medium, no drug). The data were recorded as 
mean ± SEM, n = 5. The cell viability of each cell line was significantly decreased 
(increased dead cells) in the treatment group, compared to control (non-treatment 
group). Two-way ANOVA analysis was used, P= 0.0005; post hoc multiple 
comparison t- test P<0.05 using Graph Pad prism software. 
 
 
Figure 4.9 Morphological effects of BBIQ alkaloids on Ovcar-8 cells. Time-dependent 
effects of control (A and G), carboplatin (B and H), cycleanine (C and I); 
isochondodendrine (D and J); 2′-norcocsuline (E and K) and tetrandrine (F and L) on 
the morphology of Ovcar-8 cells. There were morphological alterations of Ovcar-8 
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cells observed, after treated with carboplatin, cycleanine, isochondodendrine, 2′-
norcocsuline and tetrandrine (20 µM). These effects were reproducible in all 
experiments. (A and G) without drug. These were representative of five independent 
experiment.  
 
 
 
 
Figure 4.10 Concentration and time-dependent effects of BBIQ on the morphology of 
Ovcar-8 cells. Cycleanine (B, C, G and H); isochondodendrine (D, E, I and J); and 
control without drug treatment (A and F). Ovcar-8 cells exposed to different 
concentrations of Cycleanine and isochondodendrine (20 and 30 µM) for 24 and 48h 
respectively exhibited dose dependent effects on the morphology of the Ovcar-8 as 
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observed under phase contrast light microscope. These effects were reproducible in 
all experiments. These are representative of five independent observations. 
 
4.3.4 Apoptosis 
 
To evaluate whether the decrease in viabilities caused by cycleanine, 
isochondodendrine, 2′-norcocsuline and tetrandrine were due to apoptosis, the 
activation of caspase 3/7 activities by these compounds were evaluated.  Increased 
level of caspase activities in Ovcar-8, A2780 and Igrov-1 cells were observed (Figure 
4.11). Cycleanine, isochondodendrine, 2′-norcocsuline and tetrandrine increased 
caspase activity comparably to control, while tetrandrine and 2′-norcocsuline 
augmented caspase activity noticeably more, up to 8-fold (Figure 4.12). 
Morphological alterations of Ovcar-8 cells treated with carboplatin, cycleanine, 
isochondodendrine, 2-norcocsuline and tetrandrine were also consistent with 
apoptosis including membrane blebbing, rounding up and cell detachment (Figure 
4.9 - 4.10).   
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Figure 4.11 Caspase/apoptotic activities of BBIQ alkaloids from T. subcordata on 
three cancer cell lines. Enzymatic activities of caspase 3/7 after 48 h treatment of 
Ovcar-8 (A), A2780 (B) and Igrov-1 (C) cells with control (medium), carboplatin 
(positive control), cycleanine, isochondodendrine, 2′-norcocsuline and tetrandrine (20 
μM). The caspase activity is expressed as fold increase relative to control cells 
(mean ± SEM; n = 6). The caspase activity was significantly increased following 
carboplatin, cycleanine and tetrandrine exposure compared to cells treated with 
medium (control) where indicated (one-way ANOVA for group analysis, P<0.0001) 
Post hoc paired t-test (P<0.05, t-test) Culture medium served as negative control, 
carboplatin positive control.  
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To confirm the cells under-went apoptosis, PARP cleavage, a marker of apoptosis, 
was assessed by immunoblotting. Exposure of Ovcar-8 cells to cycleanine, 
isochondodendrine, 2′-norcocsuline, tetrandrine, or carboplatin resulted in significant 
PARP cleavage (Figure 4.13).             
 
 
 
 
 
 
142 
 
 
Figure 4.12 Western blot (PARP-cleavage) for cycleanine, isochondodendrine, 2′-
norcocsuline and tetrandrine from T. subcordata on Ovcar-8 cancer cell line. Western 
blotting analysis of the PARP-1 cleavage marker in Ovcar-8 cells after treatment with 
carboplatin, cycleanine, isochondodendrine, 2′-norcocsuline and tetrandrine. GAPDH 
was used as a loading control. A representative of three different observations is 
presented. The results showed that the treatment of carboplatin, cycleanine, 
isochondodendrine, 2′-norcocsuline and tetrandrine led to significant cleavage in 
PARP compared to control cells, respectively. There was no significant PARP-
cleavage observed in negative control. 
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To further quantify the percentage of apoptotic cells after treatment of these 
alkaloids, the cells were stained by Annexin V and PI and analysed by flow cytometry 
(Figure 4.13). Carboplatin, cycleanine isochondodendrine, 2′-norcocsuline and 
tetrandrine treatment after 48 h caused significant increase of the population of both 
early and late apoptotic cells compared to the control cells (Figure 4.13), quantified in 
4.13 G Ovcar-8 was selected to be used alone in western blot, Annexin V or cell 
cycle experiment among other four cells being used, for basic economic reasons. 
Also, particularly because ovar-8 is known to be most resistant or least sensitive 
among all the ovarian cells being used in this study. The assumption is that if ovcar-8 
could respond positively, then it is likely that other ovarian cells being used in this 
study (which are more sensitive than ovcar-8) probably would give positive response 
too. Due to limited resources, which was considered a challenge in this research all 
other ovarian cells could not be used in western blot, cell cycle and Annexin V. 
  
144 
 
 
145 
 
 
Figure 4.13 Flow cytometry analysis of apoptotic effects of carboplatin, cycleanine, 
isochondodendrine, 2′-norcocsuline and tetrandrine on Ovcar-8 cells. The scattering 
dot plots indicating the percentage of live, early and late apoptotic cells under 
treatment of medium (control) (A), carboplatin (B), cycleanine (C), isochondodendrine 
(D), 2′-norcocsuline (E), and tetrandrine (F) (20 μM) for 48 hours by using Annexin V 
& PI assay. The percentages of the total apoptotic cells caused by carboplatin, 
cycleanine, isochondodendrine, 2′-norcocsuline and tetrandrine were significant 
compared to control (G) (one-way ANOVA for group analysis, P<0.0001; post hoc 
paired t-test relative to control was done (*P <0.05; ** P <0.001 *** P <0.0001 t-test). 
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4.3.5 Cell cycle analysis 
The effects of cycleanine, isochondodendrine, 2′- norcocsuline and tetrandrine on cell 
cycle distribution of Ovcar-8 cells are shown in Figure 4.15. The percentage of 
Ovcar-8 cells in subG1 increased after exposure to carboplatin, cycleanine, 
isochondodendrine and tetrandrine for 48h compared to negative control, consistent 
with apoptosis (Figure 4.14).   
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Figure 4.14 Effects of BBIQ alkaloids on cell cycle of Ovarc-8 by flow cytometry. The 
effects of medium (control) (A), carboplatin (B); cycleanine (C); isochondodendrine 
(D), 2′-norcocsuline (E); and tetrandrine (20 μM) (F) on the Ovcar-8 cell cycle by use 
of flow cytometry analysis. The percentage of in subG1 phase (apoptotic cells) of the 
Ovcar-8 cell cycle was significantly increased compared to cells exposed to solvent-
control. While G0/G1 phase (live cells) decreased significantly compared to control 
P<0.0001, two-way ANOVA. This figure was a representation of n=3 observations. 
4.4 Discussion 
 
Cycleanine, isochondodendrine, 2′-norcocsuline and tetrandrine have been isolated 
from other plant species of the Menispermaceae family (Angerhofer et al., 1999, 
Mambu et al., 2000, Schiff, 1997, Liu et al., 2013). Cycleanine was shown to increase 
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the intracellular doxorubicin accumulation in the resistant MCF-7/Adr cell lines (Tian 
& Pan, 1997). Tetrandrine is also a common BBIQ alkaloid found in different plants 
as well as in T. subcordata (Dwuma-Badu et al., 1975). It showed various biological 
activities including anticancer, anti-allergic, anti-inflammatory, anti-malarial, and 
cardiovascular effects (Yu-Jen, 2002, Schiff, 1997). Tetrandrine inhibited the growth 
of various types of cancer cells (Yu-Jen, 2002, Xu et al., 2011, Xiao et al., 2015, Wu 
et al., 2014, He et al., 2011b) and could reverse multidrug resistance by inhibiting P-
glycoprotein activity (Sun & Wink, 2014).  
Here, cycleanine, isochondodendrine and 2′-norcocsuline have been isolated and 
characterized from T. subcordata, as part of novel contribution to knowledge. The 
analytical data (ESI-MS and NMR) were consistent with literature data for cycleanine, 
isochondodendrine (Kanyinda et al., 1997)  and 2′-norcocsuline (Liu et al., 2013). The 
change of 1H NMR signals of cycleanine by TFA was observed and such features 
were often found for the other alkaloids (Verpoorte, 1986).  Furthermore, we showed 
that both a head-to-tail BBIQ cycleanine (including TFA salt of cycleanine) and a 
head-to-head BBIQ tetrandrine which is an isomer of cycleanine and was previously 
isolated from T. subcordata (Figure 4.5) showed potent anti-ovarian cancer activities. 
While such a structural difference in BBIQ alkaloids was key to the inhibition of 
histamine release as only the head-to-tail BBIQ such as tetrandrine showed the 
inhibition (Nakamura et al., 1992).  
The induction of apoptosis by tetrandrine was observed previously in human lung 
carcinoma (Lee et al., 2002), bladder cancer (Li et al., 2011), colorectal cancer (He et 
al., 2011b), gallbladder carcinoma and prostate cancer cells (Liu et al., 2015). The 
combination of tetrandrine and cisplatin caused enhanced cytotoxicity through 
apoptosis as well as redistribution of the cell cycle in ovarian cancer cells in vitro and 
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vivo (Zhang et al., 2011). To confirm that these four BBIQ alkaloids (cycleanine, 
isochondodendrine, 2′-norcocusuline and tetrandrine) could induce apoptosis in 
ovarian cancer cell lines, two markers of apoptosis including caspases 3/7 and 
cleavage of PARP to its 89 kDa fragment were measured. Cycleanine, 
isochondodendrine, 2′-norcocusuline and tetrandrine significantly increased caspase 
3/7 activity in all cell lines tested, indicating the induction of apoptotic cell death 
(Figure 4.12). The apoptotic activity was further confirmed by the detection of the 
PARP-1 fragment in cycleanine, isochondodendrine, 2′-norcocusuline and 
tetrandrine-treated Ovcar-8 cells using immunoblotting assay (Figure 4.13). The 
percentage of the apoptotic cells caused by 2′-norcocsuline and tetrandrine are 
greater than those by isochondodendrine, cycleanine and carboplatin (Figure 4.12 
and 4.13). Tetrandrine increased population of both apoptotic sub-G1 and G1 phase 
in the lung cancer cells (Lee et al., 2002). The increase of cell fraction of sub-G1 
caused by the BBIQ alkaloids was also observed in ovarian cancer cell in this study 
indicating the induction of apoptosis because such sub-G1 peak is often regarded as 
a characteristic indicator of apoptosis (Kajstura et al., 2007). Interestingly, 
cycleanine, and isochondodendrine were shown in this study to cause apoptosis in 
ovarian cancer cells similar as tetrandrine but with less potency (Figure 4.12 - 4.16). 
Also in this study, 2’-norcocsuline was proved to cause apoptosis comparable to 
tetrandrine. All these were significant compared to control. 
In this study, also, the extracts and BBIQ alkaloids of T. subcordata were 
demonstrated to contain alkaloids (Figure 4.1) and exert significant in vitro anti-
ovarian cancer activities (Figure 4.8), which provided a scientific basis for future 
potential use of this plant for the treatment of ovarian cancer. Importantly, cycleanine 
showed a modest selectivity towards ovarian cancer cells over normal cells via 
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apoptosis, which may be used as a hit to modify its structure by semi-synthesis to 
improve its anti-cancer activity (Uche et al., 2016). To be approved as anticancer 
drugs, in vivo activities of these alkaloids and analogues must be evaluated. This 
work is ongoing in our laboratory and will be reported in the future. This study 
therefore could serve as novel scientific documentation of cycleanine, 
isochondodendrine and 2′-norcocsuline as bioactive constituents of T. subcordata. It 
could also provide scientific proof of in vitro anti-ovarian cancer activities and 
apoptosis induction of ovarian cancer cells by cycleanine, isochondodendrine and 2′-
norcocsuline. 
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CHAPTER FIVE 
 
SEMI-SYNTHESIS OF ANALOGUES OF CYCLEANINE AND THEIR ANTI-
CANCER ACTIVITIES 
 
5.1 Semi-synthesis of analogues of cycleanine 
 
The search for more potent anti-cancer bisbenzylisoquinoline (BBIQ) alkaloids with 
high selective index - SI (minimum toxicity) motivated our further study aimed at 
modification or semi-synthesis of analogues of cycleanine which was previously 
isolated from T. subcordata in this study. Cycleanine (1) was preferred as a hit drug 
among the three BBIQ isolated from T. subcordata because even though it was less 
potent than isochondodendrine (2) or 2′-norcocsuline (3), it showed the modest 
selectivity relative to others (SI > 3) in normal human ovarian epithelial cells (Uche et 
al., 2016).   
Besides, cycleanine was the most abundant in T. subcordata (about 98% yield of the 
total alkaloids); hence sufficient quantity was produced for semi-synthesis process. 
Though, 2’-norcocsuline showed high potency against ovarian cancer (IC50 0.8 – 
3µM), its SI was smaller than that of cycleanine and its percentage yield in T. 
subcordata total alkaloid was too small to guarantee sufficient quantity for semi-
synthesis.  
In this study, therefore, semi-synthesis of cycleanine analogues was carried out to 
produce chloromethylcycleanine which can subsequently react with dimethylamine, 
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and propargylamine to produce 5-[(dimethylamino)methyl]cycleanine (4), and 5-
[(propargylamino)methyl]cycleanine respectively (5) (Figure 5.1). 
  
Figure 5.1 Scheme for the semi-synthesis of (aminoalkyl)cycleanine analogues. 
Structural elucidation based on results analysis of spectroscopic data from 1H NMR 
(500 MHz, CDCl
3
) (Table 5.1) and 13C NMR (100 MHz, CDCl3) (Table 5.2). 
 
To determine the purity and molecular mass of the cycleanine analogues, the LC-MS 
analysis of the semi-synthesized products were analyzed. The results revealed the 
two products as pure (purity > 98%) and supported the structure of 5-
[(dimethylamino)methyl]cycleanine (4) and 5-[(propargylamino)methyl]cycleanine  (5) 
(Figure 5.2 and 5.3).  
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           Figure 5.2 The LC-MS spectrum of 5-[(dimethylamino)methyl] cycleanine (4). 
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Figure 5.3 The LC-MS spectrum of 5-[(propargylamino)methyl] cycleanine (5). 
Further NMR analysis confirmed these structures. The new compounds were 
identified based on the analysis of spectroscopic data of 
1
H NMR (500 MHz, CD3OD) 
and 13C NMR (125 MHz, CD3OD), HMBC, HMQC (Tables 5.1 and 5.2: Figures 5.1) 
respectively. The symmetry of cycleanine was lost after the chemical modification, 
and the peak for H-5 or 5’ in 1H NMR of cycleanine was shifted and corresponded to 
only one proton in compound 4 (Figure 5.5) or 5 which indicated the substitution of 
amino group at H-5 of cycleanine.  
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Figure 5.4    1H NMR spectrum of 4 (500 MHz, CD3OD). 
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Table 5.1 1H NMR (500 MHz, CDCl
3
) chemical shift data (δ, ppm) for two synthetic 
cycleanine analogues (4 and 5) (J values, in Hz, in parentheses). 
 
 
 
 
proton 4 5 proton 4 5  
H-1 4.27 d (10.4) 4.70 d (10.6) H-1′ 4.34 d 
(10.4) 
4.70 d 
(10.6) 
 
       
H-3 3.29 m; 2.92 m 3.65 m; 3. 28   
m 
H-3′ 3.32 m; 
2.94 m 
3.65 m; 
3. 28 m 
 
       
H-4 2.96 m; 3.24 m 3.19 m; 3.30 
m 
H-4′ 3.05 m; 
3.00 m 
3.23 m; 
3.23 m 
 
       
H-5 - - H-5′ 6.74 s 6.85 s  
H-10 7.04 7.18 brd H-10′ 7.07  7.20 
brd 
 
       
H-11 6.58 6.66 dd (8.4, 
2.7) 
H-11′ 6.60 6.65 dd 
(8.4, 
2.7) 
 
H-13 5.86 5.86 dd (8.7, 
2.7) 
H-13′ 5.81 5.81 dd 
(8.7, 
2.7) 
 
H-14 6.25 6.32 dd (8.2, 
1.7) 
H-14′ 6.29 6.31 dd 
(8.2, 
1.4) 
 
H-15 2.57 m; 3.21 m 2.70 m; 3.37 
m 
H-15′ 2.60 m; 
3.25 m 
2.70 m; 
3.37 m 
 
6-OMe 3.78 s 3.88, s  6′-
OMe 
3.82 s)  3.84 s   
7-OMe 3.37, s 3.41 s  7′-
OMe 
3.40, s  3.38 s   
N-Me 2.48 2.75 s N′-Me 2.48 s 2.72 s  
CH2 3.54 d, 12.2; 3.47 d, 
12.2 
3.44 m      
N-(CH3)2 2.28 s      
NH-CH2-CCH  3.47 m; 3.38 
m 
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Table 5.2 13C NMR (100 MHz, CDCl3) chemical shift data (δ, ppm) for synthetic 
cycleanine analogues (4 and 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Carbon 4 5 Carbon 4  5 
1  59.2 60.0 1′ 59.2  59.5 
3  44.1 43.9 3′ 43.9  43.7 
4 23.8 22.0 4′ 20.9  19.6 
4a 130.4 128.8 4a′ 130.4  128.7 
5  124.5 123.6 5′ 109.2  109.2 
6  152.3 153.5 6′ 151.7  152.5 
7  142.6 143.2 7′ 138.8  139.4 
8  143.5 144.0 8′ 143.2  143.8 
8a  127.4 127.9 8a′ 126.3  128.4 
9  129.8 128.6 9′ 130.3  128.7 
10  128.1 128.1 10′ 128.0  127.9 
11  117.4 117.7 11′ 117.3  117.6 
12  154.3 154.4 12′ 154.1  154.1 
13  114.0 114.1 13′ 113.9  114.0 
14  128.5 128.1 14′ 128.4  128.1 
15 37.3 37.8 15′ 37.3  37.5 
6-OMe  59.7 60.0 6′-OMe 54.9  54.7 
7-OMe  58.8 58.7 7′-OMe 58.4  58.7 
N-Me  40.9 39.8 N′-Me 40.9  39.8 
CH2 53.0  57.0     
-N(CH3)2 44.5      
-
NHCH2CCH 
 43.5; 72.9; 
79.2 
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5.2 Anticancer activities of semi-synthetic analogues of cycleanine on cancer 
cell lines 
 
To assay the cytotoxicity or anti-proliferative activities of 5-[(dimethylamino)methyl] 
cycleanine (4) and 5-[(propargylamino)methyl]cycleanine (5), the IC50 of the new 
compounds were evaluated on different ovarian cancer cell lines (Igrov-1, A2780 and 
Ovcar-8) after treatment for 72h. The results revealed the IC50 of 4 and 5 as ranging 
from 3.6 ± 0.5 µM to 5.2 ± 0.6 µM and from 5.6 ± 0.2 to 6.3 ± 0.6 µM respectively on 
the three ovarian cancer cell lines (Table 5.3; Figures 5.4 and 5.5).  The results 
(Table 5.3) suggest that 4 and 5 probably, exert about 2-3 times improved potency 
against ovarian cancer cells than the cycleanine with IC50 ranging from 7 to 14 µM 
(Table 4.8). 
Table 5.3 The IC50 of 5-[(dimethylamino)methyl] cycleanine (4) and 5-
[(propargylamino) methyl]cycleanine  (5) in ovarian cancer cells. 
                         
compound 
Ovarian cancer Cell lines 
Igrov-1 A2780 Ovcar-8              
4 4.4 ± 0.1 µM 3.6 ± 0.5µM 
 
5.2 ± 0.6 µM    
 
SI (4)     > 2     3 > 2 
 
5 6.1 ± 0.5 µM 
 
6.3 ± 0.6 µM 
                                                                        
5.6 ± 0.2 µM 
SI (5) 
 
   > 5                            >5                                                           6 
 
Carboplatin                       8 ± 0.7 µM                           16 ± 1.0 µM                      12 ± 0.9 µM 
 
Data represented as mean ± SEM (n= 5).  The results were significant P<0.05 (one-
way ANOVA).  HOE (4) IC50 = 10 ± 0.2 µM; (5) 32 ± 1.6 µM. SI means selective index. 
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Figure 5.5 Concentration-response curves of 4 in ovarian cancer cell lines with 
absorbance at 570nm normalized to control.  The Ovcar-8 (A), A2780 (B) and Igrov-1 
(C) ovarian cancer cell lines treated with different concentrations of 4 (0.16 – 40 µM) 
(Table 5.3, Figure 5.5-5.6) over 72h. Graph determined by four parameters fitting 
sigmoid curve (GraphPad prism demo 6.1). Data represented as mean ± SEM n= 5.  
C represents IC50 of control. 
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Figure 5.6 Concentration-response curves of (5) in ovarian cancer cell lines with 
absorbance at 570nm normalized to control. The Ovcar-8 (A), A2780 (B), and Igrov-1 
(C). Ovarian cancer cell lines treated with different concentrations of 5 (0.16 – 40 µM) 
over 72h.The dose range that showed cytotoxic activities include 2.2- 40 µM. The 
graph determined by four parameters fitting sigmoid curve (Graph Pad prism). Data 
represented as mean ± SEM, n = 5 independent experiments. A570 in y-axis 
represents normalized absorbance at 570nm (optical density).  C represents control 
(DMSO). Results were significant at P<0.05 (one way ANOVA)  
 
 
However, having demonstrated the in vitro cytotoxity of cycleanine analogues 
together with the selective index future work needs to be done to determine the in 
vivo or preclinical assay of these compounds.  
To have better understanding of the morphological effects of 5-[(dimethylamino) 
methyl] cycleanine (4) and 5-[(propargylamino)methyl] cycleanine (5) on ovarian 
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cancer cell lines, different concentrations of 4 and 5 (5 - 20 µM) were exposed to 
Ovcar-8 cells over 24 and 48 hours.  
 
     
  
Figure 5.7 Effects of 5-[(dimethylamino) methyl] cycleanine (4) on the morphology of 
Ovcar-8 cancer cells. A and D are control (no drug) for 24 and 48h respectively. B 
and E are 10 µM of 4 - treated cells after 24 and 48hrs respectively.  C and F are 20 
µM of 4 - treated ovcar-8 cells after 24 and 48 h respectively. At 10- 20 µM, over 24 
and 48h, compound 4 induced two-time point – (B and E) and two concentrations (C 
and F) –induced t changes on the morphology of Ovcar-8 as seen under phase 
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contrast light microscope. These changes were reproducible in 5 independent 
experiments. There was observed morphological alterations on ovcar-8 cells post-
treatment with two timepoint and two concentration of 5-[(dimethylamino) methyl] 
cycleanine (figure 5.7). These changes were reproducible in 5 independent 
experiments. 
 
The effects of 5-[(propargylamino)methyl] cycleanine (5) on morphology of Ovcar-8 
cancer cells were also found to be time- and concentration-dependent (Figure 5.8).  
 
 
Figure 5.8 Effects of 5-[(propargylamino)methyl] cycleanine (5) on morphology of 
Ovcar-8 cancer cells. Ovcar-8 showed morphological changes when treated with two 
concentration of 5 (10 and 20 µM) over two time points of 24h (B and E) and 48h (D 
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and F). A and D are controls for 24 and 48h, respectively; B and E were 
morphological changes observed when ovcar-8 was treated with 10 µM of 5 over 
after 24 and 48h respectively, as seen under phase contrast light microscope.; C and 
F were observed at 20 µM of 5-treated ovcar-8 cells after 24 and 48 h, respectively. 
There was observed morphological alterations on ovcar-8 cells post-treatment with 
two time point and two concentration for 5 (figure 5,8).  These changes were 
reproducible in 5 independent experiments. 
 
 
5.3 Caspase or apoptotic activities of cycleanine derivatives on cancer cell 
lines 
 
The results of anticancer activities of 5-[(dimethylamino)methyl] cycleanine (4) and 5-
[(propargylamino)methyl] cycleanine (5) prompted a detail study of the mechanism of 
cell death induced by these drugs on ovarian cancer cell lines. This study therefore 
further investigated the apoptosis induction of 4 and 5 in cancer cells by evaluation of 
caspase 3/7 activation (Figure 5.9), cleavage of PARP (Figure 5.10) and cell cycle 
assays (Figure 5.11 – 13). The aim was to determine the apoptotic effects of the new 
analogues in ovarian cancer cells. 
Results showed that 5-[(dimethylamino)] cycleanine and 5-[(propargylamino) 
methyl]cycleanine (20μM) after exposure to Ovcar-8, A2780 and Igrov-1 for 24h, 
caused activation of caspase Glo 3/7 activities which was manifested as elevation of 
caspase levels on the three ovarian (Ovcar-8: (A), A2780: (B) and Igrov-1: (C) cell 
lines (Figure 5.9). The increase in caspase activity was represented as fold increase 
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relative to the control (Figure 5.9 A, B, C).  Medium without treatment served as 
(negative) control while carboplatin was used as positive control (Figure 5.9). 
 
 
Figure 5.9 The apoptotic effects (caspase 3/7 activities) of 4 and 5 on three ovarian 
cancer cell lines. Data represented as mean ± SEM, n = 6 observations, negative 
control was the solvent without drug, carboplatin used as positive control; 4 and 5 (20 
μM) test compounds. 4 and 5 are 5-[(dimethylamino)] cycleanine and 5-
[(propargylamino) methyl] cycleanine respectively. Results were significant compared 
to control *** P<0.0001(one-way ANOVA) post hoc analysis multiple t- test compared 
with control   P<0.001 (t-test). 
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5.4 Western blot (PARP cleavage) analysis for cycleanine analogues 
 
The Western or immunoblotting was carried out as further confirmation of apoptosis 
induction on cancer cells of 5-[(dimethylamino)methyl]cycleanine (4) and 5-
[(propargylamino)methyl]cycleanine (5). The results showed that the Ovcar-8 cancer 
cell line by treatment of 4 and 5 caused a significant cleavage in PARP in a similar 
way as cycleanine compared to control cells (Figure 5.10). There was no significant 
PARP-cleavage observed in negative control. 
 
Figure 5.10 Western blotting analysis of the PARP-1 cleavage (marker) in Ovcar-8 
cells after treatment with carboplatin, 4 and 5. GAPDH was used as a loading control. 
A representative of three independent experiments is shown.  
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5.5 Evaluation of apoptotic effects of 4 and 5 on Ovcar-8 cells using flow 
cytometry   
For quantification of the percentage of apoptotic cells post - treatment with 4 and 5, 
Ovcar-8 cells were treated and stained with Annexin V and propidium iodide (PI) and 
analysed by flow cytometry (Figure 5.11). Treatment of Ovcar-8 with carboplatin, 4 
and 5 over 48h caused significant increase in the population of both early and late 
apoptotic cells compared to the control (no drug) cells (Figure 5.11). 
 
 
 
Figure 5.11 Flow cytometry analysis of apoptotic effects of 5-
[(dimethylamino)methyl]cycleanine (4) and 5-[(propargylamino)methyl]cycleanine (5) 
on Ovcar-8 cells. The scattering dot plots indicating the percentage of live, early and 
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late apoptotic cells under treatment of medium (control) (A), carboplatin (B), 4 (C), 
and 5 (D) (20 μM) for 48 hours by using Annexin V & PI assay. The percentages of 
the total apoptotic cells caused by 4 (C), 5 (D) and positive control (carboplatin) (B) 
were significant compared to negative control (A) (one way ANOVA for group 
analysis, P<0.001; post hoc paired t-test relative to control was done (* P<0.05, t-
test) (E). 
 
5.6 Cell cycle effects of 4 and 5 on Ovcar-8 cell line 
To further confirm the quantification of apoptosis induced by 5-
[(dimethylamino)methyl]cycleanine (4) and 5-[(propargylamino)methyl]cycleanine (5) 
on ovcar-8 cells, cell cycle analysis was done using propidium iodide and flow 
cytometer (Figure 5.12 and 5.13). The effect of 4 and 5 on cell cycle distribution of 
Ovcar-8 cells is shown in Figure 5.12 and Figure 5.13. Carboplatin was used as a 
positive control. Medium was used as negative control. The percentage of Ovcar-8 
cells in subG1 increased after exposure to carboplatin, 4 and 5 for 48h compared to 
negative control. This was consistent with apoptosis observed in Figure 5.12 and 
5.13. The percentage of cells at the G0/G1 phase (live cells) decreased significantly 
compared to control (Figure 5.12 and 5.13). This was consistent with results of 
isolated alkaloids, parent alkaloid (cycleanine) and other alkaloids in this study 
(Figure 4.14). 
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Figure 5.12 Effects of 4 and 5 on cell cycle distribution in Ovcar-8 cells. The effects 
of control (A), carboplatin (B), 4 (C) and 5 (D) on the cell cycle determined by use of 
flow cytometry analysis revealed that the percentage of subG1 phase (apoptotic cells) 
of the ovcar-8 cell cycle was significantly increased compared to cells exposed to 
control (no drug, A).  
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Figure 5.13 Cell cycle distribution analysis of apoptotic effects of 4 and 5 on Ovcar-8 
cell lines. Data represented as mean ± SEM, n = 4 observations. The percentage of 
subG1 phase (apoptotic cells) of the ovcar-8 cell cycle was significantly increased 
compared to cells exposed to control (no drug). While G0/G1 phase cells decreased 
significantly compared to control P< 0.0001 (one-way ANOVA) (Figure 5.12 A-D).  
 
5.7 Alkaloid uptake in Ovcar-8 cells by use of confocal microscopy 
 
To investigate the cellular uptake of BBIQ alkaloids and get good knowledge of the pattern 
alkaloids distribution in cancer cells, control, cycleanine and 5-
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[(propargylamino)methyl]cycleanine (20 µM) were administered in Ovcar-8 cells. The 
fluorescence intensities and areas occupied by the alkaloids/control (drug distribution) were 
studied after 48h exposure, by use of confocal and fluorescence microscope (Figure 5.14-
15). This was done by use of Alexa 488 azide (fluorescent dye) to monitor the intracellular 
uptake of monoalkynyl cycleanine (5) via specific click chemistry reaction with Alexa 488 
azide per previously reported procedures (Luo et al., 2013). Cycleanine is not fluorescent 
compound. The fluorescence data (Figures 5.14 and 5.15) were analysed by the 
determination of the average fluorescence intensities of the cells in a area by use of Image J 
software and evaluation of the difference from the background fluorescence values. Values 
were evaluated from 30-90 cells determined in five independent experiments. The 
fluorescence intensity was used as a measure of the distribution and uptake of 5 in Ovcar-8 
(Figures 5.14 – 5.16A). The fluorescence intensity is proportional to the magnitude of cellular 
uptake of compounds in cells (Figure 5.16 A)  (Luo et al., 2013).  The fluorescence intensity 
of compound 5 was found to be dose dependent (Figure 5.14 – 5.16 A). The mean areas 
occupied by the cells were proportional to the magnitude of apoptotic cell death (Figure 
5.16B).   Figure 5.15 A-C show 3D view of ovcar-8 cells post 48 h treatment with   different 
doses (10 - 30 µM) of 5-[(propargylamino)methyl] cycleanine as seen under confocal 
microscope. A selection of limited number of cells were made from confocal microscope 
observation and magnified further to get a better 3D view of the representative of cells 
treated. (Figure 5.15 A-C).   
The results revealed that treatment of Ovcar-8 with 5-[(propargylamino)methyl]cycleanine (5, 
20 µM) caused significant dramatic increase in mean fluorescence intensities (from 300 to 
1800) (Figure 5.16A), with decrease in the mean area occupied (from 1000 to 2400) (Figure 
5.16B) by 5-treated cells compared to control. There was no significant change in 
florescence intensity observed on cycleanine-treated cells compared to control (Figure 5.14 
and 5.16A). These results confirmed the intracellular uptake of monoalkynyl cycleanine (5), 
which indicated a similar mechanism for cycleanine. 
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Figure 5.14 Analysis intracellular uptake of cycleanine and 5 in Ovcar-8 cells using 
confocal fluorescence microscopy. A and D represent cells with dye only (control); B 
and E, 10 and 20µM of cycleanine; C and F, 10 and 20µM of 5-
[(propargylamino)methyl] cycleanine, respectively. 
 
Figure 5.15 3D view of Ovcar-8 cells after treatment with 10 µM (A); 20 µM (B); 30 
µM (C) of 5-[(propargylamino)methyl] cycleanine (5) over 48h as observed under 
172 
 
confocal microscopy. This shows the 3D view of ovcar-8 cells post 48 h treatment 
with   different doses (10 - 30 µM) of (5) as seen under confocal microscope  
 
 
 
 
 
 
Figure 5.16 Cellular uptake of 5-[(propargylamino)methyl] cycleanine (5) in Ovcar-8 
cells. (A): Shows the mean fluorescence intensity of ovcar-8 cells after 48h treatment with 
medium (control- no drug), cycleanine and 5-[(propargylamino)methyl] cycleanine. (B): 
the mean area occupied by ovcar-8 cells 48h post- treatment with medium (control- no drug), 
cycleanine and 5-[(propargylamino)methyl] cycleanine. Data represented as mean ±SEM, 
n = 5 independent experiments. Results were significant compared to control ***. P<0.0001 
(one -way ANOVA).  
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5.8 Discussion 
 
Reports showed that bisbenzylisoquinoline (BBIQ) alkaloids exerted anti-ovarian 
cancer activity (Liu et al., 2013).  BBIQ exhibits wide range of biological activities 
including anti-cancer activity (Lee et al., 2002), bladder cancer (Li et al., 2011), 
colorectal cancer (He et al., 2011b), gallbladder carcinoma and prostate cancer cells 
(Liu et al., 2015). BBIQ alkaloids of T. subcordata exerted cytotoxicity by apoptosis 
induction of ovarian cancer cells. Cycleanine was also shown to possess a moderate 
selectivity towards ovarian cancer cells over normal cells via apoptosis, which may be 
used as a hit to modify its structure by semi-synthesis to improve its anti-cancer 
activity  
Therefore, in search of BBIQ alkaloids with improved potency and optimum selective 
index, we have been able to synthesize two new BBIQ alkaloids using cycleanine as a 
hit compound (Figure 5.1 and 5.2). The new BBIQ alkaloids are 5-[(dimethylamino) 
methyl] cycleanine (4) and 5-[(propargylamino) methyl] cycleanine (5). The anticancer 
activities of these compounds have been evaluated by SRB assay on ovarian cancer 
cell lines (Figure 5.5 and 5.6).  The mechanism of cancer cell death induced by the 
new BBIQ alkaloids has been determined in this study. 5-[(dimethylamino)methyl] 
cycleanine (4) and 5-[(propargylamino)methyl] cycleanine (5) induced apoptosis by 
caspase 3/7 activation, PARP-cleavage, increase in percentage of both early and late 
apoptotic cells; and increase in SubG1 with decrease in G0/G1 cell cycle phase of the 
Ovcar-8 cells. These were consistent with unmodified cycleanine. 
The cells after exposure to 4 and 5 also showed morphological effects suggesting   
apoptosis in Ovcar-8 cells. The observed anti-proliferative activities of the synthesized 
new BBIQ alkaloids were found to be higher (about 2-3-fold increase) than the 
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observed effect with cycleanine (hit compound). This suggests that substitution at 5- 
position of cycleanine structure with dimethylamino or aminoalkynyl group could lead 
to improved cytotoxicity and biological activity of the cycleanine.  
It was also observed that attachment of aminoalkynyl moiety to cycleanine could be 
used to study pattern of uptake of BBIQ alkaloids in cancer cells using click chemistry 
and confocal or fluorescence microscope. This agreed with past studies using a similar 
click chemistry approach for other natural products (Luo et al. 2013; Zhen et al. 2014).  
This study is therefore, providing novel reports on cytotoxicity and apoptosis induction 
mechanism of 5-[(dimethylamino)methyl] cycleanine (4) and 5-
[(propargylamino)methyl] cycleanine (5). The effects of 5 on uptake of BBIQ alkaloids 
and its evaluation in cancer cells are also novel study. Their selective index (SI) were 
determined to have good knowledge of the level of toxicity of these compounds on 
normal cells or the therapeutic index (Table 5.3). However, studies are ongoing to 
modify the structure of cycleanine through other chemical pathways to produce more 
BBIQ analogues with improved potency.  The water solubility of the cycleanine 
analogues will also be determined for better understanding of the drug-like properties 
of these compounds. Future work would also be to isolate 2′-norcocsuline and 
isochondodendrine to get sufficient quantities as to carry out semi-synthesis of 
analogues of isochondodendrine and 2′-norcocsuline in search of more potent anti-
cancer drugs. 
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CHAPTER SIX 
ANTIMALARIAL ACTIVITIES OF FRACTIONS, BBIQ ALKALOIDS OF T. 
SUBCORDATA AND SEMI-SYNTHETIC ANALOGUES OF CYLEANINE 
 
 6.1 Anti-malarial activities of the crude extracts and fractions of T. subcordata 
The in vitro antimalarial screening of extracts and fractions of total alkaloids from T. 
subcordata were done on Plasmodium falciparum chloroquine resistant strain using a 
Syber green fluorescent dye as described by Smilkstein et al., (2004) and modified 
by Hasenkamp et al., (2012). Results showed that among the fractions (TSS1-3) 
(Figure 2.2) screened, TSS1, showed the most significant antimalarial activity with 
about 98% parasite growth inhibition activity. TSS1 is the total alkaloids. The TSS1 
was further subjected to silica gel column chromatography as previously described to 
produce BBIQ alkaloids of T. subcordata, which have potent anti-plasmodial activity 
(Section 6.2).  
TSS3 also showed good percentage growth inhibition next to TSS1 and was 
fractionated by silica gel column chromatography, and its resulting fractions (TSS3.1-
TSS3.8) were also evaluated for antimalarial activity (Figure 6.1). The most active 
fraction was TSS3.8. To identify possible bioactive compounds, gas chromatography 
mass spectrometer (GC-MS) was used to characterize the chemical composition of 
TSS3.8. After derivatization of TSS3.8 with N, O-Bis(trimethylsilyl)trifluoroacetamide 
(BSTFA) and pyridine. The trimethylsilyl derivatives of TSS3.8 were subjected to 
analysis by GC-MS. The GC-MS analysis revealed this fraction to be rich in fatty 
acids such cis-9-hexadecenoic acid; palmitelaidic acid; nonadecanoic acid; 
hexadecenoic acid and   11-cis-octadecenoic acid and glycosides (Table 6.1; Figures 
6.2-6.3). 
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Figure 6.1 In vitro antimalarial screening results of fractions TSS3 from T. 
subcordata ethanol extract (TSS). TSS3.1-TSS3.8 are the column chromatography 
fractions from TSS3. 
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      Figure 6.2 GC-MS chromatogram of TSS1.8 TMSi derivative. The numbers 1-8 
are fatty acid derivatives from TSS1.8 series detected by GC-MS as named in table 
6.1. 
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Figure 6.3 Mass spectrum of cis-9-hexadecenoic acid trimethylsilyl ester in TSS3.8. 
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Table 6.1 Fatty acid derivatives from TSS3.8 series detected by GC-MS. 
 
S/No Fatty acid/compounds Molecular 
mass 
RT (min) 
1 N-Pentadecanoic acid 314 16.0 
2 Pamitaidic acid trimethysilylester 326 17.0 
3 Cis-9- hexadecanoic acid trimethysilylester 328 17.5 
4 6- Heptadecanoic acid trimethysilylester 342 18.5 
5 Oleic acid trimethysilyester 354 19.2 
6 Octadecanoic acid trimethysilyester 356 19.5 
7 11-cis-Octadecenoic acid, trimethylsilyl ester 339 19.4 
8 Nanodecanoic acid trimethylsilyester 370 20.2 
9 Cis-13-Eicosenoic acid, trimethylsily ester 367 20.5 
10 Methy-2-3-anhydro-5-p-nitrobenzoyl-alpha-d-
lyxofuranoside 
295 20.7 
11 Docosanoic acid, trimethylsily ester 397 21.8 
 
 
6.2 Anti-malarial activities (IC50) of the BBIQ alkaloids from T. subcordata and 
synthetic analogues of cycleanine 
 
The in vitro antimalarial evaluation was also carried out on BBIQ alkaloids purified 
from chloroform fraction of T. subcordata and synthetic analogues of cycleanine to 
determine their IC50 on Plasmodium falciparum - chloroquine resistance 
strain(Hasenkamp et al., 2013, Smilkstein et al., 2004, Wong et al., 2011). 
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The results showed that the IC50 of isochondodendrine was least (6.1 ± 1.3 µM) 
among the three BBIQ alkaloids of T. subcordata evaluated (Table 6.2, Figure 6.4). 
This was seconded by 2′-norcocsuline (7.0 ± 1.6 µM) and highest with cycleanine 
(17.7 ± 2.0 µM). This probably implies that isochondodendrine exhibited relatively 
highest in vitro antimalarial activity while cycleanine showed least activity among the 
natural BBIQ alkaloids of T. subcordata assayed. 
To check if there would be improved potency on antimalarial activity of cycleanine, 
the IC50 of 5-[(dimethylamino)methyl]cycleanine (4) and 5-
[(propargylamino)methyl]cycleanine (5) were found to be was 0.7µM and 1.8µM, 
respectively (Figure 5.2, Table 6.2). 
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Figure 6.4 Antimalarial effects (IC50) of alkaloid and derivatives of cycleanine. (A) 
isochondodendrine (2); (B) 5-[(dimethylamino)methyl]cycleanine  (4); (C) 5-
[(propargylamino)methyl]cycleanine  (5).    
Table 6.2 In-vitro antimalarial activities of BBIQ alkaloids and synthetic analogues of 
cycleanine. 
BBIQ alkaloids of T. subcordata and 
cycleanine derivatives 
IC50 on P. falciparum  
Cycleanine (1) 17.7 ± 2.0 µM 
Isochondodendrine (2) 6.1 ± 1.3 µM 
2’-norcocsuline (3) 7.0 ± 1.6 µM 
5-[(dimethylamino)methyl]cycleanine (4) 0.7 ± 0.1 µM 
5-[(propargylamino)methyl]cycleanine  (5) 1.8 ± 0.2 µM 
 
 
6.3 Discussion 
The BBIQ alkaloids possess a range of biological activities including, antiplasmodial 
activities (Schiff 1997; Angerhofer et al. 1999; Lin et al 1993; Mashall et al.1994; Ye 
and Van Dyke 2015).The total alkaloid TSS1 was purified using combined methods 
of column chromatography (previously described in this study), recrystallization 
methods and HPLC procedure. The pure BBIQ alkaloids (1, 2 and 3) and analogues 
(4 and 5) got in this study also showed significant antimalarial activity. This is 
consistent with previous reports (Ye and Dyke 2015; Angerhofer et al. 1999; Mashall 
et al. 1994; Mambu et al. 2000; Kaur et al. 2009; Lin et al. 1993). Here compound (4) 
showed the most potent antimalarial activity followed by (5). This might suggest that 
substitution in position 5 by amino group could result to improved antimalarial activity 
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of BBIQ alkaloids. The other BBIQ alkaloids showed good antimalarial activity with 
cycleanine having the least  but good activity. For pure compounds: IC50  ˂ 1µM could 
signify excellent or potent antimalarial activity; IC50 =1 – 20µM   good activity; IC50 =21 – 100 µM   
moderate activity; IC50 =100 - 200µM low activity; IC50 ˃  200 µM inactive antimalarial (Batista et 
al., 2009b, Basco et al., 1994, Muriithi et al., 2002). 
Cycleanine has been isolated from many other plant species of the Menispermaceae 
family (Schiff, 1997). It has been shown to have anti-plasmodial effects (Table 6.1) 
(Schiff, 1997, Angerhofer et al., 1999). Isochondodendrine also previously showed 
potent antiplasmodial activity (IC50 = 0.10 µg/ml = 0.17 µM) on the strain of 3D7 
(Otshudi et al., 2005, Mambu et al., 2000). 2′-norcocsuline showed potent anti-
plasmodial activity (Angerhofer et al., 1999). These were consistent with our finding 
here (Table 6.2, Figure 6.4).   
In conclusion, the extracts and three BBIQ alkaloids - cycleanine, isochondodendrine 
and 2′-norcocsuline of T. subcordata were demonstrated to exert significant in vitro 
anti-plasmodial activities. Also, the fatty acids of T. subcordata such as cis-9- 
hexadecenoic acid; palmitelaidic acid; nonadecanoic acid; hexadecenoic acid and   
11-cis-octadecenoic acid (Table 6.1; Figure 6.2 -6.3) could probably contribute to the 
antimalarial activities of this plant. These are also novel reports of in vitro antimalarial 
effects of T. subcordata and the new cycleanine analogues -   5-
[(propargylamino)methyl]cycleanine and   5-[(dimethylamino)methyl]cycleanine. 
Compounds produced in this study were shown to exhibit up to 10 – 25-fold increase 
in antimalarial potency relative to the hit compound. However, further work may be 
necessary to determine the in vivo antimalarial effects of the BBIQ alkaloids of T. 
subcordata and the new analogues.      
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CHAPTER SEVEN 
 
PHYTOCHEMICAL, ANTIMALARIAL AND ANTICANCER EFFECTS OF 
CYLICODISCUS GABUNENSIS 
  
7.1   Phytochemical screening  
 
The phytochemical screening was carried out on C. gabunensis crude extract, according to 
standard procedures (Okokon et al., 2006, Uche & Ezugwu, 2009, Trease & Evans, 1998, 
Sofowora, 1982, Harborne, 1998, Edeoga et al., 2005).  The results revealed the presence of 
phytochemical constituents such as terpenes, flavonoids, saponins and glycosides (Table 
7.1). 
 
Table 7.1 Phytochemical screening results of ethanol extract of C. gabunensis. 
 
Phytochemical constituents  Results of colour reaction 
tests  
Flavonoids  ++ 
Terpenes  ++ 
Glycosides  + 
Saponins  + 
Alkaloids  - 
 
++ represent largely present, + slightly present, - absence. 
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7.2   Anticancer activity of the crude extract of C. gabunensis  
 
The hexane extract (CGH), ethanol crude extract (CGE) and fractions of Cylicodiscus 
gabunensis were screened for anti-proliferative activities on ovarian cancer cells 
using SRB. Results of anticancer assay of extracts/fractions of Cylicodiscus 
gabunensis showed that ethanol extract and different fractions of the crude ethanol 
extract (CGE) exhibited cytotoxicity on A2780, Igrov-1 and ovcar-8 (Table 7.1). The 
ethanol fractions used include ethyl acetate fraction (CGEA), butanol fraction 
(CGEBU), aqueous fraction (CGEAQ) and hexane extract (CGH). The CGEEA 
showed highest anti-proliferative activity in ovarian cancer cells with IC50 range of 4.5 
– 17 µg/mL on A2780, Igrov-1 and Ovcar-8 cell lines. CGEAQ and CGEBU exhibited 
nearly similar activity with IC50 of 7.7 and 9.2 µg/mL respectively for CGEAQ and 
CGEBU on A2780 cells (Table 7.2, Figure 7.1). But CGEAQ exerted significant 
higher activity than CGEBU in ovcar-8 and Igrov-1 cells (Table 7.2, Figure 7.2). The 
hexane fraction showed the least activity with IC50 greater than100 µg/mL. 
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Table 7.2 In vitro anticancer activities of crude   extracts and fractions of C. 
gabunensis. 
 
 
 
 
Crude extract or 
fractions of C. 
gabunensis   
50% Inhibitory concentration (IC50)  
of cancer cell line (µg/mL) 
  A2780 Igrov-1 
 
Ovcar-8 
CGH >100 ND 
 
> 102  
CGE 19.9 ± 1.7 
 
13.2 ± 2.2  
 
75 ± 2.1 
CGEEA 4.5 ± 0.2 
 
9.2 ± 1.1 17.0 ± 1.3 
 
CGEBU 9.2 ± 0.2 
  
16.0 ± 2.5 
  
27 ± 1.2 
CGEAQ 7.7 ± 0.5 
 
13.9 ±1.8 7.7 ± 0.5 
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Figure 7.1 Anti-proliferative effects of C. gabunensis extract and fractions on A2760 
cells with normalized absorbance at 570nm. A) The ethanol crude extracts (CGE); B) 
the ethyl acetate fraction (CGEEA); C) the aqueous fraction (CGEAQ); and D) the 
butanol fraction (CGEBU). C on x-axis is control. A570 is normalized (to control) 
absorbance (optical density) at 570nm  
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Figure 7.2 Anti-proliferative effects of C. gabunensis ethanol extract fractions on 
Ovcar-8 cells with normalized absorbance at 570nm.   (A) The ethyl acetate fraction 
(CGEEA); (B) the aqueous fraction (CGEAQ); and (C) the butanol fraction (CGEBU). 
C on x-axis is control. A570 is normalized (to control) absorbance (optical density) at 
570nm. 
7.3 Antimalarial activities of Cylicodiscus gabunensis 
 
Antimalarial screening of the extracts and fractions of C. gabunensis was carried out. 
The antimalarial activities of the plant extract and fractions against P. falciparum Dd2 
were performed using Syber Green l Fluorescence assay (Henriques et al., 2012, 
Hasenkamp et al., 2013). The ethanol extract and fractions showed stronger 
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antimalarial activity than the hexane extract (Figure 7.1). The IC50s of the fractions 
CGEEA, CGEBU, and CGEAQ were determined to be 16.06, 10.35, and 25.78 
µg/ml, respectively (Figure 7.3; Table 7.3). Among them, CGEBU fraction showed the 
most antimalarial activity.     
 
Figure 7.3 The in vitro antimalarial activities of different extracts and fractions of C. 
gabonensis. CGEEA represents ethyl acetate fraction from ethanol extract, CGEBU 
butanol fraction, CGE Ethanol extract, CGH hexane extract, and CGEAQ, aqueous 
fractions. 
Table 7.3 In vitro antiplasmodial activity (IC50) of fractions from C. gabunensis  
                    
Extracts and Fractions from C. 
gabunensis 
IC50 (µg/mL) 
CGEEA 16.1 
CGEBU 10.4 
CGEAQ 25.8 
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7.4 Discussion 
 
The phytochemical screening of crude extracts of C. gabunensis was done to get 
overview of the phyto-constituents of ethanol extract of C. gabunensis. Results 
revealed the presence of terpenes, flavonoids, saponins and glycosides. This is 
consistent with previous studies (Okokon et al., 2006).  
Due to on-going laboratory research in our group, in search of bioactive anti-ovarian 
cancer as part of  natural product drug discovery (Li et al., 2015), coupled with  the 
history of traditional use of C. gabunensis in treatment of malaria and cancer in West 
Africa (oral interview with herbalist in west Africa where the plant was sourced; 
Okonko et al., 2006), we carried out anti-proliferative assay on C. gabunensis to have 
scientific documents on the claims by Nigerian traditional medicine dealers. Results 
showed that C. gabunensis exerted in vitro anti-cancer activities in ovarian cancer 
cells (Table 7.2, Figures 7.1 and 7.2). The ethyl acetate fraction of the ethanol crude 
extract of C. gabunensis exhibited highest activity (Table 7.2, Figures 7.1 and 7.2). 
This is a novel report of anti-cancer activities of C. gabunensis. The results could 
provide a basis for traditional use of C gabunensis in cancer treatment. It could 
probably serve as a guide to explore more anti-cancer agents of natural origin. More 
studies are on-going to identify and elucidate the bioactive compounds responsible 
for anticancer effects of C. gabunensis. 
Results also showed that C. gabunensis fractions exhibited ant-malarial activity. To 
identify the most bioactive anti-plasmodial compounds we used hexane to extract the 
non-polar materials and 70 % ethanol for polar and semi-polar materials. The results 
indicated that the ethanol extract has more potent activity over the hexane extract, 
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which is a primary indication of possible antimalarial activity and come in agreement 
with previous research which used an ethanol extract in an in vivo study in mice 
infected with Plasmodium berghei. This study could provide supporting basis for use 
of C. gabunensis as local medicine for treatment of malaria. 
Plant extracts with possible antimalarial activities are classified to the highly active 
with IC50 ≤ 5 µg/ml, promisingly active 5.1-10 µg/ml, good activity 10.1-20 µg/ml, 
moderate activity 20.1-40 µg/ml, marginal potency 40.1-70 µg/ml, poor or inactive 
70.1 to ˃ 100 µg/ml (Basco et al., 1994, Batista et al., 2009, Muriithi et al., 2002) 
According to this classification, it seems that butanol fraction CGEBU has good 
antimalarial activity and presents a worthy target for further investigation. This 
investigation is ongoing. 
In conclusion, bioassay-guided extraction and fractionation of C. gabunensis yielded 
the most potent anti-plasmodial and anticancer fractions. Future study is on-going to 
characterize and elucidate the structure of bioactive compounds 
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CHAPTER EIGHT 
CONCLUSIONS AND RECOMMENDED FUTURE WORK 
 
 8.1 Summary and Conclusions 
 
In our introduction part, cyclotides were discussed as an essential cyclic protein with 
varied amino acid backbone which conferred to them wide biological activities 
including cytotoxicity. In this study, therefore cyclotides of Viola philippica and Viola 
yedoensis were studied as followed. The cyclotides of Viola philippica were isolated, 
purified, identified and characterized as Varv A, Kalata b1, Viba 15, Viba 17 and Varv 
E from Viola philippica. The cyclotides of Viola yedoensis were also identified as Varv 
A, Kalata B1, and Varv E (Cycloviolacin O12). The anti-ovarian cancer activities of 
these cyclotides were demonstrated in this study with report of Varv E as novel. Varv 
E was purified as a pure peptide from Viola yedoensis. Our results were consistent 
with available data in the literature which could imply that our strategy was reliable. 
We also got reproducible results in all our experiments. To the best of our 
knowledge, this is first report of anti-ovarian cancer activity of Viola yedoensis. 
 
Also in our introduction, it was mentioned that bisbenzylisoquinoline (BBIQ) are 
commonly found in plant families including Menispermaceae. Triclisia subcordata 
belongs to Menispermaceae family. In this study, therefore, the isolation, 
identification and characterization of three bisbenzylisoquinoline (BBIQ) alkaloids 
namely, cycleanine, isochondodendrine and 2 ′ -norcocsuline from Triclisia 
subcordata Oliv were established as a novel report. These BBIQ alkaloids and 
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extracts or fractions of T. subcordata were shown to exhibit both   in vitro anti-cancer 
and antimalarial activities in this study. This is also the first-time report of cytotoxicity 
of Cycleanine and Isochondodendrine on ovarian cancer cells and novel report of 
cycleanine, isochondodendrine and 2′-norcocsuline in Triclisia subcordata, to the 
best of our knowledge. 
 
Furthermore, the searches for anti-cancer and anti-malarial products with good 
selectivity, improved potency and bioactivities led to structural modification of 
cycleanine as hit, by semi-synthesis. Semi-synthesis of cycleanine yielded two new 
bioactive compounds which were identified and characterized in this study as 5-
[(dimethylamino)methyl] cycleanine and 5-[(propargylamino)methyl] cycleanine. 
These new compounds showed more than 25-fold improved potency for antimalarial 
and about 2-fold improved potency for anticancer activities with appreciable 
selectivity as shown in this study. These two compounds are novel compounds with 
cytotoxicity effects on ovarian cancer cells and antimalarial activity on chloroquine-
resistant Plasmodium falciparum. Their pharmacological reports are new as well. 
 
Anti-cancer agents usually kill cancer cells in low dose by programmed cell death 
known as apoptosis. The mechanism of cell death induced by both BBIQ alkaloids of 
T. subcordata and synthetic analogues of cycleanine were established in this study 
as being likely by apoptosis induction of ovarian cancer cells. These were 
demonstrated by caspase Glo 3/7 activation, cleavage of PARP to PARP-1 in 
western blot, increased SubG1 and apoptotic cells in cell cycle and annexin V 
experiments in this study. 
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It was possible to establish the drug uptake in cells by click chemistry using the new 
compound produced in this study - 5-[(propargylamino)methyl] cycleanine, with the 
aid of confocal fluorescence microscopy. This has been shown in chapter five of this 
study. The BBIQ alkaloids of T. subcordata reported in this study and the new 
compounds synthesized could probably serve as hit for future semi-synthesis or 
structural modification to produce more potent anti-cancer and antimalarial drugs. 
The in vitro antimalarial and anticancer activities of crude extract (50% ethanol extract) and 
fractions of C. gabunensis have been successfully investigated in this study. The ethyl 
acetate fraction showed the highest anti-cancer activity while the butanol fraction exerted 
highest antimalarial activity. This study reports anti-cancer effects of C. gabunensis as a 
novel report while the antimalarial activity was consistent with past studies. 
     Overall, our approach in this study is good because our findings and results are  
reproducible and consistent with available literature documentation. This study  
therefore, could provide scientific basis for support of use of T.  subcordata, 
Cylicodiscus gabunensis; V. yedoensis and V. philippica in treatment of cancer or 
malaria. It has provided scientific evidence on the invitro cytotoxicity and ant-malarial  
activity of these plants. 
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8.2 Recommendation/future work 
 
Work is on-going to identify and characterized the other unknown peptides present in 
V. yedoensis and V. philippica. The mechanism of cancer cell death induced by 
cyclotides of V. philippica and yedoensis is on-going. 
Study is on the way to determine the protein targets by the anti-cancer BBIQ 
alkaloids of T. subcordata and synthesized cycleanine- analogues using a chemo-
proteomics approach. It is a future work to study the BBIQ alkaloids distribution in 
cells using different staining for nucleus and mitochondria which is ongoing. 
The bio-availability and other pharmacokinetic studies on BBIQ alkaloids and new 
analogues in animals are among the future studies. The in vivo metabolism of 
cycleanine in the animals - rats is currently on-going. Future work would be done on 
chemical modification of BBIQ alkaloids using other methods or pathways to produce 
more potent anti-cancer and antimalarial agents. 
Finally, to be approved as anticancer drugs, in vivo activities or preclinical studies of 
these BBIQ alkaloids and analogues must be evaluated. Therefore, it is a future work 
to carry out the in vivo anti-cancer and antimalarial studies on BBIQ alkaloids and the 
new cycleanine analogues. 
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APPENDICES 
 
 
 
 
Figure A1 Positive ESI-MS of cycleanine. The mass to charge ratio (m/z) was found 
to be 623.3118. 
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Figure A2   Positive electrospray mass spectrum of isochondodendrine.  
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Figure A3 Positive electrospray mass spectrum of 2′-norcosculine. This shows the 
mass to charge (m/z) ratio of 549.2384 [M + H]+ and 275.1239 [M+2H]2+.   
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Figure A4 GC analysis/ spectra of palmitelaidic acid, trimethylsilyi ester from TSS3.8. 
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 Figure A5. GC analysis/ spectra of 11-cis- Octadecenoic acid, trimethylsilyl ester of 
TSS3.8  
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Figure A6 GC analysis/ spectra of nonadecanoic acid, trimethylsilyester in TSS3.8. 
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Figure A7 GC analysis/ spectra of Cis-13-Eicosenoic acid, trimethylsily ester in 
TSS3.8. 
 
 
                            
Figure A8 GC analysis/ spectra of docosanoic acid, trimethylsily ester in TSS3.8  
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